

Secu M-R

Ma A, Koka R, Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. *Annu Rev Immunol* 2006;24:657–79. Otettu 9.3.16

[Involvement of the NLRP3/IL-1 \$\beta\$  pathway in activation and effector functions of  \$\gamma\delta\$ T17 cells in patients with ulcerative colitis.](#)

Ma J, Wang FY, Tang XD.

*World J Gastroenterol*. 2025 Mar 28;31(12):98174. doi: 10.3748/wjg.v31.i12.98174.

PMID: 40182600 [Free PMC article](#). Otettu 31.7.25

[IL-17 as a therapeutic target in cardiovascular diseases: Mechanistic insights and translational opportunities.](#)

Ma L, Yang W, Gao W, Liu X, Dong M, An G, Meng X.

*Pharmacol Res*. 2025 Jul 24;219:107879. doi: 10.1016/j.phrs.2025.107879. Online ahead of print.

PMID: 40714302 [Free article](#). Review. Otettu 31.7.25

Dual Biologic Therapy for Psoriasis in a Patient with Atopic Dermatitis.

Ma L, Chen X, Aziz MAA, Chen A, Cai T, Chen S.  
Psoriasis (Auckl). 2025 Apr 23;15:159-161. doi:  
10.2147/PTT.S516268. eCollection 2025.

PMID: 40290565 [Free PMC article.](#) Otettu 4.6.25

Successful use of **secukinumab** in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy.

Ma VT, Lao CD, Fecher LA, Schiopus E.  
Immunotherapy. 2022 Jun;14(8):593-598. doi:  
10.2217/imt-2021-0274. Epub 2022 Apr 13.

PMID: 35416067 Otettu 30.11.22

Ma, C. S., G. Y. Chew, N. Simpson, A. Priyadarshi, M. Wong, B. Grimbacher, D. A. Fulcher, S. G. Tangye, and M. C. Cook. 2008. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. *J. Exp. Med.* 205: 1551– 1557. Otettu 9.3.16

Ma J, Yu J, Tao X, Cai L, Wang J, Zheng SG: The imbalance between regulatory and IL-17-secreting CD4+ T cells in lupus patients. *Clin Rheumatol* 2010, 29:1251-1258. Otettu 9.3.16

ty and efficacy of **secukinumab** treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis: a commentary.

Macaluso F, Guggino G, Ciccia F.

Clin Exp Rheumatol. 2020 May 20. Online ahead of print.

PMID: 32452343    Otettu 4.2.21

Safety and efficacy of **secukinumab** treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis.

Macaluso F, Guggino G, Mauro D, Rizzo C, Bignone R, Ciccia F.

Clin Exp Rheumatol. 2019 Jun 28.    Otettu 9.3.20

Ref. katsottu 11.3.20

Inhibition of **interleukin-17** in axial spondyloarthritis spectrum.

Machado PM.

Lancet. 2020 Jan 4;395(10217):6-8. doi:

10.1016/S0140-6736(19)33047-8. Epub 2019 Dec 5.

Otettu 30.11.22

Safety of **secukinumab** in psoriasis patients with latent tuberculosis infection.

Machado Á, Abreu M, Torres T.

Eur J Dermatol. 2020 Nov 24. doi:

10.1684/ejd.2020.3909. Online ahead of print.

PMID: 33237033    Otta M    Otta M    Otta myöhemmin

Role of neutrophil interleukin-23 in spondyloarthropathy spectrum disorders.

Macleod T, Bridgwood C, McGonagle D.

Lancet Rheumatol. 2023 Jan;5(1):e47-e57. doi: 10.1016/S2665-9913(22)00334-4.

PMID: 38251507 Review. Otta M

Secukinumab in Generalized Pustular Psoriasis.

Madanagobalane S.

Indian Dermatol Online J. 2018 Nov-Dec;9(6):464-466. doi: 10.4103/idoj.IDOJ\_93\_18. No abstract available.

PMID: 30505796 **Free PMC Article** **Otettu 29.2.20**

Maddur M S, Miossec P, Kaveri S V et al. Am J Pathol 2012; 181: 8–18. Otettu 9.3.16

Safety and efficacy of anti-IL-17A use in multiple sclerosis and comorbid rheumatological disease: A multi-center exploratory study.

Madill E, Galetta K, Opeyemi O, Pua DK, Gandelman S, Chitnis T, Bhattacharyya S.

J Clin Neurosci. 2025 Jun;136:111211. doi: 10.1016/j.jocn.2025.111211. Epub 2025 Apr 1. PMID: 40174548 Otta M

K. Maeshima, K. Yamaoka, S. Kubo et al., “The JAK inhibitor tofacitinib regulates synovitis through inhibition

of interferon-  $\gamma$  and interleukin-17 production by human CD4+ T cells,”

ARthr Rheum Vol 64 No 6 pp. 1790-1798, 2012

Otettu 9.3.16

Can **secukinumab** improve liver fibrosis? A pilot prospective study of 10 psoriatic patients.

Magdaleno-Tapial J, López-Martí C, Ortiz-Salvador JM, Hernández-Bel P, Tamarit-García JJ, Diago-Madrid M, Sánchez-Carazo JL, Pérez-Ferriols A.

Dermatol Ther. 2021 Jul 21:e15065. doi:

10.1111/dth.15065. Online ahead of print.

PMID: 34289229 No abstract available. Otettu

30.11.22

Maggi L, Santarlaschi V, Capone M, Peired A, Frosali F, Crome



SQ, et al. CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC. *Eur J Immunol* 2010;40: 2174–81. Otettu 9.3.16

Maggi L, Santarlaschi V, Capone M, Rossi MC, Querci V, Mazzoni A, et al. Distinctive features of classic and nonclassic (Th17 derived) human Th1 cells. *Eur J Immunol.* (2012) 42:3180–8 Otettu 8.3.20

Pathophysiology of moderate to severe plaque psoriasis: anti-IL-**17** towards disease modification.

Magina S, Filipe P.

*Drugs Today (Barc).* 2021 May;57(5):347-357. doi: 10.1358/dot.2021.57.5.3266244.

PMID: 34061129 Ei ole M

20. Magnano M, Loi C, Patrizi A, et al. Secukinumab in multi-failure psoriatic patients: the last hope?. J Dermatolog Treat. 2018;1–3. Otettu 20.9.20

VEXAS syndrome in a patient with previous spondyloarthritis with a favourable response to intravenous immunoglobulin and anti-IL17 therapy. Magnol M, Couvaras L, Degboé Y, Delabesse E, Bulai-Livideanu C, Ruyssen-Witrand A, Constantin A. Rheumatology (Oxford). 2021 Sep 1;60(9):e314-e315. doi: 10.1093/rheumatology/keab211. PMID: 33693498 No abstract available. Otettu 30.11.22

Efficacy of **Secukinumab** Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.

Magnolo N, Kingo K, Laquer V, Browning J, Reich A, Szepietowski JC, Keefe D, Papanastasiou P, Bao W, Forrer P, Patekar M.

Paediatr Drugs. 2022 Jul;24(4):377-387. doi:

10.1007/s40272-022-00507-0. Epub 2022 Jun 13.

PMID: 35698000 **Free PMC article.** Otettu 26.8.22

[A Pilot Study to Assess the Feasibility of a Web-Based Survey to Examine Patient-Reported Symptoms and Satisfaction in Patients with Ankylosing Spondylitis Receiving Secukinumab.](#)

Magrey M, Bozyczko M, Wolin D, Mordin M, McLeod L, Davenport E, Chirila C, Park Y.

Drugs Real World Outcomes. 2019 Jun;6(2):83-91.

**Free PMC Article   Otettu 28.2.20**

**Ref. katsottu 6.3.20**

[Evaluation of the Feasibility of a Web-Based Survey to Assess Patient-Reported Symptom Improvement and Treatment Satisfaction Among Patients with Psoriatic Arthritis Receiving Secukinumab.](#)

Magrey M, Bozyczko M, Wolin D, Mordin M, McLeod L, Davenport E, Chirila C, Hur P.  
Clin Drug Investig. 2019 Dec;39(12):1205-1212.

**Free PMC Article   Otettu 28.2.20**

**Ref. katsottu 16.3.20**

[Pyoderma Gangrenosum Associated With Iatrogenic Interleukin 17A Blockade: A Report of Two Cases and a Review of the Literature.](#)

Magro CM, Crowson N, Kalomeris T, Nuovo G.

J Cutan Pathol. 2024 Oct 27. doi: 10.1111/cup.14740.

Online ahead of print.

PMID: 39462244   Otta M

[The Future of Axial Spondyloarthritis Treatment.](#)

Maguire S, Sengupta R, O'Shea F.

Rheum Dis Clin North Am. 2020 May;46(2):357-365. doi:

Otettu 30.11.22

[Case report: Interleukin-17 targeted biological therapy in netherton syndrome.](#)

Mahajan R, Bakshi S, Kumar A, De D, Handa S.

Front Pediatr. 2023 Nov 29;11:1297658. doi:

10.3389/fped.2023.1297658. eCollection 2023.

PMID: 38094185 **Free PMC article.** Otettu 4.3.24

[Treatment of psoriatic arthritis with traditional DMARD's and novel therapies: approaches and recommendations.](#)

Maharaj AB, Chandran V.

Expert Rev Clin Immunol. 2017 Apr;13(4):319-331.

ei ole M    ei ole GS    Ei oteta

[Similar articles](#)

[Th1 and Th17 Predominance in the Enthesitis-related Arthritis Form of Juvenile Idiopathic Arthritis.](#)

Mahendra A, Misra R, Aggarwal A.

J Rheumatol. 2009 Aug;36(8):1730-6. doi: 10.3899/jrheum.081179. Epub 2009 Jun 16.

PMID:

Otettu 4.3.16

[Similar articles](#)

Role of **secukinumab** in ankylosing spondylitis with tubercular uveitis.

Mahendradas P, Jain VK, Thomas S, Kawali A, Sanjay S, Shetty BK.

Indian J Ophthalmol. 2020 Nov;68(11):2569-2572. doi: 10.4103/ijo.IJO\_1081\_20.

PMID: 33120695 Otettu 13.12.20

Long-term efficacy and safety of **secukinumab** in patients with psoriatic arthritis.

Mahmood A, Ali A, Haider H, Zulfiqar B.

Eur J Intern Med. 2023 Sep 6:S0953-6205(23)00307-2. doi: 10.1016/j.ejim.2023.08.023. Online ahead of print.

Otta M

Possible Relation between Vitamin D and **Interleukin-17** in the Pathogenesis of Lichen Planus.

Mahmoud SB, Anwar MK, Shaker OG, El Sharkawy DA.

Dermatology. 2021;237(6):896-901. doi:

10.1159/000510539. Epub 2020 Oct 22.

PMID: 33091918 ei oteta



Mai J, Wang H, Yang X-F. Th 17 cells interplay with Foxp3<sup>+</sup> Tregs in regulation of inflammation and auto-immunity.

Front Biosci 2010;15:986-1006. Otettu 17.3.20

Ref. katsottu 18.3.20

**Interleukin-17A (IL-17A): A silent amplifier of COVID-19.**

Maione F, Casillo GM, Raucci F, Salvatore C, Ambrosini G, Costa L, Scarpa R, Caso F, Bucci M.

Biomed Pharmacother. 2021 Oct;142:111980. doi:

10.1016/j.biopha.2021.111980. Epub 2021 Jul 29.

PMID: 34364043 **Free PMC article.** Otettu 29.8.22

10. Mair, F. et al. The NFκB-inducing kinase is essential for the developmental programming of skin-resident and IL-17-producing γδ T cells. *eLife* **4**, e10087 (2015). Otettu 25.3.20

Maitra A, et al. Distinct functional motifs within the IL-17 receptor regulate signal transduction. *Proc Natl Acad Sci U S A* 2007;104(18):7506–11. Otettu 9.3.16

Unraveling the role of IL-17A variants in pulmonary tuberculosis: Insights from a case-control study.

Majidpour M, Akbar-Abad MS, Shahriari H, Barakzaee S, Zafarmohammadi K, Mohammadghasemipour Z.

Infect Genet Evol. 2025 Mar 5;130:105735. doi:  
10.1016/j.meegid.2025.105735. Online ahead of print.  
PMID: 40054826 [Free article.](#) Otettu 4.6.25

[Unraveling the role of IL-17A variants in pulmonary tuberculosis: Insights from a case-control study.](#)

Majidpour M, Akbar-Abad MS, Shahriari H, Barakzaee S, Zafarmohammadi K, Mohammadghasemipour Z.

Infect Genet Evol. 2025 Mar 5;130:105735. doi: 10.1016/j.meegid.2025.105735. Online ahead of print.

PMID: 40054826 [Free article.](#)

[IL-17 in the Pathogenesis of Disease: Good Intentions Gone Awry.](#)

Majumder S, McGeachy MJ.

Annu Rev Immunol. 2021 Apr 26;39:537-556. doi: 10.1146/annurev-immunol-101819-092536. Epub 2021 Feb 12.

PMID: 33577346 [Free PMC article.](#) Otettu 31.8.22

[Effects of Interleukin 17A Inhibition on Myocardial Deformation and Vascular Function in Psoriasis.](#)

Makavos G, Ikonomidis I, Andreadou I, Varoudi M, Kapniari I, Loukeri E, Theodoropoulos K, Pavlidis G, Triantafyllidi H, Thymis J, Parissis J, Tsoumani M, Rafouli-Stergiou P, Katsimbri P, Papadavid E.

Can J Cardiol. 2020 Jan;36(1):100-111. Otettu 28.2.20

[\*\*Secukinumab\*\* shows reassuring low immunogenicity.](#)

Makrygeorgou A.

Br J Dermatol. 2017 Mar;176(3):573-574. doi: 10.1111/bjd.15332. No abstract available.

PMID:

28300307 Otettu 28.5.18

[Similar articles](#)

Comparative effectiveness of **secukinumab** and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison.

Maksymowych WP, Strand V, Nash P, Yazici Y, Thom H, Hunger M, Kalyvas C, Gandhi KK, Porter B, Jugl SM.

Eur J Rheumatol. 2018 Dec;5(4):216-223.

**Free PMC Article** **Otettu 28.2.20**

**Ref. katsottu 12.3.2020**

## Evidence in support of the bone marrow as the primary lesion in axial spondyloarthritis.

Maksymowych WP.

Curr Opin Rheumatol. 2023 Jul 1;35(4):213-218. doi: 10.1097/BOR.0000000000000945. Epub 2023 Apr 27. Otta M

## Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus **Secukinumab** and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis.

Maksymowych WP, Thom H, Mørup MF, Taieb V, Willems D, Lyris N, Gaffney K.

Rheumatol Ther. 2024 Aug;11(4):1023-1041. doi: 10.1007/s40744-024-00684-z. Epub 2024 Jun 25.

PMID: 38916823 **Free PMC article.** **Otettu 27.9.24**

**Secukinumab** in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence.

Malagoli P, Dapavo P, Amerio P, Atzori L, Balato A, Bardazzi F, Bianchi L, Cattaneo A, Chiricozzi A, Congedo M, Fagnoli MC, Giofrè C, Gisondi P, Guarneri C, Lembo S, Loconsole F, Mazzocchetti G, Mercuri SR, Morrone P, Offidani AM, Palazzo G, Parodi A, Pellacani G, Piaserico S, Potenza C, Prignano F, Romanelli M, Savoia P, Stingeni L, Travaglini M, Trovato E, Venturini M, Zichichi L, Costanzo A.

Dermatol Ther (Heidelb). 2024 Sep 24. doi: 10.1007/s13555-024-01255-4. Online ahead of print. PMID: 39316358 Review. Otettu 27.9.24

### [The role of IL-17 in psoriasis.](#)

Malakouti M, Brown GE, Wang E, Koo J, Levin EC.  
J Dermatolog Treat. 2015 Feb;26(1):41-4. doi:      Otettu  
28.5.18

### [Similar articles](#)

Malakouti M, Jacob SE, Anderson NJ. Treatment challenges in the management of moderate-to-severe plaque psoriasis—role of secukinumab. Clinical, cosmetic and investigational dermatology. 2016; 9:347.

4. Otettu 2.3.2020

5. Ref. katsottu 9.3.20

[Secukinumab: a promising therapeutic option in spondyloarthritis.](#)

Maldonado-Ficco H, Perez-Alamino R,  
Maldonado-Cocco JA.

Clin Rheumatol. 2016 Sep;35(9):2151-61. doi:  
10.1007/s10067-016-3350-6. Epub 2016 Jul 20.  
Review.

PMID:

27437696    Otettu 28.5.18

[Similar articles](#)

Malhotra, N. et al. A network of high-mobility group box  
transcription factors



programs innate interleukin-17 production. Immunity 38, 681–693 (2013). Otettu 9.3.16

Kids and COVID: why young immune systems are still on top.

Mallapaty S.

Nature. 2021 Sep;597(7875):166-168. doi: 10.1038/d41586-021-02423-8.

PMID: 34493845 Otettu 29.8.22

[Type I pityriasis rubra pilaris treated with tumor necrosis factor inhibitors, ustekinumab, or \*\*secukinumab\*\*: a systematic review.](#)

Maloney NJ, Hisaw LD, Worswick S.

J Am Acad Dermatol. 2018 Mar 5. pii:

S0190-9622(18)30349-9. doi: Otettu 28.5.18

[Similar articles](#)

Maloy KJ. The interleukin-23 / interleukin-17 axis in intestinal inflammation. *J Intern Med* 2008;263:584–90. Otettu 7.3.20

[IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa.](#)

Malvaso D, Calabrese L, Chiricozzi A, Antonelli F, Coscarella G, Rubegni P, Peris K. *Pharmaceutics*. 2023 Oct 11;15(10):2450. doi: 10.3390/pharmaceutics15102450. PMID: 37896210 [Free PMC article](#). Review. Otettu 4.3.24

## **IL-17 Is a Key Regulator of Mucin-Galectin-3 Interactions in Asthma.**

Mammen MJ, Ali J, Aurora A, Sharma UC, Aalinkeel R, Mahajan SD, Sands M, Schwartz SA.

Int J Cell Biol. 2021 Jun 9;2021:9997625. doi: 10.1155/2021/9997625. eCollection 2021.

PMID: 34221020 **Free PMC article.** Otettu 30.8.22

## **IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa.**

Malvaso D, Calabrese L, Chiricozzi A, Antonelli F, Coscarella G, Rubegni P, Peris K.

Pharmaceutics. 2023 Oct 11;15(10):2450. doi: 10.3390/pharmaceutics15102450.

PMID: 37896210 **Free PMC article.** Review. Otettu 14.3.24

## Inflammation and Psoriasis: A Comprehensive Review.

Man AM, Orăsan MS, Hoteiuc OA,  
Olănescu-Vaida-Voevod MC, Mocan T.

Int J Mol Sci. 2023 Nov 8;24(22):16095. doi:  
10.3390/ijms242216095.

PMID: 38003284 [Free PMC article](#). Review. Otettu  
14.3.24

## **Interleukin-17** Inhibition in Spondyloarthritis Is Associated With Subclinical Gut Microbiome Perturbations and a Distinctive **Interleukin-25**-Driven Intestinal Inflammation.

Manasson J, et al. Arthritis Rheumatol. 2020. PMID:  
31729183 [Free PMC article](#). Otettu 30.11.22

Manel N, Unutmaz D, Littman DR. The differentiation of human TH-17 cells requires transforming growth factor- $\gamma$  and induction of the nuclear receptor ROR $\gamma$  t. Nat Immunol 2008;9:641–9. Otettu 9.3.16

### Pim Kinases as Therapeutic Targets in Early Rheumatoid Arthritis.

Maney NJ, Lemos H, Barron-Millar B, Carey C, Herron I, Anderson AE, Mellor AL, Isaacs JD, Pratt AG.

Arthritis Rheumatol. 2021 Oct;73(10):1820-1830. doi: 10.1002/art.41744. Epub 2021 Aug 24.

PMID: 33779060 Otettu 30.8.22

Mangan PR et al. Transforming growth factor- $\beta$  induces development of TH17 lineage. Nature 2006;441:231–4.  
Otettu 9.3.16

[Anti-IL17 treatment in childhood chronic rheumatic diseases.](#)

Maniscalco V, Maccora I, Girodo F, Tomaselli M, Priolo G, Marrani E, Mastrolia MV, Pagnini I, Simonini G.

Expert Opin Biol Ther. 2023 May;23(5):429-441. doi: 10.1080/14712598.2023.2215923. Epub 2023 May 19. PMID: 37195125 Review. Otta M

[Comment on: Achieving inactive disease in enthesitis-related arthritis with \*\*secukinumab\*\* following TNF-inhibitor failure.](#)

Maniscalco V, Pagnini I, Marrani E, Maccora I, Rumeileh SA, Mastrolia MV, Simonini G.

Rheumatology (Oxford). 2024 Mar 9:keae148. doi: 10.1093/rheumatology/keae148. Online ahead of print. PMID: 38460185    Otta M

[Real world use of \*\*secukinumab\*\* for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry.](#)

Mann HF, Závada J, Šenolt L, Bubová K, Nekvindová L, Křístková Z, Horák P, Vencovský J, Pavelka K; and the ATTRA Registry.

Clin Exp Rheumatol. 2019 Mar-Apr;37(2):342-343.

**Free Article   Otettu 28.2.20**

**Ref. katsottu 8.3.20**

[Successful treatment of recalcitrant Sneddon-Wilkinson disease with \*\*secukinumab\*\*.](#)

Mansilla-Polo M, Martín-Torregrosa D, Martínez-Cozar V, Botella-Estrada R.

An Bras Dermatol. 2025 Aug 13;100(5):501178. doi:  
10.1016/j.abd.2025.501178. Online ahead of print.  
PMID: 40812228 **Free PMC article.** Otettu 22.8.25

The immunobiological functions and therapeutic  
applications of **interleukin-17** family in cancer.

Mansuri N, Mohamed AH, Ahsan M, Ali SA, Qureshi MA,  
A Aldhaaban W, Mallick AK, Mohammed MED, Ahmad F,  
Ahmad I, Jamali MC, Shafie A.

Curr Res Transl Med. 2025 Jul 2;73(4):103527. doi:  
10.1016/j.retram.2025.103527. Online ahead of print.  
PMID: 40644929 Review. Otta M



Burden of Moderate-to-Severe Plaque Psoriasis and  
New Therapeutic Approaches (**Secukinumab**): An  
Italian Perspective.

Mantovani L, Medaglia M, Piacentini P, Tricca M,  
Vena GA, Voza A, Castellino G, Roccia A.

Dermatol Ther (Heidelb). 2016 Jun;6(2):151-67. doi:  
10.1007/s13555-016-0114-9. Epub 2016 Apr 15.

Review.

PMID:

27083437 Otettu 27.5.18

**Free PMC Article**

[Similar articles](#)

Manzo A, Bombardieri M, Humby F, Pitzalis C.  
Secondary and ectopic lymphoid tissue responses in  
rheumatoid arthritis: from inflammation to autoimmunity  
and tissue damage/remodeling. Immunol Rev  
2010;233:267–85. Otettu 9.3.16

**Secukinumab and hidradenitis suppurativa: Friends  
or foes?**

Marasca C, Megna M, Balato A, Balato N, Napolitano  
M, Fabbrocini G.

JAAD Case Rep. 2019 Jan 30;5(2):184-187. doi: **Free  
PMC Article Otettu 28.2.20**

**Ref. katsottu 1.3.2020**

[Neonatal CARD14-Associated Papulosquamous Eruption: Response to \*\*Secukinumab\*\* During Infancy.](#)

March-Rodríguez Á, Vicente A, García AG, Launes C, Escolà H, Pérez-Jurado LA, Sánchez LF, Planas S, Pujol RM, Baselga E.

Pediatr Dermatol. 2025 Jun 17. doi: 10.1111/pde.16003.

Online ahead of print.

PMID: 40525499 Otta M

.

[\*\*Interleukin 17\*\* as a novel predictor of vascular function in rheumatoid arthritis.](#)

Marder W, Khalatbari S, Myles JD, Hench R, Yalavarthi S, Lustig S, Brook R, Kaplan MJ.

Ann Rheum Dis. 2011 Sep;70(9):1550-5. d. Epub 2011

Otettu 3.2.16

[Free PMC Article](#)

## [Similar articles](#)

Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren's syndrome: evidence- and practice-based guidance.

Marinho A, Delgado Alves J, Fortuna J, Faria R, Almeida I, Alves G, Araújo Correia J, Campar A, Brandão M, Crespo J, Marado D, Matos-Costa J, Oliveira S, Salvador F, Santos L, Silva F, Fernandes M, Vasconcelos C.

Front Immunol. 2023 Apr 17;14:1117699. doi:

10.3389/fimmu.2023.1117699. eCollection 2023.

PMID: 37138867 [Free PMC article](#). Review. Otettu 12.6.23

Toxicological considerations in the treatment of axial spondylo-arthritis.

Marino F, D'Angelo S, Masala IF, Gerratana E, Nucera V, La Corte L, Giallanza M, Sarzi-Puttini P, Atzeni F. Expert Opin Drug Metab Toxicol. 2020 Aug;16(8):663-672. doi: 10.1080/17425255.2020.1783240. Epub 2020 Jun 27. PMID: 32552128 Review. Ei ole M

[The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications.](#)

Marinoni B, Ceribelli A, Massarotti MS, Selmi C. Auto Immun Highlights. 2014 Jan 22;5(1):9-19. doi:

[Free PMC Article](#)

[Similar articles](#)

Otettu 27.5.18

Marks BR, Nowyhed HN, Choi JY, Poholek AC, Odegard JM, Flavell RA, et al. Thymic self-reactivity selects natural interleukin 17-producing T cells that can regulate

peripheral inflammation. Nat Immunol.  
2009;10:1125–32. Otettu 9.3.16

Genetic screening in new onset inflammatory bowel  
disease during anti-**interleukin 17** therapy: unmet needs  
and call for action.

Maronese CA, Zelin E, Moltrasio C, Genovese G,  
Marzano AV.

Expert Opin Biol Ther. 2021 Dec;21(12):1543-1546. doi:  
10.1080/14712598.2021.1974395. Epub 2021 Aug 30.  
PMID: 34448662 Otettu 29.8.22

Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm.

Maronese CA, Moltrasio C, Genovese G, Marzano AV.

Expert Rev Clin Immunol. 2023 Dec 22:1-21. doi: 10.1080/1744666X.2023.2298356.  
Online ahead of print.

PMID: 38130204 Review. Otta M

Effect of biologics targeting IL-23/IL-17 axis on subclinical atherosclerosis: Results of a pilot study.

Marovt M, Marko PB, Pirnat M, Ekart R.

Clin Exp Dermatol. 2020 Jan 21   Otettu 28.2.20

Relationship between Th17 immune response and cancer.

Marques HS, de Brito BB, da Silva FAF, Santos MLC, de Souza JCB, Correia TML, Lopes LW, Neres NSM, Dórea RSDM, Dantas ACS, Morbeck LLB, Lima IS, de Almeida AA, Dias MRJ, de Melo FF.

World J Clin Oncol. 2021 Oct 24;12(10):845-867. doi: 10.5306/wjco.v12.i10.845.

PMID: 34733609 **Free PMC article.** Review.   Otettu 29.8.22

Martin B, et al. Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. *Immunity*. 2009; 31:321–330. Otettu 9.3.16

Martin D A, Towne J E, Kricorian G et al. *J Invest Dermatol* 2013; 133: 17–26. Otettu 9.3.16

### **Interleukin-17 Inhibitor Combination Therapies for the Treatment of Psoriasis: A Systematic Review.**

Martin A, Thatiparthi A, Liu J, Wu JJ.



J Clin Aesthet Dermatol. 2022 Jun;15(6 Suppl 1):S19-S31.

PMID: 35784449 [Free PMC article](#). Otettu 27.8.22

Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors.

Martin G.

Dermatol Ther (Heidelb). 2023 Feb;13(2):417-435. doi: 10.1007/s13555-022-00878-9. Epub 2023 Jan 2.

PMID: 36592300 [Free PMC article](#). Review. Otettu 14.6.23

Martinez GJ, et al. SMAD2 positively regulates the generation of Th17 cells. J Biol Chem. 2010; 285:29039–29043. [PubMed: 20667820] ei ole M

Ei oteta

[Endogenous endophthalmitis and osteomyelitis associated with interleukin 17 inhibitor treatment for psoriasis in a patient with diabetes.](#)

Martinez CE, Allen JB, Davidorf FH, Cebulla CM.  
BMJ Case Rep. 2017 Jun 29;2017. pii:  
bcr-2017-219296. doi: 10.1136/bcr-2017-219296.  
PMID:

Otettu 28.5.18

[Similar articles](#)

Martinis F, Caimmi C, Carletto A, et al. Real-world efficacy and safety of secukinumab: data from Verona's cohort. Ann Rheum

Dis. 2018;77:1544–5.    ei oteta

Martin-Orozco, N., Muranski, P., Chung, Y., Yang, X.O., Yamazaki, T., Lu, S., Hwu, P., Restifo, N.P., Overwijk, W.W., and Dong, C. (2009). T helper 17 cells promote cytotoxic T cell activation in tumor immunity. *Immunity* 31, 787–798. Otettu 9.3.16

[Access, Effectiveness, Safety And Survival Of Secukinumab In Patients With Axial Spondyloarthritis And Axial Psoriatic Arthritis: Real-Life Study In Argentina.](#)

Martire MV, Marin J, Maldonado Ficco H, Benegas M, Giorgis P, Vila D, Isnardi CA, Gamba MJ, Flores Trejo JF, Perez-Alamino R, Chemez AJ, Ferreyra Garrott L, Cosatti MA, Buschiazzi EA, Correa MLA, Aguila Maldonado R, Manases Roldan B, Lizarraga C, Alfaro MA, Morbiducci J, Ingolotti LV, Pendón G, Nieto RE, Velloso MS, Martinez Muñoz A, Lloves Schenone N, Zamora NV, Saturansky E, Costi AC, Haye Salinas MJ, Airolti CA, Granel A.

J Rheumatol. 2025 May 15;jrheum.2024-1185. doi:  
10.3899/jrheum.2024-1185. Online ahead of print.  
PMID: 40374511 Otta M

**Secukinumab in Hidradenitis Suppurativa Patients Who  
Failed Adalimumab: A 52-Week Real-Life Study.**

Martora F, Marasca C, Cacciapuoti S, Fariello F, Potestio  
L, Battista T, Scalvenzi M, Megna M.

Clin Cosmet Investig Dermatol. 2024 Jan 23;17:159-166.  
doi: 10.2147/CCID.S449367. eCollection 2024.

PMID: 38283798 **Free PMC article.** Otettu 4.3.24

**Secukinumab** for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration - A Case Report.

Martora F, Annunziata MC, Potestio L, Battista T, Ruggiero A, Megna M.

Clin Cosmet Investig Dermatol. 2024 May 30;17:1275-1279. doi: 10.2147/CCID.S468268. eCollection 2024.

PMID: 38831783 [Free PMC article.](#) Otettu 6.6.24

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data.

Martora F, Scalvenzi M, Battista T, Fornaro L, Potestio L, Ruggiero A, Megna M.

Clin Cosmet Investig Dermatol. 2023 Sep 18;16:2525-2536. doi: 10.2147/CCID.S418748. eCollection 2023.

PMID: 37745273 [Free PMC article](#). Review. Otettu  
12.10.23

Hidradenitis Suppurativa in Elderly Patients: Clinical and  
Therapeutical Outcomes-A Review of the Literature.

Martora F, Tommasino N, Brescia C, Potestio L, Battista  
T, Megna M.

Medicina (Kaunas). 2024 Sep 6;60(9):1465. doi:  
10.3390/medicina60091465.

PMID: 39336506 [Free PMC article](#). Review. Otettu  
24.10.24

High adherence to **secukinumab** in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting.

Martos-Cabrera L, Llamas-Velasco M, Armesto S, Herrera-Acosta E, Vidal D, Vilarrasa E, Rivera-Diaz R, de la Cueva P, Martorell-Calatayud A, Ballescá F, Belinchón I, Carretero G, Rodríguez L, Romero-Maté A, Pujol-Montcusí J, Salgado-Boquete L, Sahuquillo-Torralba A, Coto-Segura P, Baniandrés O, Feltes R, Alsina M, Daudén E.

Int J Dermatol. 2022 Jul 22. doi: 10.1111/ijd.16365.

Online ahead of print.

PMID: 35867958   Otta M   Otta myöhemmin

[TH17 Cells in Autoimmunity and Immunodeficiency: Protective or Pathogenic?](#)

Marwaha AK, Leung NJ, McMurchy AN, Levings MK. Front Immunol. 2012 Jun 4;3:129. doi: Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

**Secukinumab** provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2.

Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Delicha EM, Rohrer S, Richards H.

RMD Open. 2017 Dec 28;3(2):e000592. doi: Otettu  
27.5.18 ja 23.12.20

**Free PMC Article**

[Similar articles](#)

**Secukinumab** and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing



## Spondylitis Through Two Years: Results From a Phase III Study.

Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Martin R, Readie A, Richards HB, Porter B; Measure 2 Study Group.

Arthritis Care Res (Hoboken). 2017

Jul;69(7):1020-1029. Otettu 27.5.18

## Free PMC Article

### Similar articles

## Excessive hair growth in a patient with psoriatic erythroderma following secukinumab administration.

Mashima E, Sawada Y, Yamaguchi T, Yoshioka H, Ohmori S, Haruyama S, Okada E, Nakamura M.

Eur J Dermatol. 2018 Aug 1;28(4):539-540. Otettu 9.3.20

Ref. katsottu 16.3.20

## Psoriatic arthropathy in patients with previous neoplasia: a case series of four patients treated with secukinumab and literature review.

Massafra UG, Giovannangeli F, Migliore A.

Eur Rev Med Pharmacol Sci. 2024 Apr;28(7):2878-2893.

doi: 10.26355/eurrev\_202404\_35919.

PMID: 38639525 **Free article**. Review. Otettu 29.5.24

IL-17 and IL-23 inhibitors dose spacing in adult psoriatic patients: a real-world pilot study.

Mastorino L, Dapavo P, Ortoncelli M, Bongiovanni E, Quaglino P, Ribero S.

J Dtsch Dermatol Ges. 2025 Jun;23(6):693-699. doi:

10.1111/ddg.15686. Epub 2025 Apr 26.

PMID: 40285562 **Free PMC article**. Otettu 31.7.25

Drug Survival, Safety, and Effectiveness of **Secukinumab** for up to 5 Years in Patients with Psoriasis and Psoriatic Arthritis: A Long-Term Real-Life Experience.

Mastorino L, Dapavo P, Cariti C, Susca S, Siliquini N, Ortoncelli M, Stroppiana E, Verrone A, Giunipero di Corteranzo I, Leo F, Quaglino P, Ribero S.

J Pers Med. 2024 Jul 3;14(7):718. doi: 10.3390/jpm14070718.

PMID: 39063973 [Free PMC article.](#) Otettu 27.9.24

Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?

Mastorino L, Dapavo P, Avallone G, Merli M, Cariti C, Rubatto M, Pala V, Quaglino P, Ribero S.

J Dermatolog Treat. 2021 Aug 30:1-8. doi: 10.1080/09546634.2021.1970706. Online ahead of print.

PMID: 34409918 ei ole M

Dose modulation strategies in psoriatic patients:  
real-world comparison between **secukinumab** and  
brodalumab for up to one year after dose spacing.

Mastorino L, Dapavo P, Ortoncelli M, Bongiovanni E, Liao Y, Pelucchi M, Leo F, Quaglino P, Ribero S.

Clin Exp Dermatol. 2025 Jun 12;llaf250. doi:  
10.1093/ced/llaf250. Online ahead of print.

PMID: 40499920    Otettu 28.7.25

Understanding the role of cytokines in the pathogenesis  
of rheumatoid arthritis.

Mateen S, Zafar A, Moin S, Khan AQ, Zubair S.

Clin Chim Acta. 2016 Feb 13;455:161-171. doi:  
10.1016/j.cca.2016.02.010. [Epub ahead of print]

Review.

PMID:

26883280      Otettu 9.3.16

[Similar articles](#)

Mateu-Puchades A, Santos-Alarcon S,  
Martorell-Calatayud A, et al. Erythrodermic  
psoriasis and secukinumab: our clinical experience.  
Dermatol Ther. 2018;31:e12607.    Otettu 7.3.20

Mathur AN, Chang HC, Zisoulis DG, Kapur R,  
Belladonna ML, Kansas GS, et al. T-bet is a critical  
determinant in the instability of the IL-17-secreting  
T-helper phenotype. Blood 2006;5:1595–601.

Otettu 19.3.20

Ref. ei katsot

Mathur AN, et al. Stat3 and Stat4 direct development of IL-17-secreting Th cells. J Immunol. 2007; 178:4901–4907. Otettu 9.3.16

Are the loading dose treatment groups superior to the 150 mg without loading dose group in the **secukinumab** FUTURE 5 study?

Matos da Cunha B.

Ann Rheum Dis. 2018 May 31. pii:

annrheumdis-2018-213770. doi:

10.1136/annrheumdis-2018-213770. [Epub ahead of

Otettu 3.9.18

[Similar articles](#)

A Case of Superimposed Linear Psoriasis That Was Successfully Treated With **Secukinumab**.

Matsumoto M, Matsudate Y, Kuroo Y, Okazaki H.

J Dermatol. 2025 Aug 12. doi:

10.1111/1346-8138.17910. Online ahead of print.

PMID: 40792452 No abstract available. Otta M

12. Matsuzaki G, Umemura M. Interleukin-17 as an effector molecule of innate and acquired immunity against infections. *Microbiol Immunol*. 2007;51(12):1139-1147. Otettu 8.3.20

Matusiak Ł, Szczęch J, Bieniek A, Nowicka-Suszek D, Szepietowski JC. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents. *J Am Acad Dermatol*. 2017;76(4):670-675

Otettu 9.3.20

Ref. katsottu 13.3.20

[The Role of Early Treatment in the Management of Axial Spondyloarthritis: Challenges and Opportunities.](#)

Mauro D, Forte G, Poddubnyy D, Ciccia F.

Rheumatol Ther. 2024 Feb;11(1):19-34. doi:

10.1007/s40744-023-00627-0. Epub 2023 Dec 18.

PMID: 38108992 [Free PMC article.](#) Otettu 13.3.24

[New onset heart failure in adolescents with inflammatory joint disease treated with TNF- \$\alpha\$  inhibitors: a case-based review.](#)

Mavrogeni S, Sapountzi E, Chiotopoulou K, Fotis L.

Rheumatol Int. 2024 Dec 18;45(1):4. doi:

10.1007/s00296-024-05750-x.

PMID: 39692771 Review. Otta M



Maxwell, J. R. *et al.* Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation. *Immunity* **43**, 739–750

(2015). Otettu 8.3.20

Ref. katsottu 26.3.20

[Emerging therapies for noninfectious uveitis: what may be coming to the clinics.](#)

Maya JR, Sadiq MA, Zapata LJ, Hanout M, Sarwar S, Rajagopalan N, Guinn KE, Sepah YJ, Nguyen QD. J Ophthalmol. 2014;2014:310329. doi:

10.1155/2014/310329. Epub 2014 Apr 24. Review.

Otettu 27.5.18

[Free PMC Article](#)

## [Similar articles](#)

### [Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter Study.](#)

Mazzanti C, Paroli M, Santoboni G, Addimanda O, Raffeiner B, Bezzi A, Visalli E, Celletti E, Farina A, Bernardi S, Larosa M, Andracco R, Del Medico P, Colella Molica AB, Giuggioli D, Lumetti F, Sandri G, Priora M, Serale F, Nucera V, Ometto F, Bravi E, Lo Gullo A, Scolieri P, Parisi S, Ravagnani V, Vitetta R, Marchetta A, Becciolini A, Angrisani C, De Simone M, Caccavalle R, Reta M, Magnani M, Mascella F, Foti R, Amato G, De Lucia F, Dal Bosco Y, Foti R, Di Penta M, Sabatini E, Del Biondo P, Girelli F, Camellino D, Bianchi G, Mansueto N, Smerilli G, Franchina V, Salvarani C, Ianniello A, Giampietro C, Di Donato E, Santilli D, Lucchini G, Arrigoni E, Platè I, Bruzzese V, Fusaro E, Ditto MC, Murgia D, Rovera G, Volpe A, Ferrero G, Adorni G, Molica FC, Ariani A.

*J Psoriasis Psoriatic Arthritis*. 2025 May 13:24755303251342503. doi:

10.1177/24755303251342503. Online ahead of print.

PMID: 40376617 [Free PMC article](#). [Otettu 31.7.25](#)

### [Treatment of Lamellar Ichthyosis in a 10-Year-Old Child With Secukinumab.](#)

Mazzetto R, Caroppo F, Milan E, Cassalia F, Fortina AB.

J Paediatr Child Health. 2025 Mar 28. doi:  
10.1111/jpc.70044. Online ahead of print.  
PMID: 40152134 Otettu 4.6.25

McAleer, J.P., and J.K. Kolls. 2011. Mechanisms  
controlling Th17 cytokine expression and host defense.  
*J. Leukoc. Biol.* 90:263–270. Otettu 20.9.20

**IL-17** and IFN-gamma-producing respiratory tissue  
resident memory CD4 T cells persist for decades in  
adults immunized as children with whole cell pertussis  
vaccines.

McCarthy KN, Hone S, McLoughlin RM, Mills KHG.  
J Infect Dis. 2024 Jan 30:jiae034. doi:  
10.1093/infdis/jiae034. Online ahead of print.

PMID: 38290045   Otettu 13.3.24

Can serum **interleukin-17** and **interleukin-10** levels predict response to biologic treatments in patients with rheumatoid **arthritis**?

McDonald S, Reed R, Baricevic-Jones I; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, Ling S, Plant D, Barton A.

Rheumatology (Oxford). 2019 Oct 1;58(10):1872-1873.

doi: 10.1093/rheumatology/kez147.

PMID: 31329971   Otettu 23.9.20

McDonald DR: TH17 deficiency in human disease. *J Allergy Clin Immunol* 2012;129: 1429–1435. Otettu 12.3.20

McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T, et al. TGF- $\beta$  and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell-mediated pathology. *Nat Immunol* 2007;8:1390–7. Otettu 9.3.16

McGeachy, M. J., and D. J. Cua. 2007. The link between IL-23 and Th17 cell-mediated immune pathologies. *Semin. Immunol.* 19: 372–376. Otettu 9.3.16

Matrix reboot: IL-17 signals CAFs to create a second tumor T cell checkpoint.

McGeachy MJ.

J Exp Med. 2022 Jun 6;219(6):e20220444. doi: 10.1084/jem.20220444. Epub 2022 May 18.

PMID: 35583818 [Free article.](#) Otettu 27.8.22

McGeachy MJ, Cua DJ. Th17 cell differentiation: the long and winding road. Immunity 2008;28:445–53.

Otettu 9.3.16

McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM, McClanahan TK, O'Shea JJ, Cua DJ: The interleukin 23 receptor is essential for the terminal differentiation of interleukin

17-producing effector T helper cells in vivo. Nat Immunol 2009, 10:314-324. Otettu 9.3.16

McGeachy MJ. GM-CSF: the secret weapon in the TH17 arsenal. Nat Immunol 2011;12:521–2. Otettu 9.3.16

The role of **IL-17A** in axial spondyloarthritis and psoriatic **arthritis**: recent advances and controversies.

McGonagle DG, McInnes IB, Kirkham BW, Sherlock J, Moots R.

Ann Rheum Dis. 2019 Sep;78(9):1167-1178. doi: 10.1136/annrheumdis-2019-215356. Epub 2019 Jul 5. PMID: 31278139 Otettu 23.9.20

Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis.

McGonagle D, Watad A, Sharif K, Bridgewood C.

Front Immunol. 2021 Mar 19;12:614255. doi:  
10.3389/fimmu.2021.614255. eCollection 2021.  
PMID: 33815371 **Free PMC article.** Otettu 31.8.22

[Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy.](#)

McGovern JL, Nguyen DX, Notley CA, Mauri C, Isenberg DA, Ehrenstein MR.

**Arthritis Rheum.** 2012 Oct;64(10):3129-38. doi:  
10.1002/art.34565.

PMID:

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)



**Secukinumab** versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.

McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, Masmitja JG, Goupille P, T, Gottlieb AB, Martin R, Ding K, Pellet P, Mpofu S, Pricop L; EXCEED Study Group.

Lancet. 2020 May 9;395(10235):1496-1505. doi: 10.1016/S0140-6736(20)30564-X.

Otettu 30.11.22

McInnes I, Sieper J, Braun J, et al. Antiinterleukin 17A monoclonal antibody & secukinumab reduces signs and symptoms of psoriatic arthritis in a 24-week multicenter, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2011; 63 (Supl):S306. ei löydy  
Ei oteta

McInnes, I. B. et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet doi:10.1016/S0140-6736(15)61134-5 Otettu 9.3.16

[Efficacy and safety of \*\*secukinumab\*\*, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.](#)

McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, Dahmen G, Wollenhaupt J, Schulze-Koops H, Kogan J, Ma S, Schumacher MM, Bertolino AP, Hueber W, Tak PP.

Ann Rheum Dis. 2014 Feb;73(2):349-56. doi:

Otettu 3.2.16

McInnes IB MP, Kirkham B, Kavanaugh A, et al. 2014.  
Secukinumab, a human anti-interleukin-17A monoclonal antibody, improves active psoriatic arthritis: 24-week efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study using subcutaneous dosing. Arthritis Rheumatol. 66:3529–40  
Abstrakti. Ei oteta

McInnes, I.B. et al. FUTURE 2 Study Group (2015)  
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386, 1137–1146  
Otettu 9.3.16

Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes.

McInnes IB, Sawyer LM, Markus K, LeReun C, Sabry-Grant C, Helliwell PS.

RMD Open. 2022 Mar;8(1):e002074. doi: 10.1136/rmdopen-2021-002074.

PMID: 35321874 [Free PMC article.](#) Otettu 26.8.22

I. B. McInnes, P. Nash, C. Ritchlin, H. Thom, S. Kanters, and E. Palaka, "THU0437 secukinumab for the treatment of psoriatic arthritis: comparative effectiveness results versus licensed biologics and apremilast from a network meta-analysis," *Annals of the Rheumatic Diseases*, vol. 75, Suppl 2, pp. 348-349, 2016. On abstrakti. Ei otet.

**Secukinumab** sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.

McInnes IB, Mease PJ, Ritchlin CT, Rahman P, Gottlieb AB, Kirkham B, Kjekshus R, Delichia EM, Pricop L, Mponu S.

Rheumatology (Oxford). 2017 Nov 1;56(11):1993-2003.

Updated 27.5.18

Ref. katsottu 9.3.20

**Free PMC Article**

[Similar articles](#)

Pyoderma gangrenosum treated with **secukinumab**: A case report.

McPhie ML, Kirchhof MG.

SAGE Open Med Case Rep. 2020 Jul  
17;8:2050313X20940430. doi:  
10.1177/2050313X20940430. eCollection 2020.  
PMID: 32733679 Otettu 20.9.20

Mease P, McInnes IB. Secukinumab: a new treatment  
option for psoriatic arthritis. Rheumatol Ther.  
2016;3(1):5–29. Otettu 12.3.20

Ref. katsottu 19.3.20

Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J,  
Hall S, et al. Secukinumab in the treatment of psoriatic  
arthritis: efficacy and safety results through 3 years from  
the year 1 extension of the randomised phase III

FUTURE 1 trial. RMD Open. 2018;4(2):e000723. Otettu 2.3.20

Ref. katsottu 12.3.20

**Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study.**

Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pellet P, Delicha EM, Pricop L, Mpofu S; FUTURE 1 study group.

ACR Open Rheumatol. 2020 Jan;2(1):18-25. doi: 10.1002/acr2.11097. Epub 2019 Nov 14.

PMID: 31943974 Free PMC article. Otettu 4.2.21

**Up-dosing of secukinumab to 2-weekly results in superior efficacy in patients with severe psoriasis weighing 90 kg or more: a real-world prospective observational study.**

McGuire N, Elamin S, Gough P, Cooke N, McGrath C, McKenna K, O'Kane D.

Clin Exp Dermatol. 2023 Feb 9;llad035. doi: 10.1093/ced/llad035. Online ahead of print. PMID: 36755389 Otta M

[Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.](#)

McInnes IB, Mease PJ, Schett G, Kirkham B, Strand V, Williams N, Fox T, Pricop L, Jugl SM, Gandhi KK; FUTURE 2 Study Group.

Arthritis Res Ther. 2018 Jun 7;20(1):113. doi: Otettu 3.9.18



## **Free PMC Article**

### **Similar articles**

Mease PJ MI, Kirkham B, Kavanaugh A, et al. 2014. Secukinumab, a human anti–interleukin-17A monoclonal antibody, improves active psoriatic arthritis and inhibits radiographic progression: efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study. *Arthritis Rheumatol.* 66:3529–40  
Abstrakti. ei oteta

**Interleukin-17A Serves a Priming Role in Autoimmunity by Recruiting IL-1 $\beta$ -Producing Myeloid Cells that Promote Pathogenic T Cells.**

McGinley AM, et al. *Immunity*. 2020. PMID: 32023490  
Free article. Otettu 7.9.22

14-3-3 $\zeta$ -TRAF5 axis governs **interleukin-17A** signaling.

McGowan J, Peter C, Kim J, Popli S, Veerman B,  
Saul-McBeth J, Conti H, Pruett-Miller SM, Chattopadhyay  
S, Chakravarti R.

*Proc Natl Acad Sci U S A*. 2020 Oct

6;117(40):25008-25017. doi:

10.1073/pnas.2008214117. Epub 2020 Sep 23.

PMID: 32968020 Free PMC article. Otettu 3.9.22

[Combined blockade of IL-17A and IL-17F may prevent the development of experimental colitis.](#)

McLean LP, Cross RK, Shea-Donohue T.  
Immunotherapy. 2013 Sep;5(9):923-5. doi:  
10.2217/imt.13.87.

PMID:

23998727 Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

[\*\*Secukinumab\*\*, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis \(FUTURE 2\): a randomised, double-blind, placebo-controlled, phase 3 trial.](#)

McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S; FUTURE 2 Study Group.

Lancet. 2015 Sep 19;386(9999):1137-46. doi:

[Similar articles](#)

## Otettu 9.3.16

10. McInnes IB, Mease PJ, Ritchlin CT, Rahman P, Gottlieb AB, Kirkham B, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology (Oxford). 2017;56(11):1993–2003. Otettu 6.2.20.

McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006;27(1):17–23. Otettu 9.3.16

[Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis.](#)

Mease PJ, Armstrong AW.

Drugs. 2014 Mar;74(4):423-41.. Review.

[Free PMC Article](#)

[Similar articles](#)

Otettu 3.2.16

.

[Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis.](#)

Mease PJ.

Curr Opin Rheumatol. 2015 Mar;27(2):127-33.

[Similar articles](#)

.

Otettu 3.2.16

Effectiveness of 6-month Use of **Secukinumab** in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.

Mease PJ, Blachley T, Dube B, McLean RR, Kim N, Hur P, Ogdie A.

J Rheumatol. 2022 Jul;49(7):700-706. doi: 10.3899/jrheum.211033. Epub 2022 Apr 15.

PMID: 35428716 [Free article.](#) Otettu 26.8.22

.

### [Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.](#)

Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu

N Engl J Med. 2015 Oct;373(14):1329-39. doi:

Otettu 9.3.16

[Similar articles](#)

[Erratum to: \*\*Secukinumab\*\*: A New Treatment Option for Psoriatic Arthritis.](#)

Mease P, McInnes IB.

Rheumatol Ther. 2016 Dec;3(2):363. No abstract available.

PMID:

27747580 Otettu 27.5.18

[Free PMC Article](#)

[Similar articles](#)

[Secukinumab: A New Treatment Option for Psoriatic Arthritis.](#)

Mease P, McInnes IB.

Rheumatol Ther. 2016 Jun;3(1):5-29. doi: Review.  
Erratum in: [Rheumatol Ther. 2016 Jul 25;:](#).

Otettu 27.5.18

**Free PMC Article**

[Similar articles](#)

**Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.**

Mease P, van der Heijde D, Landewé R, Mpofu S, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Meiser K, Radies A, Pricop L, Abrams K.

Ann Rheum Dis. 2018 Jun;77(6):890-897. doi: Otettu 27.5.18

**Free Article**



## Similar articles

Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with **secukinumab** therapy in patients with psoriatic arthritis.

Mease P, van der Heijde D, Kirkham B, Schett G, Orbai AM, Ritchlin C, Merola JF, Pricop L, James DA, Zhu X, Ligozio G.

Arthritis Res Ther. 2022 Dec 28;24(1):283. doi: 10.1186/s13075-022-02944-1.

PMID: 36578042 [Free PMC article.](#) Otettu 12.6.23

**Secukinumab** in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial.

Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pellet P, Delicha EM, Mpofu S, Pricop L.

RMD Open. 2018 Aug 13;4(2):e000723. doi: Otettu 3.9.18

[Similar articles](#)

Comparative effectiveness of **secukinumab** and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison.

Mease P, Choy E, Nash P, Kalyvas C, Hunger M, Pricop L, Gandhi KK, Jugl SM, Thom H.

Eur J Rheumatol. 2018 Jul 1;6(3):113-121. doi: Otettu 28.2.20

**Free PMC Article**

New treatments for PsA meet targeted therapy goals.  
Mease PJ.

Nat Rev Rheumatol. 2021 Feb;17(2):77-78. doi:  
10.1038/s41584-020-00561-3.  
PMID: 33328615 Otettu 2.9.22

Emerging Immunomodulatory Therapies and New  
Treatment Paradigms for Axial Spondyloarthritis.

Mease P.

Curr Rheumatol Rep. 2019 Jun 6;21(7):35. doi:  
Otettu 28.2.20

Comparative Effectiveness of Bimekizumab and **Secukinumab** in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.

Mease PJ, Warren RB, Nash P, Grouin JM, Lyris N, Willems D, Taieb V, Eells J, McInnes IB.

Rheumatol Ther. 2024 Mar 6. doi:

10.1007/s40744-024-00652-7. Online ahead of print.

PMID: 38446397 **Free article.** **Otettu 29.5.24**

**Secukinumab** Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study.

Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pellet P, Delicha EM, Pricop L, Mpofu S; FUTURE 1 study group.

ACR Open Rheumatol. 2020 Jan;2(1):18-25. doi: 10.1002/acr2.11097. Epub 2019 Nov 14.

**Free PMC Article** **Otettu 28.2.20**

**REf. katsottu 23.3.20**

**Secukinumab** provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study.

Mease PJ, Landewé R, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Readie A, Mpofu S, Delicha EM, Pricop L, van der Heijde D.

RMD Open. 2021 Jul;7(2):e001600. doi: 10.1136/rmdopen-2021-001600.

PMID: 34330846 [Free article](#). Otettu 8.8.21

A review of T helper **17** cell-related cytokines in serum and saliva in periodontitis.

Medara N, Lenzo JC, Walsh KA, Reynolds EC, Darby IB, O'Brien-Simpson NM.

Cytokine. 2021 Feb;138:155340. doi: 10.1016/j.cyto.2020.155340. Epub 2020 Nov 2.

PMID: 33144024 Review. Otettu 30.11.22

[\*\*Secukinumab \(Cosentyx\) for psoriasis.\*\*](#)

[No authors listed]

Med Lett Drugs Ther. 2015 Mar 30;57(1465):45-7. No abstract available.

PMID:

25853578 ei ole M Ei oteta

[Similar articles](#)

Lack of reactivation of tuberculosis in patients with psoriasis treated with **secukinumab** in a real-world setting of latent tuberculosis infection.

Megna M, Patruno C, Bongiorno MR, Gambardella A, Guarneri C, Foti C, Lembo S, Loconsole F, Fabbrocini G. J Dermatolog Treat. 2022 Aug;33(5):2629-2633. doi: 10.1080/09546634.2022.2062280. Epub 2022 Apr 11. PMID: 35385362 Otettu 26.8.22

**Secukinumab:** a potential safe option in psoriasis patients affected by multiple sclerosis?

Megna M, Marasca C, Ruggiero A, Camela E, Fabbrocini G.

Int J Dermatol. 2020 Aug;59(8):e308-e309. doi: 10.1111/ijd.14902. Epub 2020 May 2. PMID: 32358963 Otettu 20.9.20

Hepatitis Virus Reactivation in Patients with Psoriasis Treated with **Secukinumab** in a Real-World Setting of Hepatitis B or Hepatitis C Infection.

Megna M, Patruno C, Bongiorno MR, Gambardella A, Guarneri C, Romita P, Raimondo A, Loconsole F, Fabbrocini G.

Clin Drug Investig. 2022 Jun;42(6):525-531. doi: 10.1007/s40261-022-01163-5. Epub 2022 May 28. PMID: 35633470 [Free PMC article](#). Otettu 26.8.22

[Asymptomatic microscopic colitis induced by secukinumab.](#)

Megna M, De Lucia M, Fornaro L, Tommasino N, Castiglione F, Cacciapuoti S, Testa A.

JAAD Case Rep. 2024 Apr 9;48:11-13. doi: 10.1016/j.jdcr.2024.03.017. eCollection 2024 Jun. PMID: 38745828 [Free PMC article](#). Otettu 29.5.24



Real-life efficacy and safety of **secukinumab** in elderly patients with psoriasis over a 2-year period.

Megna M, Camela E, Cinelli E, Fabbrocini G.

Clin Exp Dermatol. 2020 May 3. doi: 10.1111/ced.14258.

Online ahead of print.

PMID: 32363583 Otettu 20.9.20

Megna M, Balato A, Napolitano M, et al. Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and

small molecules”. Clin Rheumatol. 2018;37:1739–1741.

Otettu 27.3.20

Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role?

Megna M, Caiazzo G, Parisi M, Ruggiero A, Capasso G, Mascolo M, Russo D, Gallo L, Fabbrocini G, Napolitano M, Patruno C.

Clin Exp Dermatol. 2021 Dec 4. doi: 10.1111/ced.15052.

Online ahead of print.

PMID: 34862807 Otettu 3.3.22

Effectiveness and safety of **secukinumab** in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study.

Megna M, Di Costanzo L, Argenziano G, Balato A, Colasanti P, Cusano F, Galluccio AG, Gambardella A, Lembo S, Mozzillo R, Scotto Di Luzio G, Fabbrocini G, Balato N.

Expert Opin Biol Ther. 2019 Aug;19(8):855-861. doi:

Otettu 28.2.20

Ref. katsottu 25.3.20

The risk of candidiasis during treatment with bimekizumab for the management of plaque psoriasis: a 16-week multicentre real-world experience – IL PSO (Italian Landscape Psoriasis)

Megna, Matteo

Clinical and experimental dermatology, 2025-01 Otta M

QuantiFERON TB-gold conversion rate among psoriasis patients under biologics: a 9-year retrospective study.

Megna M, Ferrillo M, Ruggiero A, Cinelli E, Gallo L, Fabbrocini G.

Int J Dermatol. 2020 Sep 29. doi: 10.1111/ijd.15217.

Otettu 30.11.22

Paradoxical gastrointestinal effects of **interleukin-17** blockers.

Mehta P, Lawrence A, Aggarwal A.

Ann Rheum Dis. 2020 Sep 28;annrheumdis-2020-218719. doi:

10.1136/annrheumdis-2020-218719. Online ahead of print.

PMID: 32988844    Otettu 3.9.22

146.

[IL-17A production in human psoriatic blood and lesions by CD146+ T cells.](#)

Mehta NN, Dagur PK, Rose SM, Naik HB, Stansky E, Doveikis J, Biancotto A, Playford MP, McCoy JP Jr.

J Invest Dermatol. 2015 Jan;135(1):311-4. doi:

10.1038/jid.2014.317. Epub 2014 Jul 24. No abstract available.

PMID:

25058615 Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Differential Changes in Inflammatory Mononuclear  
Phagocyte and T Cell Profiles within Psoriatic Skin  
during Treatment with Guselkumab versus  
**Secukinumab.**

Mehta H, Mashiko S, Angsana J, Rubio M, Hsieh YM,  
Maari C, Reich K, Blauvelt A, Bissonnette R, Muñoz-Elías  
EJ, Sarfati M.

J Invest Dermatol. 2021 Jan

29:S0022-202X(21)00032-4. doi:

10.1016/j.jid.2021.01.005. Online ahead of print.

J Invest Dermatol. 2021 Jul;141(7):1707-1718.e9. doi:

10.1016/j.jid.2021.01.005. Epub 2021 Jan 30.

PMID: 33524368

PMID: 33524368 Otettu 4.2.21

Y. Mei, F. Pan, J. Gao et al., “Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis,” *Clinical Rheumatology*, vol. 30, no. 2, pp. 269–273, 2011.  
Otettu 9.3.16

Long-term **secukinumab** efficacy in patients with moderate to severe hidradenitis suppurativa: A retrospective single-centre case series (23 patients).  
Melgosa Ramos FJ, et al. *J Eur Acad Dermatol Venereol*. 2022. PMID: 36268711   Otta M Myöhemmin

[Progress in spondylarthritis. Immunopathogenesis of spondyloarthritis: which cells drive disease?](#)

Melis L, Elewaut D.

**Arthritis Res Ther.** 2009;11(3):233. doi:  
10.1186/ar2722. Epub 2009 Jun 25. Review.

PMID:

19591637 Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

M. Mellett, P. Atzei, A. Horganetal.,  
“Orphan receptor IL-17RD tunes IL-17A signalling  
and is required for neutrophilia,” *Nature*  
*Communications*, vol. 3, article no. 1119, 2012.

Otettu 15.3.20

Ref. katsottu 19.3.20

Melnik BC, John SM, Chen W, Plewig G. T helper 17 cell/regulatory T-cell imbalance  
in hidradenitis suppurativa/acne inversa: the link to hair follicle dissection, obesity,  
smoking and autoimmune comorbidities. *Br J Dermatol.* 2018;179(2):260-272.

[Biologic drugs in hidradenitis suppurativa: what does the GP have to know? A narrative review.](#)

Mendes-Bastos P, Benhadou F, Venturini M,  
Molina-Levy A, Thomas N, Alarcon I, Bechara FG.  
Front Med (Lausanne). 2024 Jul 8;11:1403455. doi:  
10.3389/fmed.2024.1403455. eCollection 2024.  
PMID: 39040895 [Free PMC article](#). Review. Otettu  
27.9.24

[Atopic Dermatitis as a Paradoxical Effect of  
\*\*Secukinumab\*\* for the Treatment of Psoriasis.](#)

Mendes Roncada EV, Brambilla VR, Freitas Filitto B,  
Genta MP, Morgado de Abreu MAM.



Case Rep Dermatol. 2021 Jul 9;13(2):336-339. doi:  
10.1159/000513467. eCollection 2021 May-Aug.  
PMID: 34326727 [Free PMC article](#). Otettu 8.8.21

**Interleukin-17:** A potential therapeutic target in  
COVID-19.

Mendoza VMM.

J Infect. 2020 Aug;81(2):e136-e138. doi:  
10.1016/j.jinf.2020.05.072. Epub 2020 Jun 3.  
PMID: 32504739 [Free PMC article](#). Otettu 4.9.22

Increased levels of pathogenic Th17 cells and  
diminished function of CD69+ Treg lymphocytes in  
patients with overweight.

Mendoza-Pérez A, Vitales-Noyola M, González-Baranda L, Álvarez-Quiroga C, Hernández-Castro B, Monsiváis-Urenda A, Baranda L, Niño-Moreno P, Hurtado G, Sánchez-Gutiérrez R, González-Amaro R.  
*Clin Exp Immunol*. 2022 Jul 22;209(1):115-125. doi: 10.1093/cei/uxac051.  
PMID: 35576512   Otta Myöhemmin M

Menon B, Gullick NJ, Walter GJ, Rajasekhar M, Garrood T, Evans HG, et al. Interleukin-17CD8 T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. *Arthritis Rheumatol* 2014; 66:1272–81.  
Otettu 9.3.16

## **Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities.**

Menter A, Krueger GG, Paek SY, Kivelevitch D, Adamopoulos IE, Langley RG.

*Dermatol Ther (Heidelb)*. 2021 Apr;11(2):385-400. doi: 10.1007/s13555-021-00483-2. Epub 2021 Jan 29.

PMID: 33512665 [Free PMC article](#). Review. *Otettu* 31.8.22

8. Menter A, Cather JC, Jarratt M, et al. efficacy of secukinumab on moderate-to-severe plaque psoriasis affecting different body regions: a pooled analysis of four phase 3 studies. *Dermatol Ther (Heidelb)*. 2016;6:639–647 *Otettu* 6.3.20

[Switching biologics in the treatment of psoriatic arthritis.](#)

Merola JF, Lockshin B, Mody EA.

Semin Arthritis Rheum. 2017 Aug;47(1):29-37. doi: 10.1016/j.semarthrit.2017.02.001. Epub 2017 Feb 8.

Review.

PMID:

28363434 Otettu 27.5.18

[Free Article](#)

[Similar articles](#)

Effect of **Secukinumab** on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications.

Merola JF, McInnes IB, Deodhar AA, Dey AK, Adamstein NH, Quebe-Fehling E, Aassi M, Peine M, Mehta NN. Rheumatol Ther. 2022 Jun;9(3):935-955. doi: 10.1007/s40744-022-00434-z. Epub 2022 Mar 19. PMID: 35305260 **Free PMC article.** **Otettu 26.8.22**

Real-world use of biologic and targeted synthetic disease-modifying antirheumatic drugs in US patients with psoriatic arthritis: Persistence, patient characteristics associated with discontinuation, and dosing patterns.

Merola JF, Welby S, Roque H, Song J, Pilipczuk O, Lu C, Walsh JA.

J Manag Care Spec Pharm. 2025 Aug;31(8):808-821. doi: 10.18553/jmcp.2025.31.8.808. PMID: 40704853 **Otettu 28.7.25**

Meroni M, Generali E, Guidelli GM, Parodi M, Cutolo M, Selmi C. THU0319 Overall safety of 7-week secukinumab exposure during pregnancy in women with psoriatic arthritis. Annals of the Rheumatic Diseases. 2018; 77(Suppl 2):377-8. Otettu 6.3.20

Abstrakti. Ei oteta.

[Residual metabolic burden in young psoriasis patients successfully treated with biologics.](#)

Merzel Šabović EK, Kraner Šumenjak T, Janić M.

Arch Dermatol Res. 2024 Sep 27;316(9):647. doi:

10.1007/s00403-024-03403-4.

PMID: 39331218 [Free PMC article.](#) Otettu 24.10.24

Arterial function is preserved in successfully treated patients with psoriasis vulgaris.

Merzel Šabović EK, Kraner Šumenjak T, Božič Mijovski M, Janić M.

Sci Prog. 2024 Oct-Dec;107(4):368504241287893. doi: 10.1177/00368504241287893.

PMID: 39403781 [Free PMC article.](#) Otettu 24.10.24

The dark side of the moon: the immune-mediated adverse events of IL-17A/IL-17R inhibition.

Messina F, Piaserico S.

J Dermatolog Treat. 2022 Aug;33(5):2443-2454. doi: 10.1080/09546634.2022.2062281. Epub 2022 Apr 8.

PMID: 35393910 Review. ei ole M

Mesturini R, Gigliotti CL, Orilieri E, et al. Differential induction of IL-17, IL-10, and IL-9 in human T helper cells by B7h and B7.1. Cytokine. 2013;64(1):322-330.  
Otettu 9.3.16

.

[Serum and synovial fluid levels of \*\*interleukin-17\*\* in correlation with disease activity in patients with RA.](#)

Metawi SA, Abbas D, Kamal MM, Ibrahim MK.  
Clin Rheumatol. 2011 Sep;30(9):1201-7. doi: 29.  
PMID:

Otettu 9.3.16

[Similar articles](#)



Meyer Zu Horste, G. *et al.* RBPJ controls development of pathogenic Th17 cells by regulating IL-23 receptor expression. *Cell Rep.* **16**, 392–404 (2016). Otettu 27.3.20

Ref. katsottu 28.3.20

Miao, T., Raymond, M., Bhullar, P., Ghaffari, E., Symonds, A. L., Meier, U. C., *et al.* (2013). Early growth response gene-2 controls IL-17 expression and Th17 differentiation by negatively regulating Batf. *J. Immunol.* **190**, 58–65. doi: 10.4049/jimmunol.1200868  
Otettu 9.3.16

Miao, J. *et al.* Frequencies of circulating IL-17-producing CD4<sup>+</sup>CD161<sup>+</sup> T cells and CD4<sup>+</sup>CD161<sup>+</sup> T cells correlate with disease activity in

rheumatoid arthritis. *Mod. Rheumatol.* 24, 265–570 (2014). Otettu 20.9.20

IL-17A in the Psoriatic Patients' Serum and Plaque Scales as Potential Marker of the Diseases Severity and Obesity.

Michalak-Stoma A, Bartosińska J, Kowal M, Raczkiewicz D, Krasowska D, Chodorowska G.

*Mediators Inflamm.* 2020 Jun 5;2020:7420823. doi: 10.1155/2020/7420823. eCollection 2020.

PMID: 32587472 [Free PMC article.](#) Otettu 4.9.22

Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating

**secukinumab** treatment: routine care data from 13 registries in the EuroSpA collaboration.

Michelsen B, Lindström U, Codreanu C, Ciurea A, Zavada J, Loft AG, Pombo-Suarez M, Onen F, Kvien TK, Santos MJ, Iannone F, Hokkanen AM, Gudbjornsson B, Askling J, Ionescu R, Nissen MJ, Pavelka K, Sanchez-Piedra C, Akar S, Sexton J, Tomsic M, Santos H, Sebastiani M, Österlund J, Geirsson AJ, Macfarlane G, van der Horst-Bruinsma I, Georgiadis S, Brahe CH, Ørnbjerg LM, Hetland ML, Østergaard M.

RMD Open. 2020 Sep;6(3):e001280. doi: 10.1136/rmdopen-2020-001280.

PMID: 32950963 [Free PMC article](#). Otettu 13.12.20

Real-world 6 and 12-month Drug Retention, Remission and Response Rates of **Secukinumab** in 2,017 Psoriatic Arthritis patients in 13 European Countries.

Michelsen B, Georgiadis S, Di Giuseppe D, Loft AG, Nissen MJ, Iannone F, Pombo-Suarez M, Mann H, Z, Eklund KK, Kvien TK, Santos MJ, Gudbjornsson B, Codreanu C, Yilmaz S, Wallman JK, Brahe CH, Möller B, Favalli EG, Sánchez-Piedra C, Nekvindova L, Tomsic M, Trokovic N, Kristianslund EK, Santos H, Löve TJ, Ionescu

R, Pehlivan Y, Jones GT, van der Horst-Bruinsma I, Ørnbjerg LM, Østergaard M, Hetland ML.

Arthritis Care Res (Hoboken). 2021 Jan 18. doi: 10.1002/acr.24560. Online ahead of print.

PMID: 33460531 Otettu 4.2.21

Incidence of therapy switch in patients with moderate to severe palmoplantar psoriasis treated with anti-IL 17 and anti-IL 23 monoclonal antibodies: a retrospective observational study.

Michelucci A, Manzo Margiotta F, Fanetti F, Chittano B, Fidanzi C, Panduri S, Morganti R, Romanelli M, Dini V.

Expert Opin Biol Ther. 2025 May;25(5):1-6. doi: 10.1080/14712598.2025.2480756. Epub 2025 Mar 20.

PMID: 40111118 Otta M

Effectiveness of **secukinumab** versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort.

Micheroli R, Tellenbach C, Scherer A, Bürki K, Niederman K, Nissen MJ, Zufferey P, Exer P, Möller B, Kyburz D, Ciurea A.

Ann Rheum Dis. 2020 Sep;79(9):1203-1209. doi: 10.1136/annrheumdis-2019-215934. Epub 2020 Jun 24. PMID: 32581090    Otettu 20.9.20

PAF-R on activated T cells: Role in the IL-23/Th17 pathway and relevance to multiple sclerosis.

Midgley A, Barakat D, Braitch M, Nichols C, Nebozhyn M, Edwards LJ, Fox SC, Gran B, Robins RA, Showe LC, Constantinescu CS.

Immunobiology. 2021 Jan;226(1):152023. doi: 10.1016/j.imbio.2020.152023. Epub 2020 Nov 13. PMID: 33278709    Otettu 30.11.22

[Expression of IL-17, IL-23 and their receptors in minor salivary glands of patients with primary Sjögren's syndrome.](#)

Mieliauskaite D, Dumalakiene I, Rugiene R, Mackiewicz Z.

Clin Dev Immunol. 2012;2012:187258. doi: 10.1155/2012/187258. Epub 2012 Jan 3.

PMID:

22262980

[Free PMC Article](#)

[Similar articles](#)

Select item 22260068489. Otettu 3.2.16

Differences in biologics for treating ankylosing spondylitis: the contribution of network meta-analysis.

Migliore A, Gigliucci G, Integlia D, Isailovic N, Frediani B. Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):56-64. doi: 10.26355/eurrev\_202101\_24347.

PMID: 33506892    ei ole M

Variable roles of **interleukin-17F** in different cancers.

Mikkola T, Almahmoudi R, Salo T, Al-Samadi A.

BMC Cancer. 2022 Jan 11;22(1):54. doi:

10.1186/s12885-021-08969-0.

PMID: 35012470 **Free PMC article.**    Otettu 27.8.22

Miletic M, Stojanovic R, Pajic O et al (2012) Serum interleukin-17 & nitric oxide levels in patients with primary Sjögren's syndrome. Indian J Med Res

135(4):513–519

Otettu 9.3.16

[Targeting the IL-17A pathway for therapy in early-stage tendinopathy.](#)

Millar NL, McInnes IB, Kolbinger F, Raulf F, Akbar M, Li Y, Beckmann N, Accart N, Leupin O, Calonder C, Schieker M, Kneissel M, Bruns C, Siegel RM, Weber E.

RMD Open. 2025 Feb 23;11(1):e004729. doi: 10.1136/rmdopen-2024-004729.

PMID: 39988349 [Free PMC article.](#) Otettu 4.6.25

Plasma **interleukin**-23 and circulating IL-17A+IFN $\gamma$ + ex-Th17 cells predict opposing outcomes of anti-TNF therapy in rheumatoid arthritis.

Millier MJ, Fanning NC, Frampton C, Stamp LK, Hessian PA.

Arthritis Res Ther. 2022 Feb 26;24(1):57. doi: 10.1186/s13075-022-02748-3.

PMID: 35219333 [Free PMC article.](#) Otettu 27.8.22



Mills KH. Induction, function and regulation of IL-17-producing T cells. Eur J Immunol 2008;38:2636–49. Otettu 9.3.16

Milner, J. D., Brenchley, J. M., Laurence, A., Freeman, A. F., Hill, B. J., Elias, K. M., Kanno, Y. et al., Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008. 452: 773–776. Otettu 9.3.16

Milner JD. IL-17 producing cells in host defense and atopy. Curr Opin Immunol 2011;23(6):784–8. Otettu 9.3.16

## **Interleukin-17** in Chronic Inflammatory Neurological Diseases.

Milovanovic J, Arsenijevic A, Stojanovic B, Kanjevac T, Arsenijevic D, Radosavljevic G, Milovanovic M, Arsenijevic N.

Front Immunol. 2020 Jun 3;11:947. doi:

10.3389/fimmu.2020.00947. eCollection 2020.

PMID: 32582147 **Free PMC article.** Otettu 4.9.22

## Trauma-Induced Psoriatic Arthritis: A Deep Köbner Phenomenon.

Mima Y, Yamamoto M, Nishida N, Norimatsu Y, Iozumi K.

Case Rep Dermatol. 2025 Apr 3;17(1):137-142. doi:

10.1159/000545694. eCollection 2025 Jan-Dec.

PMID: 40342834 **Free PMC article.** Otettu 31.7.25

## **Interleukin-17** Cytokines and Receptors: Potential Amplifiers of Tendon Inflammation.

Mimpen JY, Snelling SJB, Carr AJ, Dakin SG.

Front Bioeng Biotechnol. 2021 Dec 23;9:795830. doi: 10.3389/fbioe.2021.795830. eCollection 2021.

PMID: 35004653 [Free PMC article.](#) Otettu 27.8.22

## **Interleukin-17A** Causes Osteoarthritis-Like Transcriptional Changes in Human Osteoarthritis-Derived Chondrocytes and Synovial Fibroblasts *In Vitro*.

Mimpen JY, Baldwin MJ, Cribbs AP, Philpott M, Carr AJ, Dakin SG, Snelling SJB.

Front Immunol. 2021 May 12;12:676173. doi: 10.3389/fimmu.2021.676173. eCollection 2021.

PMID: 34054865 [Free PMC article.](#) Otettu 30.8.22

IL-18 binding protein suppresses IL-17-induced osteoclastogenesis and rectifies type 17 helper T cell / regulatory T cell imbalance in rheumatoid arthritis.

Min HK, Kim S, Lee JY, Kim KW, Lee SH, Kim HR.

J Transl Med. 2021 Sep 16;19(1):392. doi: 10.1186/s12967-021-03071-2.

PMID: 34530864 [Free PMC article](#). Otettu 29.8.22

Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure.

Min HK, Kim HR, Lee SH, Hong YS, Kim MY, Park SH, Kang KY.

Rheumatology (Oxford). 2021 Dec 1;60(12):5743-5752.

doi: 10.1093/rheumatology/keab245.

PMID: 33725088 Otettu 30.11.22

Clinical Efficacy of Alternative TNF Inhibitor and **Secukinumab** Between Primary Non-Responder and Secondary Non-Responder of Prior TNF Inhibitor in Ankylosing Spondylitis.

Min HK, Kim HR, Lee SH, Hong YS, Kim MY, Park SH, Kang KY.

Mod Rheumatol. 2022 Feb 2;roac005. doi: 10.1093/mr/roac005. Online ahead of print. PMID: 35107167 Otettu 3.3.22

Development of pemphigus vegetans and exacerbation of pemphigus foliaceus after **secukinumab** loading in a patient with complicated generalized pustular psoriasis and pyoderma gangrenosum.

Minai L, et al. J Dermatol. 2022. PMID: 36052669 Otta M Otta myöhemmin

**Risk of fungal infection in patients with psoriasis receiving biologics: A retrospective single-center cohort study**

Minami, Yoshihito ; Hiruma, Junichiro ; Harada, Kazuharu ; Fujimori, Kazuki ; Suzuki, Risa ; Mori, Miho ; Okura, Masahiro ; Abe, Namiko ; Harada, Kazutoshi ; Okubo, Yukari  
Journal of the American Academy of Dermatology, 2025-01, Vol.92 (1), p.108-115 Otta  
M

Minegishi, Y., M. Saito, M. Nagasawa, H. Takada, T. Hara, S. Tsuchiya, K. Agematsu, M. Yamada, N. Kawamura, T. Ariga, et al. 2009. Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome. *J. Exp. Med.* 206:1291–1301. Otettu 12.3.20

Ref. ei katsot

[Olfactory-Related Adverse Events: An Analysis of the Food and Drug Administration Adverse Events Reporting System.](#)

Minutello KM, Lofgren DH, Lenkeit CP, Emmer E, Santiago Rivera O, Hasan MS, Downs A.

Otolaryngol Head Neck Surg. 2023 Dec 29. doi: 10.1002/ohn.631. Online ahead of print.

PMID: 38156529   Otta M

.

[Are T cells in rheumatoid synovium aggressors or bystanders?](#)

Miossec P.

Curr Opin Rheumatol. 2000 May;12(3):181-5. Review.

PMID:

10803746   Otettu 9.3.16

[Similar articles](#)

[Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy.](#)

Miossec P.

**Arthritis Rheum.** 2003 Mar;48(3):594-601. Review. No

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

.

[IL-17 in rheumatoid arthritis: a new target for treatment or just another cytokine?](#)

Miossec P.

**Joint Bone Spine.** 2004 Mar;71(2):87-90. No abstract available.

PMID:

Otettu 9.3.16

[Similar articles](#)



[Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified.](#)

Miossec P.

**Arthritis Rheum.** 2007 Jul;56(7):2111-5. Review. No abstract available.

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

Select item 17569750974.

[Diseases that may benefit from manipulating the Th17 pathway.](#)

Miossec P.

**Eur J Immunol.** 2009 Mar;39(3):667-9. doi: Otettu 3.2.16

[Free Article](#)

## [Similar articles](#)

### [IL-17 and Th17 cells in human inflammatory diseases.](#)

Miossec P.

Microbes Infect. 2009 Apr;11(5):625-30. d 14. Review.

PMID:

Otettu 9.3.16

## [Similar articles](#)

.

### [Interleukin-17 and type 17 helper T cells.](#)

Miossec P, Korn T, Kuchroo VK.

N Engl J Med. 2009 Aug 27;361(9):888-98. doi:

Otettu 9.3.16

## [Similar articles](#)

Local and systemic effects of IL-17 in joint inflammation: a historical perspective from discovery to targeting.

Miossec P.

Cell Mol Immunol. 2021 Apr;18(4):860-865. doi: 10.1038/s41423-021-00644-5. Epub 2021 Mar 10.

PMID: 33692481 [Free PMC article](#) Otettu 30.8.22

[Interleukin-17 and Th17 cells: from adult to juvenile arthritis--now it is serious!](#)

Miossec P.

**Arthritis** Rheum. 2011 Aug;63(8):2168-71. doi: 10.1002/art.30331. No abstract available.

PMID:

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

.

[Targeting IL-17 and TH17 cells in chronic inflammation.](#)

Miossec P, Kolls JK.

Nat Rev Drug Discov. 2012 Oct;11(10):763-76. doi:

Otettu 9.3.16

[Similar articles](#)

[Innate Error Immunities of the Th17 Immune Pathway Associated With Chronic Mucocutaneous Candidiasis: A Systematic Review.](#)

Mirza VS, Zaino ML, Feldman SR. Otta M

J Drugs Dermatol. 2023 Dec 1;22(12):1197-1203. doi: 10.36849/JDD.7579.

PMID: 38051840

AMA

APA

MLA

NLM

**Secukinumab** in HLA-B27 associated uveitis.

Miserocchi E, Giuffre C, Caporali R, Favalli EG.

Clin Exp Ophthalmol. 2021 May;49(4):388-389. doi: 10.1111/ceo.13922. Epub 2021 Apr 3.

PMID: 33742762 Otettu 30.11.22

**Interleukin-17** as a predictor of subclinical synovitis in the remission state of rheumatoid arthritis.

Misra S, Mondal S, Chatterjee S, Dutta S, Sinha D, Bhattacharjee D, Lahiri D, Ghosh A.

Cytokine. 2022 May;153:155837. doi:

10.1016/j.cyto.2022.155837. Epub 2022 Mar 4.

PMID: 35255378 Otettu 30.11.22

Neutrophil extracellular traps and extracellular histones potentiate IL-17 inflammation in periodontitis.

Kim TS, Silva LM, Theofilou VI, Greenwell-Wild T, Li L, Williams DW, Ikeuchi T, Brenchley L; NIDCD/NIDCR Genomics and Computational Biology Core; Bugge TH, Diaz PI, Kaplan MJ, Carmona-Rivera C, Moutsopoulos NM.

J Exp Med. 2023 Sep 4;220(9):e20221751. doi: 10.1084/jem.20221751. Epub 2023 Jun 1. PMID: 37261457 Otta M

Is biological therapy in systemic sclerosis the answer?  
Misra DP, et al. Rheumatol Int. 2020. PMID: 31960079  
Review. Otettu 7.9.22

136. Mitra A, Raychaudhuri SK, Raychaudhuri SP  
(2014) IL-17 and IL-17R: an auspicious therapeutic  
target for psoriatic disease. *Actas Dermosifiliogr*  
105(Suppl 1):21–33. doi:10.1016/S0001-7310(14)70015-8
137. Eiteta
138. [https://doi.org/10.1016/S0001-7310\(14\)70015-8](https://doi.org/10.1016/S0001-7310(14)70015-8)

Mitsdoerffer M, Lee Y, Jäger A, Kim HJ, Korn T, Kolls  
JK, et al. Proinflammatory T helper type 17 cells are  
effective B-cell helpers. *Proc Natl Acad Sci USA*  
2010;107: 14292–7.  
Ottu 9.3.16

CORRELATION OF CD4+T LYMPHOCYTES ACTIVATION  
WITH **INTERLEUKIN** IL-9, IL-17, IL- 22 PROFILES IN THE

## PERIPHERAL BLOOD OF PATIENTS WITH PLAQUE PSORIASIS.

Mitskevich N, Tsertsvadze T, Maisuradze N, Datuashvili M, Khaled Z, Kobalia G, Mekokishvili L.

Georgian Med News. 2021 Mar;(312):75-78.

PMID: 33964831    Ei oteta

## Improvement of the initial stage of interstitial lung disease during psoriasis treatment with secukinumab.

Miyachi H, Nakamura Y, Nakamura Y, Matsue H.

J Dermatol. 2017 Dec;44(12):e328-e329. doi:

10.1111/1346-8138.14026. Epub 2017 Sep 11. No abstract available.

PMID:

28891081    Otettu 28.5.18

[Similar articles](#)



Characteristics of anti-IL-17/23 biologics-induced  
interstitial pneumonia in patients with psoriasis.

Miyagawa H, Hara H, Araya J, Minagawa S, Numata T,  
Umezawa Y, Asahina A, Nakagawa H, Kuwano K.

PLoS One. 2021 Jan 7;16(1):e0245284. doi:

10.1371/journal.pone.0245284. eCollection 2021.

PMID: 33411857 [Free PMC article.](#) Otettu 2.9.22

Precision medicine using different biological DMARDs  
based on characteristic phenotypes of peripheral T  
helper cells in psoriatic arthritis.

Miyagawa I, Nakayamada S, Nakano K, Kubo S, Iwata  
S, Miyazaki Y, Yoshikawa M, Yoshinari H, Tanaka Y.

Rheumatology (Oxford). 2018 Apr 2. doi: Otettu  
28.5.18

## [Similar articles](#)

Suppression of IL-23-mediated psoriasis-like inflammation by regulatory B cells.

Mizumaki K, Horii M, Kano M, Komuro A, Matsushita T.

Sci Rep. 2021 Jan 22;11(1):2106. doi:

10.1038/s41598-021-81588-8.

PMID: 33483537 [Free PMC article](#). Otettu 1.9.22

[Bony proliferations in rheumatoid arthritis, psoriatic arthritis and osteoarthritis using high-resolution peripheral quantitative computed tomography-A systematic literature review.](#)

Moen HV, Hänel M, Therkildsen J, Klose-Jensen R, Keller KK, Hauge EM.

Int J Rheum Dis. 2024 Feb;27(2):e15068. doi:

10.1111/1756-185X.15068.

PMID: 38334245 Review. Oya

Moens,E.,Brouwer,M.,Dimova,T.,Goldman,M.,Willems,F.  
andVer- mijlen, D., IL-23R and TCR signaling drives the  
generation of neonatal Vgamma9Vdelta2 T cells  
expressing high levels of cytotoxic mediators and  
producing IFN-gamma and IL-17. J. Leukoc. Biol. 2011.  
89: 743–752.     Otettu 9.3.16

**Interleukin 17**, the double-edged sword in  
atherosclerosis.

Moeinafshar A, Razi S, Rezaei N.

Immunobiology. 2022 May;227(3):152220. doi:  
10.1016/j.imbio.2022.152220. Epub 2022 Apr 18.

PMID: 35452921 Review. Otettu 30.11.22

Further development in the trees of the immune system is expected to elucidate the mechanisms of blood pressure elevation

Mogi, Masaki

Hypertension research, 2024-12 Otta M

**Secukinumab** treatment and vaccination efficacy.

Mohammed A, Singh R, Feldman SR.

Clin Exp Dermatol. 2021 Nov 8. doi: 10.1111/ced.15004.

Online ahead of print.

PMID: 34747527 Otettu 3.3.22

The expression of GAS5, THRIL, and RMRP lncRNAs is increased in T cells of patients with rheumatoid arthritis.

Moharamoghli M, Hassan-Zadeh V, Dolatshahi E, Alizadeh Z, Farazmand A.

Clin Rheumatol. 2019 Nov;38(11):3073-3080. doi: 10.1007/s10067-019-04694-z. Epub 2019 Jul 25. PMID: 31346885 Otettu 23.9.20

Moisan, J., Grenningloh, R., Bettelli, E., Oukka, M., and Ho, I. C. (2007). Ets-1 is a negative regulator of Th17 differentiation. J. Exp. Med. 204, 2825–2835. doi: 10.1084/jem.20070994  
Otettu 9.3.16

Mok MY, Wu HJ, Lo Y, Lau CS. The relation of interleukin 17 (IL-17) and IL-23 to TH1/TH2 cytokines and disease activity in systemic lupus erythematosus. J Rheumatol 2010;37(10):2046–52. Otettu 4.3.16

Molet S, Hamid QA, Davoine F, et al. Interleukin-17 is increased in asthmatic airways and induces human fibroblasts to produce cytokines. J Allergy Clin Immunol 2001; 108: 103–109.  
Otettu 20.9.20

**Secukinumab for the Treatment of Deficiency of Interleukin 36 Receptor Antagonist in an Adolescent.**

Molho-Pessach V, Alyan R, Gordon D, Jaradat H, Zlotogorski A.

JAMA Dermatol. 2017 May 1;153(5):473-475.

Otettu 28.5.18

Ref. katsottu 15.3.20

Linkin siirto ei onnistu

[Similar articles](#)

Effectiveness and safety of **secukinumab** in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort.

Molica Colella F, Zizzo G, Parrino V, Filosa MT, Cavaliere R, Fazio F, Molica Colella AB, Mazzone A.

Adv Rheumatol. 2023 Mar 27;63(1):15. doi:

10.1186/s42358-023-00295-2.

PMID: 36973825 Otettu 12.6.23

Momose M, Asahina A, Umezawa Y, et al. Long-term clinical efficacy and safety of secukinumab for Japanese

patients with psoriasis: a single-center experience. J Dermatol. 2018;45:318–21. Otettu 7.3.20

Comprehensive Insights into Psoriasis: Pathophysiology, An Advanced Exploration of Current Landscape and Future Prospects in "Therapeutic Strategies".

Monis M, Mathur P, Ritu, Mishra AK, Rani L.

Recent Adv Inflamm Allergy Drug Discov.

2025;19(2):158-172. doi:

10.2174/0127722708300943240724051518.

PMID: 40667592 Review. Otta M

Methotrexate Treatment Immunomodulates Abnormal Cytokine Expression by T CD4 Lymphocytes Present in DMARD-Naïve Rheumatoid Arthritis Patients.



Montserrat Sanz J, Bohórquez C, Gómez AM, Movasat A, Pérez A, Ruíz L, Diaz D, Sánchez AI, Albarrán F, Sanz I, Álvarez-Mon M.

Int J Mol Sci. 2020 Sep 18;21(18):6847. doi: 10.3390/ijms21186847.

PMID: 32961930 **Free PMC article.** Otettu 3.9.22

Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysis.

Montezuma T, Probst LF, Almeida MO.

Adv Rheumatol. 2024 Mar 21;64(1):21. doi: 10.1186/s42358-024-00361-3.

PMID: 38515177 Otettu 29.5.24

## Enrichment of Polyfunctional IL-17-Producing T Cells in Paradoxical Psoriasis Skin Lesions.

Moran B, et al. *J Invest Dermatol*. 2020. PMID: 31682840

[Free article.](#) Otettu 8.9.22

Moran EM, Mullan R, McCormick J, Connolly M, Sullivan O, Fitzgerald O, et al. 2009. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. *Arthritis Res Ther* 11(4):R113. Otettu 25.3.20

.  
[Interleukin-17A induction of angiogenesis, cell migration, and cytoskeletal rearrangement.](#)

Moran EM, Connolly M, Gao W, McCormick J, Fearon U, Veale DJ.

**Arthritis Rheum.** 2011 Nov;63(11):3263-73. doi:

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

[IL-17A expression is localised to both mononuclear and polymorphonuclear synovial cell infiltrates.](#)

Moran EM, Heydrich R, Ng CT, Saber TP, McCormick J, Sieper J, Appel H, Fearon U, Veale DJ.

PLoS One. 2011;6(8):e24048. doi:

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Moran B, Sweeney CM, Hughes R, et al. Hidradenitis Suppurativa Is Characterized by Dysregulation of the

Th17:Treg Cell Axis, Which Is Corrected by Anti-TNF Therapy. *J Invest Dermatol*. 2017;137(11):2389-2395  
Otettu 2.3.20

### Th17 Lymphocytes in Children with Asthma: Do They Influence Control?

Moreno-Córdova V, Berra-Romani R, Flores Mendoza LK, Reyes-Leyva J.

*Pediatr Allergy Immunol Pulmonol*. 2021  
Dec;34(4):147-152. doi: 10.1089/ped.2021.0067.  
PMID: 34958246 ei oteta

**Secukinumab** for pyoderma gangrenosum: A case report.

Moreno García M, Madrid González M, Prada Lobato JM.

Med Clin (Barc). 2018 Aug 22. pii:

S0025-7753(18)30430-5. doi:

10.1016/j.medcli.2018.06.011. [Epub ahead of print]

English, Spanish. No abstract available.

PMID:

30144933 ei oteta

[Similar articles](#)

Real-World Effectiveness and Treatment Retention of **Secukinumab** in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry.

Moreno-Ramos MJ, Sanchez-Piedra C, Martínez-González O, Rodríguez-Lozano C, Pérez-García C, Freire M, Campos C, Cáliz-Caliz R, Calvo J, Blanco-Madrigal JM, Pérez-Gómez A, Moreno-Martínez MJ, Linares L, Sánchez-Alonso F, Sastré C, Castrejón I.

Rheumatol Ther. 2022 Aug;9(4):1031-1047. doi:

10.1007/s40744-022-00446-9. Epub 2022 Apr 25.

PMID: 35467242 [Free PMC article.](#) Otettu 26.8.22

Moriggl R, et al. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. *Immunity*. 1999; 10:249–259. [PubMed: 10072077] Otettu 9.3.16

[Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab.](#)

Morita A, Tani Y, Matsumoto K, Yamaguchi M, Teshima R, Ohtsuki M.

*J Dermatol*. 2020 Mar 15. doi:

10.1111/1346-8138.15278. [Epub ahead of print] Otettu 29.3.20

1. Morrison, P.J., Ballantyne, S.J. & Kullberg, M.C. Interleukin-23 and Thelper 17-type responses in intestinal inflammation: from cytokines to T-cell plasticity. *Immunology* 133, 397–408 (2011).  
Otettu 19.3.20

Morrison, P. J., D. Bending, L. A. Fouser, J. F. Wright, B. Stockinger, A. Cooke, and M. C. Kullberg. 2013. Th17-cell plasticity in *Helicobacter hepaticus*-induced intestinal inflammation. *Mucosal Immunol.* 6: 1143–1156. Otettu 15.3.20

Ref. katsottu 18.3.20

Mose M, Kang Z, Raaby L et al. Exp Dermatol 2013; 22: 476–481. Otettu 9.3.16

.

[Interleukin-17 family and IL-17 receptors.](#)

Moseley TA, Haudenschield DR, Rose L, Reddi AH. Cytokine Growth Factor Rev. 2003 Apr;14(2):155-74.

Otettu 9.3.16

[Similar articles](#)

[Biologic and small molecule therapies for psoriasis in individuals with Down syndrome: Two cases and a systematic review.](#)

Moshkovich M, Perlmutter JW, Vender R.



SAGE Open Med Case Rep. 2025 Jul  
22;13:2050313X251359029. doi:  
10.1177/2050313X251359029. eCollection 2025.  
PMID: 40717838 [Free PMC article.](#) [Otettu 22.8.25](#)

Drug Retention and Safety of **Secukinumab** in a  
Real-World Cohort of Ankylosing Spondylitis and  
Psoriatic Arthritis Patients.

Moskal M, Krawiec P, Zaręba W, Świerczek I, Ratusznik J,  
Raputa W, Zieliński M, Batko K, Huk M, Batko B.

Int J Environ Res Public Health. 2022 Nov  
29;19(23):15861. doi: 10.3390/ijerph192315861.  
PMID: 36497938 [Free PMC article.](#) [otettu 12.6.23](#)

Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study.

Motedayen Aval L, Yiu ZZN, Alabas OA, Griffiths CEM, Reynolds NJ, Hampton PJ, Smith CH, Warren RB; BADBIR Study Group.

J Eur Acad Dermatol Venereol. 2025 May 29. doi: 10.1111/jdv.20739. Online ahead of print.  
PMID: 40439435 Otettu 4.6.25

43. Mourik BC, Lubberts E, de Steenwinkel JEM, Ottenhoff THM, Leenen PJM. Interactions between type 1 interferons and the Th17 response in tuberculosis: Lessons learned from autoimmune diseases. Front Immunol. 2017; 8. Otettu 28.3.20

44. <https://doi.org/10.3389/fimmu.2017.00294> PMID: 28424682

Efficacy and safety of **secukinumab** in moderate to severe palmoplantar pustular psoriasis over 148 weeks: extension of the 2PRECISE study.

Mrowietz U, Bachelez H, Burden AD, Rissler M, Sieder C, Orsenigo R, Jagiello P.

J Am Acad Dermatol. 2020 Jun

18:S0190-9622(20)31102-6. doi:

10.1016/j.jaad.2020.06.038. Online ahead of print.

PMID: 32565211    Otettu 20.9.20

Mrabet D, Laadhar L, Sahli H, Zouari B, Haouet S, Makni S, Sellami S. Synovial fluid and serum levels of IL-17, IL-23, and CCL-20 in rheumatoid arthritis and psoriatic arthritis: a Tunisian cross- sectional study. Rheumatol Int. 2013; 33:265–266. [PubMed: 22083617]  
Otettu 9.3.16

[Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial \(SCULPTURE\).](#)

Mrowietz U, Leonardi CL, Girolomoni G, Toth D, Morita A, Balki SA, Szepietowski JC, Regnault P, Thurston H, Papavassilis C; SCULPTURE Study Group.

J Am Acad Dermatol. 2015 Jul;73(1):27-36.e1. doi:

Otettu 9.3.16 Maksullinen

[Similar articles](#)

U. Mrowietz, H. Bachelez, A. D. Burden et al.,  
“Secukinumab for moderate-to-severe palmoplantar  
pustular psoriasis: results of the 2precise study,”  
*Journal of the American Academy of Dermatology*,  
vol. 80, no. 5, pp. 1344–1352, 2019. Otettu  
12.3.20

Mucida, D., Park, Y., Kim, G., Turovskaya, O., Scott, I.,  
Kronenberg, M. and Cheroutre, H., Reciprocal TH17 and  
regulatory T cell differentiation mediated by retinoic acid.  
Science 2007. 317: 256–260. ei oteta

[Secukinumab for Acrodermatitis Continua of Hallopeau.](#)

Muggli D, Maul JT, Anzengruber F, Fopp MW,  
Navarini AA.

JAMA Dermatol. 2017 Apr 1;153(4):336-337. doi:  
Otettu 27.5.18

**Free Article**

[Similar articles](#)

Mugheddu C, Atzori L, Lappi A, et al. Successful secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis. J Eur Acad Dermatol Venereol. 2017; 31(9):e420–e421. Otettu 7.3.20

Safety of **secukinumab** treatment in COVID-19 affected psoriatic patients.

Mugheddu C, Sanna S, Atzori L, Rongioletti F.

Dermatol Ther. 2020 Dec 27:e14710. doi:  
10.1111/dth.14710. Online ahead of print.

PMID: 33368887 Otettu 4.2.21

Evaluation of interleukins (IL-1 $\alpha$ , IL-1Ra, IL-12, IL-17A, IL-31, and IL-33) and chemokines (CXCL10 and CXCL16) in the serum of male patients with ankylosing spondylitis.

Muhsin HY, Khazaal AQ, Ismaeel HM, Alosami MH, Ad'hiah AH.

Int Immunopharmacol. 2024 Mar 10;129:111697. doi: 10.1016/j.intimp.2024.111697. Epub 2024 Feb 15.

PMID: 38364743 Otta M

Successful treatment with **secukinumab** of three psoriatic patients undergoing dialysis.

Mukai M, Kurihara Y, Ito Y, Shintani Y, Takahashi H, Kubo A, Amagai M, Umegaki-Arao N.  
J Dermatol. 2020 Jan;47(1):e26-e28. ei oteta

Mukasa, R. et al. Epigenetic instability of cytokine and transcription factor gene loci underlies plasticity of the T helper 17 cell lineage. *Immunity* 32, 616–627 (2010). Otettu 9.3.16

Murakami, M. et al. Local microbleeding facilitates IL-6– and IL-17–dependent arthritis in the absence of tissue antigen recognition by activated T cells. *J. Exp. Med.* 208, 103–114 (2011). Otettu 9.3.16

Murakami M, Hagforsen E, Morhenn V, Ishida-Yamamoto A, Iizuka H.  
Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion



and serum. *Exp Dermatol* (2011) 20(10):845–7.  
Otettu 15.3.20

Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. *Blood*. 2008;112:362-373. Otettu 15.3.20

Ref. katsottu 21.3.2020

Muranski P, et al. (2011) Th17 cells are long lived and retain a stem cell-like molecular signature. *Immunity* 35(6):972–985.  
Otettu 4.2.21

Muranski P, Restifo NP: Essentials of Th17 cell commitment and plasticity. Blood 2013, 121:2402–2414. Otettu 9.3.16

[The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases.](#)

Murdaca G, Colombo BM, Puppo F.  
Intern Emerg Med. 2011 Dec;6(6):487-95. doi:  
10.1007/s11739-011-0517-7. Epub 2011 Jan 22.  
Review.

PMID:

ei oteta

[Similar articles](#)

Regulation of NFKBIZ gene promoter activity by STAT3, C/EBP $\beta$ , and STAT1.

Muromoto R, Sato A, Komori Y, Nariya K, Kitai Y,  
Kashiwakura JI, Matsuda T.

Biochem Biophys Res Commun. 2022 Jul 12;613:61-66.  
doi: 10.1016/j.bbrc.2022.04.140. Epub 2022 May 3.  
PMID: 35537286

**Interleukin-17A** (IL-17A) is a cytokine that affects the  
functions of non-immune cells, including keratinocytes,  
and thereby amplifies immune responses. ...

Otettu 30.11.22

[British Association of Dermatologists and British  
Society for Rheumatology living guideline for managing  
people with Behçets 2024.](#)

Murphy R, Moots RJ, Brogan P, Çelik AF, Clement-Jones  
M, Coulson I, Croft AP, Crozier S, Forrest L, Harrold J,  
Higgins S, Jawad ASM, Kalra S, Khan SS, McKee H, Pain  
CE, Petrushkin H, Poveda-Gallego A, Setterfield J,  
Sharma P, West R, Wlodek C, Hashme M, Manounah L,  
Mohd Mustapa MF, Constantin AM.

Br J Dermatol. 2024 Sep 10;ljae263. doi:  
10.1093/bjd/ljae263. Online ahead of print.  
PMID: 39253835 Otettu 27.9.24

Murphy, C.A., C.L. Langrish, Y. Chen, W. Blumenschein, T. McClanahan, R.A. Kastelein, J.D. Sedgwick, and D.J. Cua. 2003. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. *J. Exp. Med.* 198:1951–1957.

Otettu 15.3.20

Ref. ei katsot.

Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. *J Immunol.* 2009 Oct;183(7):4169–75. Otettu 12.3.20  
Ref. ei otet.

## Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis.

Muruganandam M, Ariza-Hutchinson A, Patel RA, Sibbitt WL Jr.

J Inflamm Res. 2023 Oct 17;16:4633-4660. doi: 10.2147/JIR.S379815. eCollection 2023.

PMID: 37868834 [Free PMC article](#). Review. Otettu 29.5.24

[\[Interleukin-17 in chronic inflammatory and autoimmune diseases: rheumatoid arthritis, Crohn's disease and Wegener's granulomatosis\].](#)

Müller A, Lamprecht P.

Z Rheumatol. 2008 Feb;67(1):72-4. Review. German.

PMID:

18004573 Otettu 9.3.16

[Similar articles](#)

Paradoxical palmoplantar pustulosis induced by **secukinumab** and brodalumab: a report of three cases.

Mössner R, Pinter A.

Eur J Dermatol. 2020 Apr 13. doi:

10.1684/ejd.2020.3702. Online ahead of print.

PMID: 32293563 Otta M

Ei ole PUBMED x 2 Otta myöhemmin

[Association of \*IL-17A\* and \*IL-10\* Polymorphisms with Juvenile Idiopathic Arthritis in Finnish Children.](#)

Möttönen M, Teräsjarvi J, Rahikkala H, Kvist S, Mertsola J, He Q.

Int J Mol Sci. 2024 Jul 30;25(15):8323. doi:  
10.3390/ijms25158323.

PMID: 39125893 **Free PMC article.** Otettu 24.10.24

S.Y. Na, M.J. Park, S. Park, E.S. Lee, Up-regulation  
of th17 and related cytokines in behçet's disease  
corresponding to disease activity, Clin. Exp.  
Rheumatol. 31 (2013). 31: S32-S40 Otettu  
12.3.20

New-Onset Uveitis Possibly Caused by **Secukinumab** in  
a 47-Year-Old Male Patient with Long-Standing  
Ankylosing Spondylitis.

Nadwi H, Janaini M, Zammo M, Cheikh M, Almoallim H.

Int Med Case Rep J. 2020 Aug 5;13:331-334. doi:  
10.2147/IMCRJ.S265812. eCollection 2020.  
PMID: 32801946 [Free PMC article.](#) [Otettu 20.9.20](#)

[Review of phase 2/3 trials in polymyalgia rheumatica  
and giant cell arteritis.](#)

Nageswaran P, Ahmed S, Tahir H.

Expert Opin Emerg Drugs. 2024 Mar;29(1):5-17. doi:  
10.1080/14728214.2024.2303093. Epub 2024 Jan 13.  
PMID: 38180809 Review. [Otta M](#)

[Systems model identifies baseline cytokine  
concentrations as potential predictors of rheumatoid  
arthritis inflammatory response to biologics.](#)

Nakada T, Mager DE.

Br J Pharmacol. 2022 Aug;179(16):4063-4077. doi:  
10.1111/bph.15845. Epub 2022 Apr 22.



PMID: 35355255 Otettu 30.11.22

Nakae S, Iwakura Y, Suto H, Galli SJ. Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol. 2007; 81:1258–1268. Otettu 9.3.16

Subacute thyroiditis in a patient with psoriatic arthritis switched from **secukinumab** to adalimumab: a case report and literature review.

Nakagawa J, Fujikawa K, Akagi M, Nakaji K, Yasui J, Hanatani Y, Hara T, Mizokami A, Kawakami A.

Mod Rheumatol Case Rep. 2020 Jul 31:1-4.

Otettu 30.11.22

Reliability, stability during long-term storage, and intra-individual variation of circulating levels of osteopontin, osteoprotegerin, vascular endothelial growth factor-A, and interleukin-17A.

Nakamizo T, Cologne J, Kishi T, Takahashi T, Inoue M, Ryukaku H, Hayashi T, Kusunoki Y, Fujiwara S, Ohishi W.

Eur J Med Res. 2024 Feb 17;29(1):133. doi: 10.1186/s40001-024-01722-w.

PMID: 38368424 **Free PMC article.** Otettu 13.3.24

Adiposity induced by interleukin-17A blockade.

Nakamura T, Iwasaki Y, Yamane S, Ogura M, Yasoda A, Nagashima K, Inagaki N.

Diabetes Metab. 2017 Feb;43(1):93-94. doi: Otettu 28.5.18

## [Similar articles](#)

Recent Updates in the Immunopathology of Type 3 Immunity-Mediated Enthesitis.

Nakamura A, Haroon N.

Curr Rheumatol Rep. 2021 Apr 24;23(5):31. doi: 10.1007/s11926-021-00995-y.

PMID: 33893896 Review. Otta Myöhemmin

Pathogenesis, assessment, and management of bone loss in axial spondyloarthritis.

Nakamura A, Towheed T.

Semin Arthritis Rheum. 2024 Feb;64:152345. doi: 10.1016/j.semarthrit.2023.152345. Epub 2023 Dec 12.

PMID: 38103486 Review. Otta M

## Arteriosclerosis Derived from Cutaneous Inflammation Is Ameliorated by the Deletion of IL-17A and IL-17F.

Nakanishi T, Iida S, Maruyama J, Urushima H, Ichishi M, Matsushima Y, Mizutani K, Nakayama Y, Sugioka K, Nishimura M, Umaoka A, Iwakura Y, Kondo M, Habe K, Tsuruta D, Yamamoto O, Imai Y, Yamanaka K.

Int J Mol Sci. 2023 Mar 12;24(6):5434. doi: 10.3390/ijms24065434.

PMID: 36982506 [Free PMC article.](#) Otettu 14.6.23

### Interleukin-17 and systemic lupus erythematosus: current concepts

Nalbandian, A ; Crispín, J.C ; Tsokos, G.C

Clinical and experimental immunology, 2009-08, Vol.157 (2), p.209-215 Otettu 4.6.25

Nalbandian A, Crispin JC, Tsokos GC: Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol 2009, 157:209-215. Otettu 9.3.16

From the Genetics of Ankylosing Spondylitis to New Biology and Drug Target Discovery.

Nancy Z, Yan L, Hui S, Paul B, Liye C.

Front Immunol. 2021 Feb 17;12:624632. doi:

10.3389/fimmu.2021.624632. eCollection 2021.

PMID: 33679768 [Free PMC article](#). Otettu 30.8.22

From Host Defense to Metabolic Signatures: Unveiling the Role of  $\gamma\delta$  T Cells in Bacterial Infections.

Nanda N, Alphonse MP.

Biomolecules. 2024 Feb 15;14(2):225. doi: 10.3390/biom14020225.  
PMID: 38397462 [Free PMC article](#).

## Usage and Adherence of Seven Advanced Therapies with Differing Mechanisms of Action for Inflammatory Arthritis in Canada.

Nantel F, et al. *Rheumatol Ther*. 2022. PMID: 36045308  
[Free article](#). Otettu 26.9.22

Napolitani, G., Acosta-Rodriguez, E.V., Lanzavecchia, A. & Sallusto, F. Prostaglandin E2 enhances Th17 responses via modulation of IL-17 and IFN- $\gamma$  production by memory CD4<sup>+</sup> T cells. *Eur. J. Immunol.* 39, 1301–1312 (2009).  
Otettu 20.9.20

Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study.

Narcisi A, Valenti M, Cortese A, Toso F, Pavia G, Gargiulo L, Borroni R, Costanzo A.

*Dermatol Ther.* 2022 Feb;35(2):e15228. doi: 10.1111/dth.15228. Epub 2021 Nov 30.

PMID: 34820969 Otettu 3.3.22

Nash P, Mcinnes I, Mease P, et al. Secukinumab for the treatment of psoriatic arthritis: comparative effectiveness versus adalimumab using a matching-adjusted indirect comparison. *Arthritis Rheumatol.* 2016;68(Suppl 10). Otettu 20.9.20

**Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.**

Nash P, McInnes IB, Mease PJ, Thom H, Hunger M, Karabis A, Gandhi K, Mpofu S, Jugl SM.

Rheumatol Ther. 2018 Jun;5(1):99-122. doi: 10.1007/s00067-018-0450-2. Epub 2018 Jun 15.

**Free PMC Article**

[Similar articles](#)

**Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).**

Nash P, Mease PJ, McInnes IB, Rahman P, Ritchlin CT, Blanco R, Dokoupilova E, Andersson M, Kjekshus R, Mpofu S, Pricop L; FUTURE 3 study group.



Arthritis Res Ther. 2018 Mar 15;20(1):47. doi: Otettu  
27.5.18

**Free PMC Article**

[Similar articles](#)

Correction to: **Secukinumab** Versus Adalimumab for  
Psoriatic Arthritis: Comparative Effectiveness up to 48  
Weeks Using a Matching-Adjusted Indirect Comparison.

Nash P, McInnes IB, Mease PJ, Thom H, Hunger M,  
Karabis A, Gandhi K, Mpofu S, Jugl SM.

Rheumatol Ther. 2018 Jun 1. doi:

10.1007/s40744-018-0117-3. [Epub ahead of print]

PMID:

29858770 Otettu 3.9.18

**Free Article**

[Similar articles](#)

**Secukinumab** provides sustained improvement in nail psoriasis, signs and symptoms of psoriatic arthritis and low rate of radiographic progression in patients with concomitant nail involvement: 2-year results from the Phase III FUTURE 5 study.

Nash P, Mease PJ, Kirkham B, Singhal A, Quebe-Fehling E, Pricop L, Gaillez C.

Clin Exp Rheumatol. 2021 Sep 3. Online ahead of print.  
Otettu 30.11.22

**The role of interleukin 17 in the pathogenesis of giant cell arteritis: new possibilities for pharmacotherapy**

Nasonov, E. L. ; Beketova, T. V. ; Satybaldyev, A. M.

Nauchno-prakticheskaiâ revmatologîia, 2024-12, Vol.62 (6), p.582-589

PEER REVIEWED

OPEN ACCESS Otta M

Serum Immunoglobulin E and **Interleukin-17** Levels in Patients with Chronic Plaque Psoriasis: A Case-Control Study.

Nassar AA, Bakr NM, Elyousefi EH, Elkholy BM, Fawzy MM.

J Cosmet Dermatol. 2022 Aug 11. doi: 10.1111/jocd.15299. Online ahead of print. PMID: 35957511 Otta Myöhemmin

National Institute for Health and Care Excellence.  
Secukinumab for ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors. 2016. <http://www.nice.org.uk>. Accessed 11 Feb 2019. ei oteta

[A Breakthrough in the Treatment of Necrobiosis Lipoidica? Update on Treatment, Etiopathogenesis, Diagnosis, and Clinical Presentation.](#)

Naumowicz M, Modzelewski S, Macko A, Łuniewski B, Baran A, Flisiak I.

Int J Mol Sci. 2024 Mar 20;25(6):3482. doi: 10.3390/ijms25063482.

PMID: 38542454 [Free PMC article](#). Review. Otettu 29.5.24

[A Breakthrough in the Treatment of Necrobiosis Lipoidica? Update on Treatment, Etiopathogenesis, Diagnosis, and Clinical Presentation.](#)

Naumowicz M, Modzelewski S, Macko A, Łuniewski B, Baran A, Flisiak I.

Int J Mol Sci. 2024 Mar 20;25(6):3482. doi: 10.3390/ijms25063482.

PMID: 38542454 [Free PMC article](#). Review. Otettu 29.5.24

## Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future.

Navarini L, Currado D, Costa L, Tasso M, Chimenti MS, Caso F.

J Exp Pharmacol. 2020 Nov 16;12:487-502. doi: 10.2147/JEP.S265633. eCollection 2020.

PMID: 33235521 [Free PMC article.](#) Otettu 2.9.22

## Axial spondyloarthritis.

Navarro-Compán V, Sepriano A, El-Zorkany B, van der Heijde D.

Ann Rheum Dis. 2021 Dec;80(12):1511-1521. doi: 10.1136/annrheumdis-2021-221035. Epub 2021 Oct 6. PMID: 34615639 Review. Otettu 30.11.22

[Ixezumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration.](#)

Navarro-Compán V, Reveille JD, Rahman P, Maldonado-Cocco JA, Magrey M, Bolce R, Panni T, Kronbergs A, Rudwaleit M.

Adv Ther. 2025 Jul 22. doi:

10.1007/s12325-025-03305-5. Online ahead of print.

PMID: 40694276 Otettu 31.7.25

[Secukinumab-induced paradoxical hidradenitis suppurativa.](#)

Navarro-Triviño FJ, Sanchez-Parera R, Ruiz-Villaverde R.

Dermatol Ther. 2020 Jan;33(1):e13150. Otettu 28.2.20

[Recent updates in enthesitis-related arthritis.](#)

Naveen R, Guleria S, Aggarwal A.

Rheumatol Int. 2023 Mar;43(3):409-420. doi:

10.1007/s00296-023-05274-w. Epub 2023 Jan 11.

PMID: 36629936 Review. Otta M

[Interleukin 17C is elevated in lesional tissue of hidradenitis suppurativa.](#)

Navrazhina K, et al. Br J Dermatol. 2020. PMID: 31556100 [Free PMC article](#). No abstract available. Otettu 30.11.22

[Paradoxical eczema in psoriasis patients following treatment with secukinumab.](#)

Neema S, Pathania V, Nyalam P, Kamboj P, Gb P.

Indian J Dermatol Venereol Leprol. 2024 Sep 30;1-3. doi:  
10.25259/IJDVL\_898\_2024. Online ahead of print.  
PMID: 39361839 **Free article.** Otettu 24.10.24

Widespread Superficial Dermatophytosis in Patient on  
**Secukinumab** for Treatment of Chronic Plaque  
Psoriasis.

Neema S, Singh S, Pathak N, Khan MA.

Indian Dermatol Online J. 2019 Jan-Feb;10(1):76-78.  
**Free PMC Article Otettu 28.2.20**



## Is Psoriasis Treatment a Risk Factor for Inflammatory Bowel Disease?

Nehring P, Przybyłkowski A.

Pharmaceut Med. 2020 Aug;34(4):257-262. doi: 10.1007/s40290-020-00340-1.

PMID: 32514931 [Free PMC article](#). Otettu 4.9.22

[The expression of IL17RA on sputum macrophages in asthma patients.](#)

Nejman-Gryz P, Paplińska-Goryca M, Proboszcz M, Grabczak M, Hermanowicz-Salamon J, Krenke R. Cytokine. 2021 Jul;143:155518. doi: 10.1016/j.cyto.2021.155518. Epub 2021 Apr 8.

PMID: 33840588 [Free article](#). Otettu 30.8.22

**Secukinumab** Therapy in Refractory Juvenile Idiopathic Arthritis.

Nelson MC, Manos CK.

J Investig Med High Impact Case Rep. 2023 Jan-Dec;11:23247096231200403. doi: 10.1177/23247096231200403.

PMID: 37731263 [Free PMC article.](#) [Otettu 12.10.23](#)

**Giant Cell Arteritis and Polymyalgia Rheumatica: Treatment Approaches and New Targets.**

Nepal D, Putman M, Unizony S.

Rheum Dis Clin North Am. 2023 Aug;49(3):505-521. doi: 10.1016/j.rdc.2023.03.005. Epub 2023 Apr 18.

PMID: 37331730 Review. [Otta M](#)

Nestle F O, Kaplan D H, Barker J. N Engl J Med 2009;  
361: 496–509. Otettu 9.3.16

.

[Altered immunometabolic response to fasting in  
humans living with obesity.](#)

Neudorf H, Sandilands RE, Ursel S, Shaba H, Barg D,  
Tsusaka T, Moya-Garzón MD, Vaz E, Schimweg P,  
Goldberg EL, Long JZ, Krüger K, Islam H, Little JP.  
iScience. 2025 Jun 11;28(7):112872. doi:  
10.1016/j.isci.2025.112872. eCollection 2025 Jul 18.  
PMID: 40662191 **Free PMC article.** Otettu 31.7.25

Targeting cytokines in psoriatic arthritis.

Neurath L, Sticherling M, Schett G, Fagni F.

Cytokine Growth Factor Rev. 2024 Aug;78:1-13. doi: 10.1016/j.cytogfr.2024.06.001. Epub 2024 Jul 23.

PMID: 39068140 **Free article.** Otettu 24.10.24

IL-17 Inhibitor **Secukinumab** Achieves Remission in Relapsing Polychondritis: A Case Report.

Neycheva S, Kamburova A.

Am J Case Rep. 2025 Mar 20;26:e946916. doi: 10.12659/AJCR.946916.

PMID: 40108787 **Free PMC article.** Otettu 4.6.25

Active pulmonary tuberculosis in a patient with **secukinumab** treatment.

Ngoc CT, et al. *Radiol Case Rep.* 2022. PMID: 36340221  
[Free PMC article.](#) Otettu 20.11.22

**Secukinumab** in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study.

Nguyen T, Churchill M, Levin R, Valenzuela G, Merola JF, Ogdie A, Orbai AM, Scher JU, Kavanaugh A, Kianifard F, Rollins C, Calheiros R, Chambenoit O.

*J Rheumatol.* 2022 Aug;49(8):894-902. doi: 10.3899/jrheum.210912. Epub 2022 Apr 15.

PMID: 35428722 [Free article.](#) Clinical Trial. Otettu 26.8.22

Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjögren's syndrome: findings in humans and mice.

Nguyen CQ, Hu MH, Li Y, Stewart C, Peck AB.  
**Arthritis Rheum.** 2008 Mar;58(3):734-43. doi

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

The Impact of Interleukin-17 Inhibitors on Major Adverse Cardiovascular Events in Psoriasis or Psoriatic Arthritis Patients Naive to Biologic Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Ni R, Zheng J, Varghese J, Kumar B.

Cureus. 2024 May 24;16(5):e60980. doi:

10.7759/cureus.60980. eCollection 2024 May.

PMID: 38910708 **Free PMC article.** Otettu 27.9.24

Gastric Juice Expression of Th-**17** and T-Reg Related Cytokines in Scleroderma Esophageal Involvement.

Nicola S, Rolla G, Bucca C, Geronazzo G, Ridolfi I, Ferraris A, Fusaro E, Peroni CL, Dughera L, Brussino L. Cells. 2020 Sep 16;9(9):E2106. doi: 10.3390/cells9092106. PMID: 32947843 Otettu 21.9.20

Three years of methotrexate and **secukinumab**: Outcomes of psoriatic arthritis in a real-life setting.

Nicola S, Cassarino SG, Rolla G, Geronazzo G, Fornero M, Brussino L.

J Am Acad Dermatol. 2021 Feb 4:S0190-9622(21)00317-0. doi: 10.1016/j.jaad.2021.02.004. Online ahead of print. PMID: 33549655 Otettu 30.11.22

## Gastric Juice Expression of Th-17 and T-Reg Related Cytokines in Scleroderma Esophageal Involvement.

Nicola S, Rolla G, Bucca C, Geronazzo G, Ridolfi I, Ferraris A, Fusaro E, Peroni CL, Dughera L, Brussino L. Cells. 2020 Sep 16;9(9):2106. doi: 10.3390/cells9092106.

PMID: 32947843 [Free PMC article.](#) Otettu 3.9.22

## Treatment of psoriatic arthritis with secukinumab: a case series.

Nicola S, Rolla G, Monti R, Brussino L.

J Dermatolog Treat. 2018;29(sup1):6-8 Otettu 9.3.20

## IL-17C/IL-17RE: Emergence of a Unique Axis in T<sub>H</sub>17 Biology.

Nies JF, Panzer U.



Front Immunol. 2020 Feb 26;11:341. doi:  
10.3389/fimmu.2020.00341. eCollection 2020.  
PMID: 32174926 **Free PMC article.** Otettu 6.9.22

New-Onset Vitiligo During Treatment with **Secukinumab**:  
Report of Two Cases and Review of the Literature.  
Nieto-Benito LM, Baniandr  s-Rodr  guez O.  
Clin Drug Investig. 2020 Aug 30. doi: 10.1 Otettu  
20.9.20

[MicroRNA-146a expresses in interleukin-17 producing  
T cells in rheumatoid arthritis patients.](#)

Niimoto T, Nakasa T, Ishikawa M, Okuhara A, Izumi B,  
Deie M, Suzuki O, Adachi N, Ochi M.  
BMC Musculoskelet Disord. 2010 Sep 15;11:209.

PMID:

20840794 Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab.

Nikolakis G, Kreibich K, Vaiopoulos A, Kaleta K, Talas J, Becker M, Zouboulis CC.

F1000Res. 2021 May 13;10:381. doi:

10.12688/f1000research.52100.2. eCollection 2021.

PMID: 34540202 [Free PMC article.](#) Otettu 29.8.22

Impact of **IL-17F** 7488T/C Functional Polymorphism on Progressive Rheumatoid **Arthritis**: Novel Insight from the Molecular Dynamic Simulations.

Nisar H, Pasha U, Mirza MU, Abid R, Hanif K,  
Kadarmideen HN, Sadaf S.

Immunol Invest. 2020 Jun 16:1-11. doi:  
10.1080/08820139.2020.1775642. Online ahead of  
print.

PMID: 32543936 Otettu 21.9.20

Combining **secukinumab** and fingolimod to  
successfully treat ankylosing spondylitis and multiple  
sclerosis - A novel approach.

Nisar MK.

Biologicals. 2019 Jul;60:93-94. Otettu 9.3.20

Successful **secukinumab** treatment of recalcitrant juvenile generalized pustular  
psoriasis.

Nishida M, Takeichi T, Kono M, Imanishi A, Maekawa N, Akiyama M, Fukai K.

J Dermatol. 2020 Jan 6. doi: 10.1111/1346-8138 Otettu 28.2.20

Nishihara, M., Ogura, H., Ueda, N., Tsuruoka, M., Kitabayashi, C., Tsuji, F., et al. (2007).

IL-6-gp130-STAT3 in T cells directs the development of IL-17<sup>+</sup> Th with a minimum effect on that of Treg in the steady state. *Int. Immunol.* 19, 695–702. doi:

10.1093/intimm/dxm045

Otettu 9.3.16

Nishimoto, S., H., S. Tsuruta, N. Shimizu, M. Ito, T. Shichita, R. Morita, H. Takahashi, M. Amagai, and A. Yoshimura. 2013. Th17 cells carrying TCR recognizing epidermal autoantigen induce psoriasis-like skin inflammation. *J. Immunol.* 191: 3065–3072. Otettu 19.3.20

Ref. ei katsot

[Anti-aquaporin-4 immune complex stimulates complement-dependent Th17 cytokine release in neuromyelitis optica spectrum disorders.](#)

Nishiyama S, Seok JM, Wright AE,, Mikami T, Drosu NC, Bobrowski-Khoury N, Anderson MR, Bilodeau PA, Schindler P, Paul F, Aoki M, Yeaman MR, Levy M; Guthy-Jackson Charitable Foundation CIRCLES Study Group.

Sci Rep. 2024 Feb 7;14(1):3146. doi: 10.1038/s41598-024-53661-5.

PMID: 38326464 [Free PMC article.](#) Otettu 13.3.24

[Interleukin-17-producing T cells are enriched in the joints of children with \*\*arthritis\*\*, but have a reciprocal relationship to regulatory T cell numbers.](#)

Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, Wedderburn LR.

**Arthritis Rheum.** 2008 Mar;58(3):875-87. doi:

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Nistala K, Wedderburn LR. Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis. *Rheumatology* 2009;48:602–606. [PubMed:] Otettu 9.3.16

.

[Th17 plasticity in human autoimmune \*\*arthritis\*\* is driven by the inflammatory environment.](#)

Nistala K, Adams S, Cambrook H, Ursu S, Olivito B, de Jager W, Evans JG, Cimaz R, Bajaj-Elliott M, Wedderburn LR.

Proc Natl Acad Sci U S A. 2010 Aug  
17;107(33):14751-6.

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Niu X, He D, Zhang X, Yue T, Li N, Zhang JZ, et al.  
2010. IL-21 regulates Th17 cells in rheumatoid arthritis.  
Hum Immunol 71(4):334–341. Otettu 9.3.16

.  
[Disturbed Th17/Treg balance in patients with  
rheumatoid arthritis.](#)

Niu Q, Cai B, Huang ZC, Shi YY, Wang LL.  
Rheumatol Int. 2012 Sep;32(9):2731-6. doi:  
10.1007/s00296-011-1984-x. Epub 2011 Aug 2.  
PMID:

Otettu 9.3.16

[Similar articles](#)

Effects of Methotrexate Alone or Combined With  
**Arthritis**-Related Biotherapies in an in vitro Co-culture  
Model With Immune Cells and Synoviocytes.

Noack M, Miossec P.

Front Immunol. 2019 Dec 20;10:2992. doi:  
10.3389/fimmu.2019.02992. eCollection 2019.

PMID: 31921217 [Free PMC article.](#) Otettu 21.9.20

Noack, M. and Miossec, P. (2014) Th17 and regulatory T  
cell balance in autoimmune and inflammatory diseases.  
Autoimmun. Rev. 13, 668–677 Otettu 9.3.16



Orai1: CRACing the Th17 response in AKI.

Noel S. J Clin Invest. 2019. PMID: 31609248 [Free PMC article.](#) Otettu 8.9.22

[Kidney double positive T cells have distinct characteristics in normal and diseased kidneys.](#)

Noel S, Newman-Rivera A, Lee K, Gharaie S, Patel S, Singla N, Rabb H.

Sci Rep. 2024 Feb 23;14(1):4469. doi:

10.1038/s41598-024-54956-3.

PMID: 38396136 [Free PMC article.](#) Otettu 13.3.24

Nograles KE, Zaba LC, Guttman-Yassky E et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008; 159:1092–102. Otettu 9.3.16

Risk of tuberculosis reactivation with **interleukin (IL)-17** and IL-23 inhibitors in psoriasis - time for a paradigm change.

Nogueira M, Warren RB, Torres T.

J Eur Acad Dermatol Venereol. 2021 Apr;35(4):824-834.

doi: 10.1111/jdv.16866. Epub 2020 Sep 1.

PMID: 32790003 Review. Otettu 30.11.22

**Interleukin-17** acts in the hypothalamus reducing food intake.

Nogueira G, et al. Brain Behav Immun. 2020. PMID:

31863824 Otettu 30.11.22

Nogueira E, Hamour S, Sawant D, et al. Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA- associated vasculitis. Nephrol Dial Transplant. 2010;25(7):2209-2217.  
Otettu 9.3.16

[Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis.](#)

Noordenbos T, Yeremenko N, Gofita I, van de Sande M, Tak PP, Cañete JD, Baeten D.

**Arthritis Rheum.** 2012 Jan;64(1):99-109. doi:

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

55. Noordenbos T, Blijdorp I, Chen S, Stap J, Mul E, Cañete JD, Lubberts E, Yeremenko N, Baeten D (2016) Human mast cells capture, store, and

release bioactive, exogenous IL-17A. J Leukoc Biol  
100:453–462. Otettu 7.3.20  
56. <https://doi.org/10.1189/jlb.3HI1215-542R>

Anti-drug antibodies of IL-17 inhibitors for psoriasis: a  
systematic review.

Norden A, Oulee A, Munawar L, Javadi SS, Han G, Wu JJ.  
J Dermatolog Treat. 2022 Aug 16:1-12. doi:  
10.1080/09546634.2022.2114288. Online ahead of  
print.  
PMID: 35972196 Review. ei ole M

J, Deza G, Vilarrasa E, et al. Treatment of patients  
with plaque psoriasis with secukinumab in a real-life

setting: a 52-week, multicenter, retrospective study in Spain. J Dermatol Treat. 2018:1-21. Otettu

Treatment of patients with plaque psoriasis with **secukinumab** in a real-life setting: a 52-week, multicenter, retrospective study in Spain.

J, Deza G, Vilarrasa E, Valentí F, Muñoz C, Mollet J, Rocamora V, Carrascosa JM, Del Alcázar E, Alsina M, Vidal D, Puig L, López-Ferrer A, Riera J, Gallardo F, Ferran M.  
J Dermatolog Treat. 2019 Aug;30(5):424-429. Otettu 28.2.20

The current standard of care and the unmet needs for axial spondyloarthritis.

Noureldin B, Barkham N.

Rheumatology (Oxford). 2018 Aug 1;57(suppl\_6):vi10-vi17. doi: 10.1093/rheumatology/key217. Review.

**Free PMC Article Otettu 28.2.20**

**Ref Katsottu 11.4.20.**

Nowak EC, et al. IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med. 2009; 206:1653–1660. [PubMed: 19596803] Otettu 9.3.16

Novartis US. Summary of prescribing information (Secukinumab). <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx.pdf>. Accessed May 17, 2018. Otettu 6.3.20

The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges.

Noviello D, Mager R, Roda G, Borroni RG, Fiorino G, Vetrano S.

Front Immunol. 2021 May 17;12:611256. doi: 10.3389/fimmu.2021.611256. eCollection 2021. PMID: 34079536 **Free PMC article.** Otettu 30.8.22

Cutaneous and systemic improvements in psoriasis patients after different biologic treatments in a real-world longitudinal prospective study.

Ntawuyamara E, Deng B, Liang Y.

Sci Rep. 2025 May 3;15(1):15528. doi:

10.1038/s41598-025-99075-9.

PMID: 40319105 [Free PMC article.](#) Otettu 4.6.25

Numasaki M, Fukushi J, Ono M, et al.: Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003, 101:2620–2627. Otettu 9.3.16

Numasaki, M., Lotze, M. T., and Sasaki, H. (2004). Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. *Immunol. Lett.* 93, 39–43. doi: 10.1016/j.imlet.2004. 01.014    Otettu 9.3.16

Nurieva R, Yang XO, Martinez G, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. *Nature* 2007;448:480.    Otettu 9.3.16

1. Nurieva, R., X. O. Yang, Y. Chung, and C. Dong. 2009. Cutting edge: in vitro generated Th17 cells maintain their cytokine expression program in normal but not lymphopenic hosts. *J. Immunol.* 182: 2565–2568.    Otettu 21.3.20



[Rationale and early clinical data on IL-17 blockade in psoriasis.](#)

Nwe SM, Champlain AH, Gordon KB.

Expert Rev Clin Immunol. 2013 Jul;9(7):677-82. doi:

Otettu 9.3.16

[Similar articles](#)

The Cost-Effectiveness of Anti-IL17 Biologic Therapies for Moderate-to-Severe Plaque Psoriasis Treatment in Italy and Germany: A Sequential Treatment Analysis.

Nyholm N, Danø A, Schnack H, Colombo GL.

Clinicoecon Outcomes Res. 2023 Jul 28;15:607-619. doi: 10.2147/CEOR.S417922. eCollection 2023.

PMID: 37533798 [Free PMC article.](#) Otettu 12.10.23

Peripheral Blood Mononuclear Cells from Patients with Type 1 Diabetes and Diabetic Retinopathy Produce Higher Levels of IL-17A, IL-10 and IL-6 and Lower Levels of IFN- $\gamma$ -A Pilot Study.

Obasanmi G, Lois N, Armstrong D, Hombrebueno JMR, Lynch A, Chen M, Xu H.

Cells. 2023 Jan 31;12(3):467. doi: 10.3390/cells12030467.

PMID: 36766809 [Free PMC article.](#) Otettu 14.6.23

New-Onset Collagenous Colitis in a Patient With Psoriatic Arthritis: Can It Be **Secukinumab**?

Obeidat AE, Murakami TT.

Cureus. 2021 Jul 3;13(7):e16147. doi: 10.7759/cureus.16147. eCollection 2021 Jul.

PMID: 34367765 [Free PMC article.](#) Otettu 3.3.22

Obermajer, N., J. L. Wong, R. P. Edwards, K. Chen, M. Scott, S. Khader, J. K. Kolls, K. Odunsi, T. R. Billiar, and P. Kalinski. 2013. Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling. *J. Exp. Med.* 210: 1433–1445. Otettu 9.3.16

Two functionally distinct subsets of IL-17 producing  $\gamma\delta$  T cells.

O'Brien RL, Born WK.

*Immunol Rev.* 2020 Nov;298(1):10-24. doi:

10.1111/imr.12905. Epub 2020 Jul 22.

PMID: 32700361 Review. Otettu 30.11.22

## Drivers of Inflammation in Psoriatic Arthritis: the Old and the New.

O'Brien-Gore C, Gray EH, Durham LE, Taams LS, Kirkham BW.

Curr Rheumatol Rep. 2021 Apr 28;23(6):40. doi: 10.1007/s11926-021-01005-x.

PMID: 33909160 Review. Otta Myöhemmin

## Secukinumab May Be an Effective Treatment Option for Axial Spondyloarthritis and Psoriatic Arthritis Patients with a History of Malignancy: Multicenter Real-Life Experience from Turkey.

Ocak T, Yağız B, Ocak B, Yoğurtçu Ö, Başıbüyük F, Tezcan D, Ermurat S, İnanç E, Yamancan G, Albayrak F, Sağır RP, Bayındır Akbaş AN, Cüre O, Coşkun BN, Yolbaş S, Karasu U, Kısacık B, Koca SS, Sarı İ, Akar S, Dalkılıç E, Pehlivan Y.

J Clin Med. 2024 Oct 18;13(20):6216. doi: 10.3390/jcm13206216.

PMID: 39458166 Free PMC article. Otettu 1.3.25

A case of secondary IgA nephropathy accompanied by psoriasis treated with **secukinumab**.

Ochi M, Toyama T, Ando M, Sato K, Kamikawa Y, Sagara A, Kitajima S, Hara A, Iwata Y, Sakai N, Shimizu M, Furuichi K, Hamaguchi Y, Kaneko S, Wada T.

CEN Case Rep. 2019 Aug;8(3):200-204. doi: **Free PMC Article Otettu 28.2.20**

**Ref. katsottu 6.3.2020**

Evaluating **Secukinumab** as Treatment for Axial  
Spondyloarthritis and Psoriatic Arthritis in Patients with  
Comorbidities: Multicenter Real-Life Experience.

Ocak T, Yağız B, Coşkun BN, Akkuzu G, Bayındır Akbaş AN, Kudaş Ö, İnanç E, Yoğurtçu Ö, Başıbüyük F, Zontul S, Albayrak F, Akar ZA, Sunkak S, Ermurat S, Tezcan D, Küçük A, Yolbaş S, Sarı İ, Yiğit M, Akar S, Kısacık B, Bes C, Dalkılıç E, Pehlivan Y.

J Clin Med. 2025 Jul 22;14(15):5181. doi:  
10.3390/jcm14155181.

PMID: 40806803 **Free PMC article.** Otettu 22.8.25

UCP3 reciprocally controls CD4<sup>+</sup> Th17 and Treg cell differentiation.

O'Connor EB, Muñoz-Wolf N, Leon G, Lavelle EC, Mills KHG, Walsh PT, Porter RK.

PLoS One. 2020 Nov 19;15(11):e0239713. doi: 10.1371/journal.pone.0239713. eCollection 2020. PMID: 33211703 [Free PMC article](#). Otettu 2.9.22

O'Connor W, Kamanaka M, Booth CJ, *et al.* a protective function for interleukin 17a in T cell-mediated intestinal inflammation. *Nat Immunol* 2009;10:603–9. Otettu 7.3.20  
Ref. katsottu 9.3.20

O'Connor W. Jr, Zenewicz L.A., Flavell R.A. The dual nature of TH17 cells: shifting the focus to function. Nat Immunol 2010;11:471–476. Otettu 9.3.16

1. O'Garra A, Stockinger B, Veldhoen M. Differentiation of human T(H)-17 cells does require TGF- beta! Nat Immunol. 2008;9(6):588-590. Otettu 12.3.20
2. Ref. ei katsot



## Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis.

Ogdie A, Gladman DD, Coates LC, Pournara E, Parikh B, Mease PJ.

Rheumatol Ther. 2023 May 6. doi:

10.1007/s40744-023-00548-y. Online ahead of print.

PMID: 37148474 [Free article.](#) Otettu 12.6.23

## Tissue-resident-like CD4<sup>+</sup> T cells secreting IL-17 control *Mycobacterium tuberculosis* in the human lung.

Ogongo P, Tezera LB, Ardain A, Nhamoyebonde S, Ramsuran D, Singh A, Ng'oepe A, Karim F, Naidoo T, Khan K, Dullabh KJ, Fehlings M, Lee BH, Nardin A, Lindestam Arlehamn CS, Sette A, Behar SM, Steyn AJ, Madansein R, Kløverpris HN, Elkington PT, Leslie A.

J Clin Invest. 2021 May 17;131(10):e142014. doi:

10.1172/JCI142014.

PMID: 33848273 [Free PMC article.](#) Clinical Trial. Otettu 30.8.22

.

[Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction.](#)

Ogura H, Murakami M, Okuyama Y, Tsuruoka M, Kitabayashi C, Kanamoto M, Nishihara M, Iwakura Y, Hirano T.

Immunity. 2008 Oct 17;29(4):628-36. doi:

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

Evaluation of the efficacy, safety, and side effects of **secukinumab** in patients with moderate-to-severe psoriasis: real-world data from a retrospective multicenter study.

Oguz Topal I, Baysak S, Altunay İK, Kara Polat A, Arıkan EE, Özkur E, Aytekin S, Dogan B, Özkök Akbulut T, Topaloğlu Demir F, Karadağ AS.

An Bras Dermatol. 2022 Jul 14:S0365-0596(22)00120-9.  
doi: 10.1016/j.abd.2021.11.002. Online ahead of print.  
PMID: 35843765 **Free article.** Otettu 26.8.22

Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: A single-center experience.

Ohata C, Ohyama B, Katayama E, Nakama T.  
J Dermatol. 2020 Jan 28. Otettu 28.2.20

Ohman L, Dahlen R, Isaksson S, et al. Serum IL-17A in newly diagnosed treatment-naive patients with ulcerative colitis reflects clinical disease severity and predicts the

course of disease. Inflamm Bowel Dis.  
2013;19:2433-2439. Otettu 15.3.20

Ref. katsottu 15.3.20

**Secukinumab** efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.

Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A, Shima T, Papavassilis C, Nakagawa H; ERASURE Study Japanese subgroup.

J Dermatol. 2014 Dec;41(12):1039-46. doi: Otettu  
9.3.16

[Similar articles](#)

Inflammatory bowel disease new-onset during **secukinumab** therapy: real-world data from a tertiary center.

Ojeda Gómez A, Madero Velázquez L, Buendía Sanchez L, Pascual Sánchez I, Pérez Rabasco E, García Monsalve A, González Ferrández JA, García Sepulcre MF.

Rev Esp Enferm Dig. 2021 Dec;113(12):858-859. doi: 10.17235/reed.2021.8397/2021.

PMID: 34696593 [Free article.](#) Otettu 3.3.22

Okamoto K, et al. IkappaBzeta regulates T(H)17 development by cooperating with ROR nuclear receptors. Nature. 2010; 464:1381–1385. [PubMed: 20383124] Otettu 9.3.16

Okamoto Yoshida, Y. et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced

granuloma in the lung. J. Immunol. **184**, 4414–4422 (2010). Otettu 25.3.20

A case of psoriasis and atopic dermatitis-like rash induced by **interleukin-17** and interleukin-23 inhibitors successfully controlled with upadacitinib.

Okazaki T, Takahashi T, Sugiura R, Shimada-Omori R, Asano Y.

JAAD Case Rep. 2025 Jul 5;63:73-76. doi:

10.1016/j.jdcr.2025.06.033. eCollection 2025 Sep.

PMID: 40787046 **Free PMC article**. No abstract available. Otettu 22.8.25

The Role of Doxycycline and **IL-17** in Regenerative Potential of Periodontal Ligament Stem Cells: Implications in Periodontitis.

Okić Đorđević I, Kukolj T, Živanović M, Momčilović S, Obradović H, Petrović A, Mojsilović S, Trivanović D, Jauković A.

Biomolecules. 2023 Sep 24;13(10):1437. doi: 10.3390/biom13101437.

PMID: 37892119 [Free PMC article](#). Otettu 14.3.24

**Secukinumab:** Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab.

Okita AL, Benini T, Longhi DR.

Dermatol Pract Concept. 2020 Oct 26;10(4):e2020102. doi: 10.5826/dpc.1004a102. eCollection 2020 Oct.

PMID: 33150038 [Free PMC article](#). Otettu 13.12.20

Transcriptome analysis of immune cells from Behçet's syndrome patients: the importance of IL-17-producing cells and antigen-presenting cells in the pathogenesis of Behçet's syndrome.

Okubo M, Sumitomo S, Tsuchida Y, Nagafuchi Y, Takeshima Y, Yanaoka H, Shirai H, Kobayashi S, Sugimori Y, Maeda J, Hatano H, Iwasaki Y, Shoda H, Okamura T, Yamamoto K, Fujio K.

Arthritis Res Ther. 2022 Aug 8;24(1):186. doi: 10.1186/s13075-022-02867-x.

PMID: 35941595 [Free PMC article.](#) Otettu 27.8.22

[Risk of adverse events of psoriasis treatment with biologic agents and new small molecules-BIOBADADERM Registry.](#)

Olivares-Guerrero M, Daudén E, Riera-Monroig J, González-Quesada A, Sahuquillo-Torralba A, Rivera-Díaz R, Carrascosa JM, Belinchón I, Gómez-García FJ, Herrera-Acosta E, Ruiz-Genao DP, Baniandrés-Rodríguez O, Ferrán M, de la Cueva P, Rodríguez L, Mateu A, Ruiz-Carrascosa JC, Ara-Martín M, Abalde-Pintos MT, Roncero-Riesco M, Pujol-Marco C, García-Donoso C, Llamas-Velasco M, Del Alcázar E, Suárez-Pérez J,



Rodríguez-Sánchez B, Díez-Madueño K, Ruiz-Villaverde R, Lezcano-Biosca V, González-Sixto B, Descalzo MÁ, García-Doval I.

J Eur Acad Dermatol Venereol. 2025 May 19. doi: 10.1111/jdv.20738. Online ahead of print.  
PMID: 40387427 Otta M

**Secukinumab** in refractory non-infectious anterior uveitis.

Olivas-Vergara OM, Hernanz I, Borges-Deniz PE, Romero-Bueno F, Sanchez-Pernaute O, Carreño E. Front Ophthalmol (Lausanne). 2025 Feb 27;5:1491981. doi: 10.3389/fopht.2025.1491981. eCollection 2025. PMID: 40084348 **Free PMC article.** Otettu 4.6.25

Circulating **interleukin-17A** in patients with acute and chronic coronary syndromes.

Oliveira DC, Oliveira CGC, Mendes EB Jr, Silveira MM, Cabral JV, Ferreira E.

Am J Cardiovasc Dis. 2021 Dec 15;11(6):704-709.  
eCollection 2021.

PMID: 35116182 [Free PMC article.](#) Otettu 28.7.22

Olivito B, Simonini G, Ciullini S, Moriondo M, Betti L, Gambineri E, et al. Th17 transcription factor RORC2 is inversely correlated with FOXP3 expression in the joints of children with juvenile idiopathic arthritis. J Rheumatol 2009;36:2017–24. Otettu 4.3.16

Olsen T, Rismo R, Cui G, et al. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. *Cytokine*. 2011;56:633–640.  
Otettu 20.9.20

### The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease.

Olveira A, Augustin S, Benlloch S, Ampuero J, Suárez-Pérez JA, Armesto S, Vilarrasa E, Belinchón-Romero I, Herranz P, Crespo J, Guimerá F, Gómez-Labrador L, Martín V, Carrascosa JM. *Life (Basel)*. 2023 Feb 2;13(2):419. doi: 10.3390/life13020419.  
PMID: 36836776 [Free PMC article](#). Otettu 14.6.23

## Osteopoikilosis in a young ankylosing spondylitis patient.

Omelchenko V, Letyagina E, Korolev M.

J Rheum Dis. 2024 Oct 1;31(4):253-256. doi: 10.4078/jrd.2024.0040. Epub 2024 Aug 27.

PMID: 39355545 [Free PMC article.](#) Otettu 1.3.25

Omoyinmi, E., Hamaoui, R., Pesenacker, A., Nistala, K., Moncrieffe, H., Ursu, S., Wedderburn, L. R., Woo, P. (2012) Th1 and Th17 cell subpopulations are enriched in the peripheral blood of patients with systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 51, 1881–1886. Otettu 9.3.16

**Secukinumab** as a potential trigger of inflammatory bowel disease in ankylosing spondylitis or psoriatic arthritis patients.

Onac IA, Clarke BD, Tacu C, Lloyd M, Hajela V, Batty T, Thoroughgood J, Smith S, Irvine H, Hill D, Baxter G, Horwood N, Mahendrakar S, Rajak R, Griffith S, Kiely PDW, Galloway J.

Rheumatology (Oxford). 2021 Mar 2:keab193. doi: 10.1093/rheumatology/keab193. Online ahead of print. PMID: 33677579 Otettu 8.8.21

Onishi RM, Gaffen SL (2010) Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 129:311–321 Otettu 9.3.16

Interleukin-17A is a potential therapeutic target predicted by proteomics for systemic sclerosis patients at high risk of pulmonary arterial hypertension.

Ono Y, Mogami A, Saito R, Seki N, Ishigaki S, Takei H, Yoshimoto K, Chiba K, Takeuchi T, Kaneko Y.

Sci Rep. 2024 Nov 27;14(1):29484. doi: 10.1038/s41598-024-76987-6.

PMID: 39604413 [Free PMC article](#). Otettu 1.3.25

**Secukinumab** reduces synovitis in PsA.

Onuora S.

Nat Rev Rheumatol. 2021 Nov;17(11):644. doi: 10.1038/s41584-021-00701-3.

PMID: 34584259 Otettu 3.3.22

**Secukinumab** might improve enthesitis in SpA.

Onuora S.

Nat Rev Rheumatol. 2022 Jan;18(1):4. doi:  
10.1038/s41584-021-00734-8.

PMID: 34862492    Otettu 3.3.22

**Secukinumab** effective for nr-axSpA.

Onuora S.

Nat Rev Rheumatol. 2020 Aug 25. doi:  
10.1038/s41584-020-0496-z. Online ahead of print.

PMID: 32843736    Otettu 20.9.20

Long-term fatigue relief with **secukinumab** for AS.

Onuora S.

Nat Rev Rheumatol. 2020 Dec 2. doi:  
10.1038/s41584-020-00557-z. Online ahead of print.

PMID: 33268835    Otettu 13.12.20

Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis.

Ooms A, Al-Mossawi H, Bennett L, Bogale M, Bowness P, Francis A, Goodyear C, Kirkham BW, Lalnunhlmi S, McInnes IB, Richards D, Siebert S, Taams LS, Tulunay Virlan A, Yager N, Coates LC.

BMJ Open. 2023 Sep 28;13(9):e078539. doi: 10.1136/bmjopen-2023-078539.

PMID: 37770264 [Free PMC article](#). [Otetu 12.10.23](#)

O'Quinn, D.B., Palmer, M.T., Lee, Y.K., and Weaver, C.T. (2008). Emergence of the Th17 pathway and its role in host defense. Adv. Immunol. 99, 115–163. [ei ole M](#)



Effect of **Secukinumab** on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients.

Orbai AM, McInnes IB, Coates LC, Husni ME, Gladman DD, Gossec L, Pricop L, Chambenoit O, Meng X, Mease PJ.

J Rheumatol. 2019 Oct 15. pii: jrheum.190507. doi: 10.3899/jrheum.190507. [Epub ahead of print]

PMID: 31615919 **Free Article** **Otettu 28.2.20**

**Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies.**

Orbai AM, Husni ME, Gladman DD, Leung YY, Siebert S, Tillett W, Vis M, Chambenoit O, Meng X, Mease PJ.

Rheumatol Ther. 2021 Sep;8(3):1223-1240. doi:

10.1007/s40744-021-00337-5. Epub 2021 Jul 3.

PMID: 34218429 **Free PMC article.** **Otettu 30.8.22**

**Interleukin-17A induces vascular remodeling of small arteries and blood pressure elevation.**

Orejudo M, García-Redondo AB, Rodrigues-Diez RR, Rodrigues-Díez R, Santos-Sanchez L, Tejera-Muñoz A, Egido J, Selgas R, Salaices M, Briones AM, Ruiz-Ortega M.

Clin Sci (Lond). 2020 Mar 13;134(5):513-527. doi:  
10.1042/CS20190682.  
PMID: 32104886    ei ole M

Orgun, N. N., M. A. Mathis, C. B. Wilson, and S. S. Way.  
2008. Deviation from a strong Th1-dominated to a  
modest Th17-dominated CD4 T cell response in the  
absence of IL-12p40 and type I IFNs sustains protective  
CD8 T cells. J. Immunol. 180: 4109–4115.  
Otettu 9.3.16

Pyoderma gangrenosum caused by **secukinumab**  
successfully treated with risankizumab: a case report  
and literature review.

Orita A, Hoshina D, Hirosaki K.

Clin Exp Dermatol. 2022 Jul;47(7):1372-1374. doi:  
10.1111/ced.15183. Epub 2022 Apr 22.

PMID: 35298047 Review. Otettu 30.11.22

A Case for Targeting Th17 Cells and IL-17A in  
SARS-CoV-2 Infections.

Orlov M, Wander PL, Morrell ED, Mikacenic C, Wurfel  
MM.

J Immunol. 2020 Aug 15;205(4):892-898. doi:  
10.4049/jimmunol.2000554. Epub 2020 Jul 10.

PMID: 32651218 [Free PMC article](#). Otettu 30.11.22

93.

[Is there a need for new agents with novel mechanisms  
of action in psoriatic arthritis?](#)

Orr C, Veale DJ.

Ann Rheum Dis. 2014 Jun;73(6):951-3. doi:  
10.1136/annrheumdis-2013-204934. No abstract  
available.

PMID:

Otettu 9.3.16

[Similar articles](#)

Inflammatory bowel disease events after exposure to  
the IL-17 inhibitors, **secukinumab** and ixekizumab: A  
post-marketing analysis from the RADAR (Research  
on Adverse Drug events And Reports) Program.

Orrell KA, Murphrey M, Kelm RC, Lee HH, Pease DR,  
Laumann AE, West DP, Nardone B.

J Am Acad Dermatol. 2018 Jun 16. pii:

S0190-9622(18)32146-7. doi: Otettu 3.9.18

[Similar articles](#)

Ortega C, Fernandez A S, Carrillo J M et al. J  
Leukoc Biol 2009; 86: 435–443. Otettu 9.3.16

A prospective multicenter study assessing  
effectiveness and safety of **secukinumab** in a  
real-life setting in 158 patients.

Ortiz-Salvador JM, Saneleuterio-Temporal M,  
Magdaleno-Tapial J, Velasco-Pastor M, Pujol-Marco  
C, Sahuquillo-Torralba A, Mateu-Puchades A,  
Pitarch-Bort G, Marí-Ruiz JI, Mataix-Díaz J,  
Montesinos-Villaescusa E, Miralles-Botella J,  
García-Fernández L, Martorell-Calatayud A,  
Belinchón-Romero I, Sánchez-Carazo JL,  
Pérez-Ferriols A.

J Am Acad Dermatol. 2019 Aug;81(2):427-432.

**Free Article   Otettu 28.2.20**

**Ref. katsottu 4.3.2020**

**Secukinumab** Drug Survival in Psoriasis and Psoriatic Arthritis Patients: A 24-Month Real-Life Study.

, Lorenzin M, Leo G, Pampaloni F, Messina F, Doria A, Piaserico S, Ramonda R.

Dermatology. 2022 Mar 9:1-7. doi: 10.1159/000522008.

Online ahead of print.

PMID: 35263743   ei oteta

823.

[Signal transduction and Th17 cell differentiation.](#)

O'Shea JJ, Steward-Tharp SM, Laurence A, Watford WT, Wei L, Adamson AS, Fan S.

Microbes Infect. 2009 Apr;11(5):599-611. doi: 10.1016/j.micinf.2009.04.007. Epub 2009 Apr 18.

Review.

PMID:

19379825 Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

**[The effect of interleukin-17 on the course of juvenile idiopathic arthritis](#)**

Oshlyanska, O.A. ; Dzyublyk, I.V. ; Melanchuk, N.A.

The Journal of V.N. Karazin Kharkiv National University. Series "Medicine" (Online), 2024-12 (51), p.453-463

*... – The aim is to study the influence of interleukin 17 on the course of idiopathic arthritis...*

PEER REVIEWED

OPEN ACCESS Otta M

Osorio F, LeibundGut-Landmann S, Lochner M, Lahl K, Sparwasser T, Eberl G, Reis e Sousa C. DC activated via dectin-1 convert Treg into IL-17 producers. Eur J Immunol. 2008; 38:3274– 3281. Otettu 17.3.20

Increased expression of psoriasin (S100A7) and **interleukin 17** (IL-17) in lesional skin in lichen planopilaris.

Otlewska-Szpotowicz A, Baran W, Woźniak Z, Szepietowski J, Batycka-Baran A.

Postepy Dermatol Alergol. 2024 Aug;41(4):364-371. doi: 10.5114/ada.2024.142179. Epub 2024 Aug 12.

PMID: 39290897 **Free PMC article.** Otettu 24.10.24



Ouyang, W., J.K. Kolls, and Y. Zheng. 2008. The biological functions of T helper 17 cell effector cytokines in inflammation. *Immunity*. 28:454–467. Otettu 9.3.16

Ouyang, X., Zhang, R., Yang, J., Li, Q., Qin, L., Zhu, C., et al. (2011). Transcription factor IRF8 directs a silencing programme for TH17 cell differentiation. *Nat. Commun.* 2:314. doi: 10.1038/ncomms1311 Otettu 9.3.16

[The effect of therapy on TRM in psoriatic lesions.](#)

Owczarczyk-Saczonek A, Kasprowicz-Furmańczyk M, Czerwińska J, Krajewska-Włodarczyk M, Placek W.

[Postepy Dermatol Alergol. 2022 Feb;39\(1\):209-220. doi: 10.5114/ada.2021.113125. Epub 2022 Feb 4.](#)

PMID: 35369631 [Free PMC article.](#) Otettu 26.8.22

**Secukinumab**-induced IgA vasculitis in a patient with psoriatic arthritis.

Ozince RB, Ak T, Erzin YZ, Melikoglu M, Seyahi E.

Int J Rheum Dis. 2023 Mar 16. doi:

10.1111/1756-185X.14667. Online ahead of print.

PMID: 36929128 Otta M

Qian Y, Liu C, Hartupée J, Altuntas CZ, Gulen MF, Jane-Wit D, et al. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol 2007;8:247–56. Otettu 9.3.16

Qin H, et al. TGF-beta promotes Th17 cell development through inhibition of SOCS3. J Immunol. 2009; 183:97–105. Otettu 9.3.16

### COVID-19: a case for inhibiting IL-17?

Pacha O, Sallman MA, Evans SE.

Nat Rev Immunol. 2020 Jun;20(6):345-346. doi: 10.1038/s41577-020-0328-z.

PMID: 32358580 [Free PMC article](#). Otettu 5.9.22

### Enhanced Type 1 Interferon Signature in Axial Spondyloarthritis Patients Unresponsive to Secukinumab Treatment.

Pacheco A, Maguire S, Qaiyum Z, Tang M, Bridger A, Lim M, Tavasolian F, Yau E, Crome SQ, Haroon N, Inman RD.

Arthritis Rheumatol. 2024 Aug 19. doi:  
10.1002/art.42974. Online ahead of print.  
PMID: 39160761    Otta M

[The danger model approach to the pathogenesis of the  
rheumatic diseases.](#)

Pacheco-Tena C, González-Chávez SA.  
J Immunol Res. 2015;2015:506089. doi:. Epub 2015 Apr  
20. Review.  
PMID:

[Free PMC Article](#)

[Similar articles](#)

Select item 2595730744. Otettu 3.2.16

**Secukinumab** therapy in reactive arthritis: Report of two  
cases.

Padhan P, Maikap D.

Mod Rheumatol Case Rep. 2022 Jan 7;6(1):22-24. doi: 10.1093/mrcr/rxab014.

PMID: 34508266 Otettu 3.3.22

**Interleukin 17A rs2275913 polymorphism is associated with susceptibility to systemic lupus erythematosus: A meta and trial sequential analysis.**

Padhi S, Sarangi S, Nayak N, Barik D, Pati A, Panda AK.

Lupus. 2022 May;31(6):674-683. doi: 10.1177/09612033221090172. Epub 2022 Mar 30.

PMID: 35353646 Otettu 30.11.22

**Mild therapeutic response of alopecia areata during treatment of psoriasis with secukinumab.**

Pagnanelli G, Cavani A, Canzona F, Mazzanti C.

Eur J Dermatol. 2020 Oct 1;30(5):602-603. doi:  
10.1684/ejd.2020.3866.  
PMID: 33185532 Otettu 13.12.20

[Targeting the interleukin-23/17 axis in axial  
spondyloarthritis.](#)

Paine A, Ritchlin CT.

Curr Opin Rheumatol. 2016 Jul;28(4):359-67. doi:  
Otettu 27.5.18

**[Free PMC Article](#)**

[Similar articles](#)

Comment on "**Secukinumab** drug survival in patients with psoriasis: A multicenter, real-world, retrospective study".

Palacios-García L, Gómez-de Castro C, Mir-Bonafé M, Calzón C, Galache C, Santos-Juanes J.

J Am Acad Dermatol. 2019 Sep;81(3):e81-e82.

Otettu 28.2.20

Ref. katsottu 4.3.20

Neutrophil extracellular traps in giant cell arteritis biopsies: presentation, localization and co-expression with inflammatory cytokines.

Palamidas DA, Argyropoulou OD, Georgantzoglou N, Karatza E, Xingi E, Kapsogeorgou EK, Anagnostopoulos CD, Lazaris AC, Ritis K, Goules AV, Kambas K, Tzioufas AG.

Rheumatology (Oxford). 2022 Apr 11;61(4):1639-1644.  
doi: 10.1093/rheumatology/keab505.  
PMID: 34260696 Otetu 30.11.22

Resolution of post-adalimumab vitiligo with  
**secukinumab** in a patient with psoriasis vulgaris.

Palazzo G.

Oxf Med Case Reports. 2020 Jan 31;2020(1):omz134.

**Free PMC Article Otettu 28.2.20**

**Ref. katsottu 12.3.20**

Management of Dactylitis in Patients With Psoriatic  
Arthritis: An Updated Literature Review Informing the  
2021 GRAPPA Treatment Recommendations.



Palominos PE, Fernández-Ávila DG, Coates LC, Adebajo A, Toukap AN, Abogamal A, Polachek A, van Kuijk AWR, Caso F, de Marco G, Kaeley GS, Steinkoenig I, Chau J, Feletar M, Vis M, Elkayam O, Sewerin P, d'Angelo S, Aydin SZ, AlShehhi W, Helliwell PS.

J Rheumatol. 2023 Feb;50(2):265-278. doi:

10.3899/jrheum.220311. Epub 2022 Nov 1.

PMID: 36319013 **Free article.** Review. Otettu 12.10.23

The Safety Profiles of Adalimumab, Infliximab, Etanercept, **Secukinumab** and Ustekinumab in Psoriasis - A 30-month Observational Cohort Prospective Study of Adverse Events in Biologic Therapy.

Paluch Z, Marques E, Boháč P, Zemková K, Hercogová J.

Acta Dermatovenereol Croat. 2024 Mar;32(1):7-16.

PMID: 38946182 Otta M

Ixekizumab therapy following secukinumab inadequate response in psoriatic arthritis: a case series focusing on axial disease.

Panagiotopoulos A, Koutsianas C, Kougkas N, Moschou D, Bournia VK, Gazi S, Tektonidou MG, Vassilopoulos D, Sfrikakis PP, Fragoulis GE.

Rheumatol Int. 2023 May;43(5):969-973. doi: 10.1007/s00296-023-05289-3. Epub 2023 Feb 25. PMID: 36840819 Otta M

586.

[Developments in the immunology of rheumatoid arthritis, a personal perspective.](#)

Panayi GS.

Rheumatology (Oxford). 2011 May;50(5):815-7. doi: 10.1093/rheumatology/ker024. No abstract available.

PMID:

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

**Secukinumab** in Erythrodermic Psoriasis: Real World Experience of 6 Patients Successfully Treated by Injecting at Unconventional Sites.

Panda M, Raj C, Panda AK, Debata I.

Indian J Dermatol. 2021 Nov-Dec;66(6):677-680. doi: 10.4103/ijd.ijd\_221\_21.

PMID: 35283534 [Free PMC article](#). Otettu 26.8.22

Regulation of IL-17A-Producing Cells in Skin Inflammatory Disorders.

Pandiyan P, McCormick TS.

J Invest Dermatol. 2022 Mar;142(3 Pt B):867-875. doi: 10.1016/j.jid.2021.06.036. Epub 2021 Sep 22.

PMID: 34561088 Review. Otettu 30.11.22

**Secukinumab** efficacy in patients with PsA is not dependent on patients' body mass index.

Pantano I, Iacono D, Favalli EG, Scalise G, Costa L, Caso F, Guggino G, Scarpa R, Ciccio F.  
Ann Rheum Dis. 2020 Mar 13. pii: annrheumdis-2020-217251. doi: Otettu 29.3.20

Pantelyushin S, Haak S, Ingold B et al. J Clin Investig 2012; 122: 2252–2256. Otettu 9.3.16

**Facial Erysipelas After Secukinumab Therapy.**

Pantoja Zarza L, Díez Morrondo C.

Reumatol Clin. 2018 Aug 20. pii:  
S1699-258X(18)30171-2. doi:  
10.1016/j.reuma.2018.07.012. [Epub ahead of print]  
English, Spanish. No abstract available.  
PMID:

30139691    Ei oteta

**Free Article**

[Similar articles](#)

Neutrophil Extracellular Traps and **Interleukin 17** in  
Ankylosing Spondylitis.

Papagoras C, Chrysanthopoulou A, Mitsios A, Tsironidou  
V, Ritis K.

Mediterr J Rheumatol. 2021 Jun 30;32(2):182-185. doi:  
10.31138/mjr.32.2.182. eCollection 2021 Jun.

PMID: 34447919 **Free PMC article.**    Otettu 29.8.22

IL-17A expressed on neutrophil extracellular traps promotes mesenchymal stem cell differentiation toward bone-forming cells in ankylosing spondylitis.

Papagoras C, Chrysanthopoulou A, Mitsios A, Ntinopoulou M, Tsironidou V, Batsali AK, Papadaki HA, Skendros P, Ritis K.

Eur J Immunol. 2021 Apr;51(4):930-942. doi: 10.1002/eji.202048878. Epub 2021 Jan 22. PMID: 33340091 [Free article.](#) [Otettu 2.9.22](#)

[Achieving inactive disease in enthesitis-related arthritis with \*\*secukinumab\*\* following TNF- inhibitor failure.](#)

Papailiou S, Onoufriou M, Mentessidou L, Syggelou A, Tsolia MN, Maritsi DN.

Rheumatology (Oxford). 2023 Dec 7:kead656. doi: 10.1093/rheumatology/kead656. Online ahead of print. PMID: 38058199 No abstract available. [Otta M](#)

Myasthenia gravis associated with muscle-specific kinase antibodies in a patient treated with **interleukin-17** inhibitor.

Papi C, Granata G, Galluzzo M, Iorio R.

Neurol Sci. 2023 Mar;44(3):1105-1107. doi: 10.1007/s10072-022-06498-7. Epub 2022 Nov 11.

PMID: 36357816 Otta M

[Candida infections in psoriatic patients on anti-IL17 therapy: a case series.](#)

Papini M, Natalini Y.

J Dermatolog Treat. 2018;29(sup2):3-4. Otettu 9.3.20

Ref. katsottu 12.3.20

**Secukinumab** shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study.

Papini M, Cusano F, Romanelli M, Burlando M, Stinco G, Girolomoni G, Peris K, Potenza C, Offidani A, Bartezaghi M, Aloisi E, Costanzo A; SUPREME study group.

Br J Dermatol. 2019 Aug;181(2):413-414. doi: Otettu 28.2.20

**Secukinumab** is an effective and safe treatment for refractory pityriasis rubra pilaris: a case report and literature review.

Papini M, Russo A, Natalini Y, Troiani L, Cassiani L. G Ital Dermatol Venereol. 2020 Nov 12. doi: 10.23736/S0392-0488.20.06743-7. Online ahead of print.

PMID: 33179881 ei oteta



Papotto PH, Ribot JC, Silva-Santos B. IL-17 +  
gammadelta T cells as kick-starters of inflammation. Nat  
Immunol. 2017;18(6):604–11. Otettu 7.3.20

Ref. katsottu 22.3.20

[Crosstalk between  \$\gamma\delta\$  T cells and the microbiot.](#)

Papotto PH, Yilmaz B, Silva-Santos B.

Nat Microbiol. 2021 Sep;6(9):1110-1117. doi:  
10.1038/s41564-021-00948-2. Epub 2021 Aug 2.  
PMID: 34341528 Review. Otettu 30.8.22

Effectiveness and safety of **secukinumab** up dosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.

Papp KA, Gooderham M, Lynde C, Brassard D, Al-Mohammed F, Prajapati VH, Delorme I, Albrecht L, Haydey R, Alam MS, Beecker J, Siddha S, Maguin M, Farag MS, Vieira A, Rihakova L, Langley RG.

Arch Dermatol Res. 2024 Jun 8;316(7):362. doi: 10.1007/s00403-024-03122-w.

PMID: 38850346 [Free PMC article.](#) Otettu 27.9.24

Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-Analysis.

Papp KA, Vender R, Purdy K, Lovegrove F, Oroz I, Grewal P, Lansang P, Park-Wyllie L, Abbarin N, Yang YW, Hooper B, Vigelis S, Disher T, Langley RG.

Dermatol Ther (Heidelb). 2025 Jul 17. doi: 10.1007/s13555-025-01463-6. Online ahead of print.

PMID: 40676461 Otettu 28.7.25

Effectiveness and Safety of **Secukinumab** in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data.

Papp KA, Gooderham M, Dei-Cas I, LopezTello A, Garcia-Rodriguez JC, Taveras CY, Rousselin AH, Lavieri A, Maiolino M, Quintero DGV, Rihakova L, Salibe M, Pertuz W.

Dermatol Ther (Heidelb). 2023 Jan;13(1):269-283. doi: 10.1007/s13555-022-00849-0. Epub 2022 Dec 10. PMID: 36496547 [Free PMC article](#). otettu 12.6.23

Papp KA, Reid C, Foley P, et al. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol. 2012;132(10):2466–2469. Otettu 9.3.16

[Efficacy and safety of \*\*secukinumab\*\* in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.](#)

Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB.

Br J Dermatol. 2013 Feb;168(2):412-21. doi: 10.1

Otettu 9.3.16

[Similar articles](#)

Pappu R, Ramirez-Carrozzi V, N et al. J Clin Immunol 2010; 30: 185–195. Otettu 9.3.16

Pappu R, Ramirez-Carrozzi V, Sambandam A. The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases. Immunology. 2011;134(1):8–16.  
Otettu 9.3.16

The Th17/IL-17 Axis and Kidney Diseases, With Focus on Lupus Nephritis.

Paquissi FC, Abensur H.

Front Med (Lausanne). 2021 Sep 3;8:654912. doi: 10.3389/fmed.2021.654912. eCollection 2021.

PMID: 34540858 [Free PMC article](#). Otettu 29.8.22

Neutrophils mediate Th17 promotion in COVID-19 patients.

Parackova Z, Bloomfield M, Klocperk A, Sediva A.

J Leukoc Biol. 2021 Jan;109(1):73-76. doi:

10.1002/JLB.4COVCRA0820-481RRR. Epub 2020 Dec 2.

PMID: 33289169 [Free PMC article](#). Otettu 2.9.22

Paradowska A, Masliniski W, Grzybowska-Kowalczyk A, Lacki J. The function of interleukin 17 in the pathogenesis of rheumatoid arthritis. Arch Immunol Ther Exp (Warsz). 2007; 55:329–34. Otettu 19.3.20

Ref. katsottu 20.3.20

Paradowska-Gorycka A, Wojtecka-Lukasik E, Trefler J, Wojciechowska B, Lacki JK, Maslinski S. Association between IL-17F gene polymorphisms and susceptibility to and severity of rheumatoid arthritis (RA). Scand J Immunol 2010;72(2):134–41.

<http://dx.doi.org/10.1111/j.1365-3083.2010.02411.x>.

Otettu 7.3.20

Divergent molecular networks program functionally distinct CD8<sub>+</sub> skin-resident memory T cells.

Park SL, Christo SN, Wells AC, Gandolfo LC, Zaid A, Alexandre YO, Burn TN, Schröder J, Collins N, Han SJ, Guillaume SM, Evrard M, Castellucci C, Davies B, Osman M, Obers A, McDonald KM, Wang H, Mueller SN, Kannourakis G, Berzins SP, Mielke LA, Carbone FR, Kallies A, Speed TP, Belkaid Y, Mackay LK.

Science. 2023 Dec;382(6674):1073-1079. doi:

10.1126/science.adi8885. Epub 2023 Nov 30.

PMID: 38033053 Otta M

In vivo Function of Differential Subsets of Cutaneous Dendritic Cells to Induce Th17 Immunity in Intradermal *Candida albicans* Infection.

Park J, Kim SH, Lee J, Che L, Roh WS, Park CO, Lee MG, Kim TG.

J Vis Exp. 2021 Jul 20;(173). doi: 10.3791/62731.

PMID: 34369939    ei ole M

Retinoic Acid Receptor-Related Receptor Alpha Ameliorates Autoimmune **Arthritis** via Inhibiting of Th17 Cells and Osteoclastogenesis.

Park JS, Moon SJ, Lim MA, Byun JK, Hwang SH, Yang S, Kim EK, Lee H, Kim SM, Lee J, Kwok SK, Min JK, Lee MO, Shin DY, Park SH, Cho ML.



Front Immunol. 2019 Oct 4;10:2270. doi:  
10.3389/fimmu.2019.02270. eCollection 2019.  
PMID: 31636631 Otettu 21.9.20

Park H et al. A distinct lineage of CD4 T cells regulates  
tissue inflammation by producing IL-17. Nat Immunol  
2005;6:1133–41. tai Nat Immunol 2005, 6:1069-1070.  
Otettu 9.3.16  
Ref. ei katsot.

Role of innate lymphoid cells in chronic colitis during  
anti-IL-17A therapy.

Park CH, et al. Sci Rep. 2020. PMID: 31941937 Free PMC  
article. Otettu 7.9.22

[Celastrol regulates psoriatic inflammation and autophagy by targeting IL-17A.](#)

Park A, Heo TH.

Biomed Pharmacother. 2024 Mar;172:116256. doi: 10.1016/j.biopha.2024.116256. Epub 2024 Feb 16. PMID: 38367550 **Free article.** **Otettu 13.3.24**

[The link of HLA-B27 with interleukin-23/interleukin-17 axis in coexisting systemic lupus erythematosus and ankylosing spondylitis.](#)

Park SJ, Kim JH, Pai KS, Shin JI.

Lupus. 2011 Dec;20(14):1566. doi:

Otettu 9.3.16

[Similar articles](#)

Park, J., Park, M., Lee, S., Oh, H., Lim, M., Cho, W. et al. (2012) TWEAK promotes the production of interleukin-17 in rheumatoid arthritis. Cytokine 60: 143–149. Otettu 9.3.16

[Retinal attenuates inflammatory arthritis by reciprocal regulation of IL-17-producing T cells and Foxp3\(+\) regulatory T cells and the inhibition of osteoclastogenesis.](#)

Park MK, Jhun JY, Lee SY, Oh HJ, Park MJ, Byun JK, Yoon BY, Park EM, Lee DG, Kwok SK, Park SH, Kim HY, Cho ML.

Immunol Lett. 2012 Nov-Dec;148(1):59-68. doi: 10.1016/j.imlet.2012.05.008. Epub 2012 Jul 24.

PMID:

Otettu 9.3.16

[Similar articles](#)

[CD70-expressing CD4 T cells produce IFN- \$\gamma\$  and IL-17 in rheumatoid arthritis.](#)

Park JK, Han BK, Park JA, Woo YJ, Kim SY, Lee EY, Lee EB, Chalan P, Boots AM, Song YW.

Rheumatology (Oxford). 2014 Oct;53(10):1896-900. doi: 10.1093/rheumatology/keu171. Epub 2014 May 9.

PMID:

Otettu 9.3.16

[Similar articles](#)

[Role of innate lymphoid cells in chronic colitis during anti-IL-17A therapy.](#)

Park CH, Lee AR, Ahn SB, Eun CS, Han DS.

Sci Rep. 2020 Jan 15;10(1):297.

**Free PMC Article** Otettu 28.2.20

**Ref. katsottu 8.3.20**

[The role of interleukin-17 in neurological disorders.](#)

Park SE, Ferreira AFF, Kwon H, Yu J, Diniz L, Ulrich H, Britto LRG, Kim E.

Anim Cells Syst (Seoul). 2025 Jun 3;29(1):372-386. doi: 10.1080/19768354.2025.2510994. eCollection 2025.

PMID: 40469524 [Free PMC article](#). Review. Otettu  
31.7.25

[Restriction of innate  \$\gamma\delta\$ 17 cell plasticity by an AP-1  
regulatory axis.](#)

Parker ME, Mehta NU, Liao TC, Tomaszewski WH,  
Snyder SA, Busch J, Ciofani M.

Nat Immunol. 2025 Aug;26(8):1299-1314. doi:  
10.1038/s41590-025-02206-7. Epub 2025 Jun 27.

PMID: 40579554 Otta M

The Double Game Played by Th17 Cells in Infection:  
Host Defense and Immunopathology.

Paroli M, Caccavale R, Fiorillo MT, Spadea L, Gumina S, Candela V, Paroli MP.

Pathogens. 2022 Dec 15;11(12):1547. doi: 10.3390/pathogens11121547.

PMID: 36558881 [Free PMC article](#). Review. Otettu 14.6.23

## The Role of Interleukin-17 in Juvenile Idiopathic Arthritis: From Pathogenesis to Treatment.

Paroli M, Spadea L, Caccavale R, Spadea L, Paroli MP, Nante N.

Medicina (Kaunas). 2022 Oct 28;58(11):1552. doi: 10.3390/medicina58111552.

PMID: 36363508 [Free PMC article](#). otettu 12.6.23

Parsonage G, Filer A, Bik M, Hardie D, Lax S, Howlett K, et al.

2008. Prolonged, granulocyte-macrophage colony-stimulating factor-dependent, neutrophil survival following rheumatoid synovial fibroblast activation by IL-17 and TNFalpha. Arthritis Res Ther 10(2):R47.

Otettu 9.3.16

Dual Immune-Related Toxicities: **Secukinumab**-Induced Bullous Pemphigoid Following ICI-Associated Psoriasis in a Cancer Patient.

Paschou IA, Drantaki VI, Gerochristou M, Stefanaki I, Lingria A, Stratigos AJ, Nikolaou V.

Int J Dermatol. 2025 Apr 16. doi: 10.1111/ijd.17778.

Online ahead of print.

PMID: 40237141 No abstract available. Otta M

New insights on hidradenitis suppurativa phenotypes and treatment response: An exploratory automated analysis of the SUNSHINE and SUNRISE trials.

Passera A, Muscianisi E, Demanse D, Okoye GA, Jemec GBE, Mayo T, Hsiao J, Shi VY, Byrd AS, Wei X, Uhlmann L, Vandemeulebroecke M, Ravichandran S, Porter ML.

J Eur Acad Dermatol Venereol. 2024 Aug 5. doi: 10.1111/jdv.20234. Online ahead of print.

PMID: 39101698 Otettu 27.9.24

**Secukinumab** in adult patients with lichen planus: Efficacy and safety results from the randomised, placebo-controlled, proof-of-concept PRELUDE study.

Passeron T, Reinhardt M, Ehst B, Weiss J, Sluzevich J, Sticherling M, Reygagne P, Wohlrab J, Hertl M, Fazel N, Muscianisi E, Fan H, Hampele I, Compagno N.



Br J Dermatol. 2024 May 13;ljae181. doi:  
10.1093/bjd/ljae181. Online ahead of print.  
PMID: 38735684 Otettu 29.5.24

Passos ST, et al. IL-6 promotes NK cell production of  
IL-17 during toxoplasmosis. J. Immunol. 2010;  
184:1776–1783. Otettu 22.3.20

[RORγT agonists as immune modulators in anticancer  
therapy.](#)

Pastwińska J, Karwaciak I, Karaś K, Bachorz RA,  
Ratajewski M.

Biochim Biophys Acta Rev Cancer. 2023

Nov;1878(6):189021. doi:

10.1016/j.bbcan.2023.189021. Epub 2023 Nov 10.

PMID: 37951483 **Free article.** Review. Otettu 14.3.24

.  
[Effect of IL-17A blockade with \*\*secukinumab\*\* in autoimmune diseases.](#)

Patel DD, Lee DM, Kolbinger F, Antoni C.

Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii116-23. doi:

Otettu 9.3.16

[Similar articles](#)

Patel DD, Kuchroo VK. Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions. Immunity. **2015**;43(6):1040–1051. Otettu 12.3.20

Ref. katsottu 16.3.20

[A Review of the Use of \*\*Secukinumab\*\* for Psoriatic Arthritis.](#)

Patel NU, Vera NC, Shealy ER, Wetzel M, Feldman SR.

Rheumatol Ther. 2017 Dec;4(2):233-246. doi: Otettu  
27.5.18

[Free PMC Article](#)

[Similar articles](#)

## Increased Development of Th1, Th17, and Th1.17 Cells Under T1 Polarizing Conditions in Juvenile Idiopathic Arthritis.

Patrick AE, Shoaff K, Esmond T, Patrick DM, Flaherty DK, Graham TB, Crooke PS 3rd, Thompson S, Aune TM.

Front Immunol. 2022 Jul 4;13:848168. doi:

10.3389/fimmu.2022.848168. eCollection 2022.

PMID: 35860254 [Free PMC article.](#) Otettu 27.8.22

.  
[Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial.](#)

Paul C, Reich K, Gottlieb AB, Mrowietz U, Philipp S, Nakayama J, Harfst E, Guettner A, Papavassilis C; CAIN457A2211 study group.

J Eur Acad Dermatol Venereol. 2014

Dec;28(12):1670-5.

Otettu 9.3.16

[Similar articles](#)

[Efficacy, safety and usability of \*\*secukinumab\*\* administration by autoinjector/pen in psoriasis: a randomized, controlled trial \(JUNCTURE\).](#)

Paul C, Lacour JP, Tedremets L, Kreutzer K, Jazayeri S, Adams S, Guindon C, You R, Papavassilis C; JUNCTURE study group.

J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1082-90.

Otettu 9.3.16

[Similar articles](#)

[Synovial fibroblasts directly induce Th17 pathogenicity via the cyclooxygenase/prostaglandin E2 pathway, independent of IL-23.](#)

Paulissen SM, van Hamburg JP, Davelaar N, Asmawidjaja PS, Hazes JM, Lubberts E.

J Immunol. 2013 Aug 1;191(3):1364-72. doi: 10.4049/jimmunol.1300274. Epub 2013 Jul 1.

PMID:

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

Paunovic V, Carroll HP, Vandenbroeck K et al.  
Signalling, inflammation and arthritis: crossed signals:  
the role of interleukin (IL)-12, -17, -23 and -27 in  
autoimmunity. Rheumatology 2008;47:771-6. Otettu  
9.3.16

Efficacy, safety, and tolerability of **secukinumab** in  
patients with active ankylosing spondylitis: a  
randomized, double-blind phase 3 study, MEASURE  
3.

Pavelka K, Kivitz A, Dokoupilova E, Blanco R,  
Maradiaga M, Tahir H, Pricop L, Andersson M,  
Readie A, Porter B.

Arthritis Res Ther. 2017 Dec 22;19(1):285 ; 1-10.

Otettu 27.5.18

**Free PMC Article**

**Similar articles**

**Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study.**

Pavelka K, Kivitz AJ, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, Wang Y, Porter BO, Stefanska A, Richards HB, Rohrer S; MEASURE 3 study group.

ACR Open Rheumatol. 2020 Feb;2(2):119-127.

**Free PMC Article Otettu 28.2.20**

**Ref. katsottu 1.3.20**

**Recognition of *Candida albicans* and Role of Innate Type 17 Immunity in Oral Candidiasis.**

**Pavlova A, Sharafutdinov I.**

**Microorganisms. 2020 Sep 2;8(9):1340. doi: 10.3390/microorganisms8091340.**

**PMID: 32887412 Free PMC article. Otettu 3.9.22**

**Secukinumab: A positive outcome in a patient with severe psoriasis and HBV-HCV co-infection.**

Peccerillo F, Odorici G, Pellacani G, Conti A.

Dermatol Ther. 2018 Apr 6:e12601. doi: Otettu  
28.5.18

[Similar articles](#)

.

**Breaking old paradigms: Th17 cells in autoimmune arthritis.**

Peck A, Mellins ED.

Clin Immunol. 2009 Sep;132(3):295-304. doi:  
10.1016/j.clim.2009.03.522. Epub 2009 Apr 28. Review.  
PMID:



Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Peck A, Mellins ED. Plasticity of T-cell phenotype and function: the T helper type 17 example. Immunology 2010;129:147–53. Otettu 9.3.16

Peck A, Mellins ED. Precarious balance: Th17 cells in host defense. Infect Immun. 2010;78:32–8. Otettu 9.3.16

The Pathogenesis of Ankylosing Spondylitis: an Update.  
Pedersen SJ, Maksymowych WP.

Curr Rheumatol Rep. 2019 Nov 11;21(10):58. doi:  
10.1007/s11926-019-0856-3.  
PMID: 31712904 Otettu 21.9.20

Immunomodulatory effect of human bone  
marrow-derived mesenchymal stromal/stem cells on  
peripheral blood T cells from rheumatoid **arthritis**  
patients.

Pedrosa M, Gomes J, Laranjeira P, Duarte C, Pedreiro S,  
Antunes B, Ribeiro T, Santos F, Martinho A, Fardilha M,  
Domingues MR, Abecasis M, P da Silva JA, Paiva A.

J Tissue Eng Regen Med. 2020 Jan;14(1):16-28 Otettu  
21.9.20

Palmoplantar pompholyx secondary to interleukin 17A  
inhibitor therapy for psoriasis: A case series.

Peera M, Smith A.

JAAD Case Rep. 2021 Apr 20;13:46-48. doi:

10.1016/j.jdc.2021.03.052. eCollection 2021 Jul.

PMID: 34141846 [Free PMC article](#). Otettu 8.8.21

### Adverse skin reaction to **Secukinumab**.

Peigottu MF, Montesu MA.

J Eur Acad Dermatol Venereol. 2017

Oct;31(10):e432-e433. Otettu 28.5.18

[Similar articles](#)

[A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor.](#)

Pelechas E, Memi T, Voulgari PV, Drosos AA.

Rheumatol Ther. 2017 Dec;4(2):509-513. doi: Otettu  
27.5.18

[Free PMC Article](#)

[Similar articles](#)

[Unmet needs in the treatment of ankylosing spondylitis: a long-term observational study from a single university center.](#)

Pelechas E, Kaltsonoudis E, Voulgari PV, Drosos AA.

Rheumatol Int. 2019 Apr;39(4):663-668. doi: Otettu  
28.2.20

Ref. katsottu 8.3.2020

**Secukinumab** in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study.

Pellegrini C, et al. *Dermatol Ther (Heidelb)*. 2022. PMID: 36169883 [Free PMC article](#). Otettu 20.11.22

[Evidence for a cross-talk between human neutrophils and Th17 cells.](#)

Pelletier M, Maggi L, Micheletti A, Lazzeri E, Tamassia N, Costantini C, Cosmi L, Lunardi C, Annunziato F, Romagnani S, Cassatella MA.

Blood. 2010 Jan 14;115(2):335-43. doi:

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

Palmoplantare Pustulose unter Secukinumab bei zwei Patienten ohne Psoriasis.

Penalba-Torres M, Rivera-Díaz R.

J Dtsch Dermatol Ges. 2022 Jan;20(1):106-111. doi: 10.1111/ddg.14639\_g.

PMID: 35040576 German. Otettu 3.3.22

.

[Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes.](#)

Pène J, Chevalier S, Preisser L, Vénéreau E, Guilleux MH, Ghannam S, Molès JP, Danger Y, Ravon E, Lesaux S, Yssel H, Gascan H.

J Immunol. 2008 Jun 1;180(11):7423-30.

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

Peng, M.Y. et al. Interleukin 17-producing  $\gamma\delta$  T cells increased in patients with active pulmonary tuberculosis. Cell. Mol. Immunol. **5**, 203–208 (2008). Otettu 25.3.20

Psoriatic lesional expression of SARS-CoV-2 receptor ACE2 is reduced by blockade of IL-17 signaling but not by other biologic treatments.

Peng G, Okumura K, Ogawa H, Ikeda S, Niyonsaba F.

J Am Acad Dermatol. 2022 Sep;87(3):714-715. doi: 10.1016/j.jaad.2022.01.041. Epub 2022 Jan 29.

PMID: 35104583 [Free PMC article](#).

Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating **Interleukin-17** Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System.

Penso L, Bergqvist C, Meyer A, Herlemont P, Weill A, Zureik M, Dray-Spira R, Sbidian E.

Arthritis Rheumatol. 2022 Feb;74(2):244-252. doi: 10.1002/art.41923.

PMID: 34279061   Otettu 30.11.22

Pepper, M. et al. Different routes of bacterial infection induce long- lived TH1 memory cells and short-lived



TH17 cells. Nat. Immunol. 11, 83–89 (2010). Otettu  
18.3.20

### Vitiligo: Pathogenesis and New and Emerging Treatments.

Perez-Bootello J, Cova-Martin R, Naharro-Rodriguez J,  
Segurado-Miravalles G.

Int J Mol Sci. 2023 Dec 9;24(24):17306. doi:  
10.3390/ijms242417306.

PMID: 38139134 [Free PMC article](#). Review. Otettu  
4.3.24

### DNA Methylation of the IL-17A Gene Promoter Is Associated with Subclinical Atherosclerosis and Coronary Artery Disease: The Genetics of Atherosclerotic Disease Mexican Study.

Pérez-Hernández N, Posadas-Sánchez R, Vargas-Alarcón  
G, Pérez-Méndez Ó, Luna-Luna M, Rodríguez-Pérez JM.

Curr Issues Mol Biol. 2023 Dec 5;45(12):9768-9777. doi: 10.3390/cimb45120610.

PMID: 38132456 [Free PMC article.](#) Otettu 13.3.24

Biological Disease-Modifying Antirheumatic Drugs  
Decrease Uric Acid Levels in the Sera of Patients with  
Psoriatic Arthritis.

Perković D, Petrić M, Maleš M, Erceg Maleš I, Radić M.

Curr Issues Mol Biol. 2025 Feb 22;47(3):142. doi: 10.3390/cimb47030142.

PMID: 40136396 [Free PMC article.](#) Otettu 4.6.25

IgA vasculitis during **secukinumab** therapy.

Perkovic D, Simac P, Katic J.

Clin Rheumatol. 2020 Aug 29. doi:  
10.1007/s10067-020-05364-1. Online ahead of print.  
PMID: 32860543 Review. Otettu 20.9.20

Association of Treatment With **Secukinumab** With  
Exacerbation of Dermatomyositis in a Patient With  
Psoriasis.

Perna DL, Callen JP, Schadt CR.

JAMA Dermatol. 2022 Feb 16. doi:  
10.1001/jamadermatol.2021.6011. Online ahead of  
print.

PMID: 35171205 Otettu 3.3.22

.

Th17 cells in rheumatoid **arthritis** and systemic lupus  
erythematosus.

Pernis AB.

J Intern Med. 2009 Jun;265(6):644-52. doi. Review.  
PMID:

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

[Characterization of Super-Responder Profile in Patients with Psoriatic Arthritis Treated with b/tsDMARDs: A Retrospective Study of a Longitudinal Cohort.](#)

Perrotta FM, Lubrano E.

Rheumatol Ther. 2025 Aug 15. doi:

10.1007/s40744-025-00789-z. Online ahead of print.

PMID: 40815357 [Free article.](#) Otettu 22.8.25

Assessment of bone morphogenic protein 2 and **interleukin-17A** in patients with axial spondyloarthritis and their potential role in the new bone formation: a cross-sectional study.

Perrta FM, Scriffignano S, Lubrano E.  
Clin Exp Rheumatol. 2019 Nov-Dec;37(6):1044-1047.  
Epub 2019 Jul 19.  
PMID: 31376251   Otettu 3.3.22

Remission, low disease activity and improvement of  
pain and function in psoriatic arthritis patients treated  
with IL-12/23 and IL-17 inhibitors. A multicenter  
prospective study.

Perrta FM, Delle Sedie A, Scriffignano S, Volpe P,  
Cordisco E, Milano N, Gabini M, Lubrano E.  
Reumatismo. 2020 Apr 10;72(1):52-59. doi:  
10.4081/reumatismo.2020.1266.  
PMID: 32292021   Otettu 20.9.20

The transcriptional regulator Sin3A balances IL-17A and Foxp3 expression in primary CD4 T cells.

Perucho L, Icardi L, Di Simone E, Basso V, Agresti A, Vilas Zornoza A, Lozano T, Prosper F, Lasarte JJ, Mondino A.

EMBO Rep. 2023 May 4;24(5):e55326. doi:

10.15252/embr.202255326. Epub 2023 Mar 16.

PMID: 36929576 [Free PMC article.](#) Otettu 14.6.23

Pesce, B. *et al.* Effect of interleukin-6 receptor blockade on the balance between regulatory

T cells and T helper type 17 cells in rheumatoid arthritis patients. *Clin. Exp. Immunol.* 171, 237–242 (2013).

Otettu 25.3.20

IL-17A contributes to propagation of inflammation but does not impair adipogenesis and/or insulin response, in adipose tissue of obese individuals.

Pestel J, et al. *Cytokine*. 2020. PMID: 31629101 Otettu 8.9.22

Peters, A., Y. Lee, and V. K. Kuchroo. 2011. The many faces of Th17 cells. *Curr.*

*Opin. Immunol.* 23: 702–706. Otettu 20.9.20

Peters J H, Tjabringa G S, Fasse E et al. J Dermatol Sci 2013; 69: 44–53. Otettu 9.3.16

The impact of comorbidities on **interleukin-17** inhibitor therapy in psoriatic arthritis: a Danish population-based cohort study.

Petersen MB, Hansen RL, Egeberg A, Jørgensen TS, Merola JF, Coates LC, Kristensen LE.

Rheumatol Adv Pract. 2023 Apr 3;7(2):rkad035. doi: 10.1093/rap/rkad035. eCollection 2023.

PMID: 37091296 [Free PMC article.](#) Otettu 14.6.23

IL-17 inhibitors and inflammatory bowel diseases: a post-marketing study in Vigibase®.

Petitpain N, D'Amico F, Yelehe-Okouma M, Jouzeau JY, Netter P, Peyrin-Biroulet L, Gillet P.



Clin Pharmacol Ther. 2021 Jan 7. doi: 10.1002/cpt.2155.  
Online ahead of print.  
PMID: 33411953   Otettu 30.11.22

### Is Th17-Targeted Therapy Effective in Systemic Lupus Erythematosus?

Petrić M, Radić M.

Curr Issues Mol Biol. 2023 May 15;45(5):4331-4343. doi: 10.3390/cimb45050275.

PMID: 37232744 [Free PMC article.](#)   otettu 12.6.23

### Biological treatment in severe psoriasis: Influence on peripheral blood dendritic cells.

Petrovic A, Bergen LLT, Solberg SM, Sarkar I, Bergum B, Davies R, Jonsson R, Appel S.

Scand J Immunol. 2023 Dec;98(6):e13321. doi: 10.1111/sji.13321. Epub 2023 Aug 13.

PMID: 38441394   Otta M

Oral *Candida* Infection in Psoriatic Patients Treated with IL17A Inhibitors: Report of 3 Cases and a Comprehensive Review of the Literature.

Pettas E, Savva V, Theofilou VI, Georgaki M, Nikitakis NG. *Diagnostics (Basel)*. 2021 Dec 21;12(1):3. doi: 10.3390/diagnostics12010003.

PMID: 35054170 [Free PMC article](#). Otettu 3.3.22

Pyoderma gangrenosum induced by **secukinumab** in a patient with psoriasis successfully treated with ustekinumab.

Petty AJ, Whitley MJ, Balaban A, Ellington K, Marano AL.  
JAAD Case Rep. 2020 Jun 16;6(8):731-733. doi:  
10.1016/j.jdc.2020.06.011. eCollection 2020 Aug.  
PMID: 32715064 [Free PMC article](#). Otettu 20.9.20

PD-1 Expression Defines Epidermal CD8<sup>+</sup>CD103<sup>+</sup> T Cells  
Preferentially Producing IL-17A and Using Skewed TCR  
Repertoire in Psoriasis.

Phadungsaksawasdi P, Fujiyama T, Kurihara K, Ito T,  
Honda T, Tokura Y.

J Invest Dermatol. 2021 Oct;141(10):2426-2435.e5. doi:  
10.1016/j.jid.2021.03.011. Epub 2021 Apr 9.  
PMID: 33845077 Otta Myöhemmin

Effectiveness and Safety of Anti-interleukin-17  
Therapies in Elderly Patients with Psoriasis.

Phan C, Beneton N, Delaunay J, Reguiai Z, Boulard C, Fougousse AC, Cinotti E, Romanelli M, Mery-Bossard L, Thomas-Beaulieu D, Parier J, Maccari F, Perrot JL, Ruer-Mulard M, Bastien M, Begon E, Samimi M, Jacobzone C, Quiles-Tsimaratos N, Descamps V, Steff M, Bilan P, Vermersch-Langlin A, Kemula M, Amazan E, Kupfer-Bessagnet I, Cottencin AC, Prignano F, Livideanu B, Gottlieb J, Beauchet A, Mahé E; the Groupe d'Etudes Multicentriques (GEM) RESOPSO.

*Acta Derm Venereol.* 2020 Nov 4;100(18):adv00316. doi: 10.2340/00015555-3678.

PMID: 33111960 Otettu 13.12.20

Candidiasis in patients with APS-1: low IL-17, high IFN- $\gamma$ , or both?

Philippot Q, Casanova JL, Puel A.

*Curr Opin Immunol.* 2021 Oct;72:318-323. doi: 10.1016/j.coi.2021.08.001. Epub 2021 Aug 26.

PMID: 34455138 **Free article.** Review Otettu 29.8.22

[Secukinumab dose optimization in adult psoriasis patients: A retrospective, multicenter case series.](#)

Phung M, Georgakopoulos JR, Ighani A, Giroux L, Yeung J.

JAAD Case Rep. 2018 Mar 31;4(4):310-313. doi: Otettu 27.5.18

[Free PMC Article](#)

[Similar articles](#)

[Off-Label High-Dose \*\*Secukinumab\*\* for the Treatment of Moderate-to-Severe Psoriasis.](#)

Phung M, Ighani A, Georgakopoulos JR, Vender R, Giroux L, Lansang P, Yeung J.

J Cutan Med Surg. 2019 Jul/Aug;23(4):391-393. doi:

Otettu 28.2.20

Ref. katsottu 18.3.20

Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO).

Piaserico S, Riedl E, Pavlovsky L, Vender RB, Mert C, Tangsirirap N, Hastrup N, Gallo G, Schuster C, Brunner PM.

Front Med (Lausanne). 2023 Jun 29;10:1185523. doi: 10.3389/fmed.2023.1185523. eCollection 2023.

PMID: 37457564 [Free PMC article.](#) Otettu 12.10.23

Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (**secukinumab**).

Picciani BLS, Dziedzic A, Werneck JT, Marinho MA, Dick TNA, Quintanilha NR, Dias EP.

BMC Oral Health. 2021 Jun 8;21(1):292. doi: 10.1186/s12903-021-01653-6.

PMID: 34103043 [Free PMC article](#). Otettu 8.8.21

Management of tuberculosis risk, screening and preventive therapy in patients with chronic autoimmune arthritis undergoing biotechnological and targeted immunosuppressive agents.

Picchianti-Diamanti A, Aiello A, De Lorenzo C, Migliori GB, Goletti D.

Front Immunol. 2025 Feb 3;16:1494283. doi: 10.3389/fimmu.2025.1494283. eCollection 2025.

PMID: 39963138 [Free PMC article](#). Review. Otettu 1.3.25

1. Piccinni M-P, Lombardelli L, Logiodice F, Tesi D, Kullolli O, Biagiotti R, et al. Potential pathogenetic role of Th17, Th0, and Th2 cells in erosive and reticular oral lichen planus. *Oral Dis.* (2014) 20:212–8. Otettu 8.3.20

.

[IL-17 contributes to angiogenesis in rheumatoid arthritis.](#)

Pickens SR, Volin MV, Mandelin AM 2nd, Kolls JK, Pope RM, Shahrara S.

J Immunol. 2010 Mar 15;184(6):3233-41. doi:

[Free PMC Article](#)

[Similar articles](#)

. Otettu 3.2.16



**Interleukin-10 improves stroke outcome by controlling the detrimental Interleukin-17A response.**

Piepke M, Clausen BH, Ludewig P, Vienhues JH, Bedke T, Javidi E, Rissiek B, Jank L, Brockmann L, Sandrock I, Degenhardt K, Jander A, Roth V, Schädlich IS, Prinz I, Flavell RA, Kobayashi Y, Renné T, Gerloff C, Huber S, Magnus T, Gelderblom M.  
J Neuroinflammation. 2021 Nov 13;18(1):265. doi: 10.1186/s12974-021-02316-7.  
PMID: 34772416 [Free PMC article](#). Otettu 29.8.22

**IL-17A-producing  $\gamma\delta$  T cells: A novel target in stroke immunotherapy.**

Piepke M, Jander A, Gagliani N, Gelderblom M.  
Eur J Immunol. 2024 Dec;54(12):e2451067. doi: 10.1002/eji.202451067. Epub 2024 Oct 13.  
PMID: 39396374 [Free PMC article](#). Otettu 1.3.25

Role of CD20+ T cells in cancer, autoimmunity and obesity.

Pinho ACO, Laranjeira P, Carvalho E.

J Endocrinol. 2024 Feb 12;260(3):e230242. doi: 10.1530/JOE-23-0242. Print 2024 Mar 1.

PMID: 38236766 Review. Otta M

Comparative Effectiveness and Durability of Biologics Through 24 Months for Patients with Moderate-to-Severe Psoriasis: Results from the International, Observational Psoriasis Study of Health Outcomes (PSoHO).

Pinter A, Brnabic A, Trovato E, Puig L, Carrascosa JM, Boyé T, Megna M, Sabatino S, De La Torre I, Maul JT.

Dermatol Ther (Heidelb). 2025 Jul 23. doi: 10.1007/s13555-025-01494-z. Online ahead of print.

PMID: 40699538 Otettu 28.7.25

Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO).

Pinter A, Puig L, Schäkel K, Reich A, Zaheri S, Costanzo A, Tsai TF, Smith SD, Lynde C, Brnabic A, Reed C, Hill J, Schuster C, Riedl E, Paul C.

J Eur Acad Dermatol Venereol. 2022 Jun 29. doi: 10.1111/jdv.18376. Online ahead of print.

PMID: 35766124 Otettu 26.8.22

Characterization of responder groups to **secukinumab** treatment in moderate to severe plaque psoriasis.

Pinter A, Gerdes S, Papavassilis C, Reinhardt M.

J Dermatolog Treat. 2019 Jul 16:1-7. doi:

Otettu 20.9.20

Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa: Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa

Pinto Salgueiro, Gonçalo ; Yilmaz, Orhan ; Nogueira, Miguel ; Torres, Tiago

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2025-01, Vol.39 (1), p.53-74

PEER REVIEWED

OPEN ACCESS Otettu 4.6.25

**Secukinumab** as Biological Treatment for Psoriatic Arthritis in Real Clinical Practice.

Pinto Tasende JA, Maceiras Pan FJ, Mosquera Martínez JA, Fernández Dominguez L, Correa Rey B, García Porrúa C.

Reumatol Clin. 2019 Sep 3. pii: S1699-258X(19)30112-3. doi: 10.1016/j.reuma.2019.07.002. [Epub ahead of print] English, Spanish.

PMID: 31492601 **Free Article** ei oteta

Increased synovial immunohistochemistry reactivity of TGF- $\beta$ 1 in erosive peripheral psoriatic arthritis.

Pinto Tasende JA, Fernandez-Moreno M, Vazquez-Mosquera ME, Fernandez-Lopez JC, Oreiro-Villar N, De Toro Santos FJ, Blanco-García FJ. BMC Musculoskelet Disord. 2023 Mar 30;24(1):246. doi: 10.1186/s12891-023-06339-4.

PMID: 36997896 [Free PMC article.](#) Otettu 14.6.23

Impact of Interleukin-17 Inhibitor Therapy on Arterial Intima-media Thickness among Severe Psoriatic Patients.

Piros ÉA, Szabó Á, Rencz F, Brodszky V, Szalai K, Galajda N, Szilveszter B, Dósa E, Merkely B, Holló P. Life (Basel). 2021 Sep 5;11(9):919. doi: 10.3390/life11090919.

PMID: 34575068 [Free PMC article.](#) Otettu 3.3.22

## Impact of **Interleukin-17** Inhibitor Therapy on Arterial Intima-media Thickness among Severe Psoriatic Patients.

Piros ÉA, Szabó Á, Rencz F, Brodszky V, Szalai K, Galajda N, Szilveszter B, Dósa E, Merkely B, Holló P.

Life (Basel). 2021 Sep 5;11(9):919. doi: 10.3390/life11090919.

PMID: 34575068 **Free PMC article.** Otettu 29.8.22

## Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters' Levels, but Has No Effect on Body Composition Parameters.

Piros ÉA, Szabó Á, Rencz F, Brodszky V, Wikonkál N, Miheller P, Horváth M, Holló P.

Life (Basel). 2021 Jun 9;11(6):535. doi:  
10.3390/life11060535.

PMID: 34207504 **Free PMC article.**    **Otettu 8.8.21**

Level of inflammatory cytokines tumour necrosis factor  $\alpha$ , interleukins 12, 23 and **17** in patients with psoriasis in the context of metabolic syndrome.

Pirowska M, Podolec K, Lipko-Godlewska S, Sułowicz J, Brzewski P, Obtułowicz A, Pastuszczyk M, Wojas-Pelc A.

Postepy Dermatol Alergol. 2019 Feb;36(1):70-75. doi:  
10.5114/ada.2018.73136. Epub 2019 Feb 2.

PMID: 30858782    Otettu 13.12.20    Otettu 24.10.24

Risankizumab Versus **Secukinumab**: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy.

Pirro F, Caldarola G, Bernardini N, Celeste MG, Dattola A, De Luca E, Galluzzo M, Giordano D, Izzi C, Maretti G, Marcelli L, Ravasio R, Richetta AG, Skroza N, Talamonti M, Zangrilli A, Bianchi L, Pellacani G, Persechino S, Potenza C, Peris K, De Simone C.

*Dermatol Pract Concept*. 2025 Jan 30;15(1):4838. doi: 10.5826/dpc.1501a4838.

PMID: 40117618 [Free PMC article](#). Otettu 4.6.25

Model-Informed Drug Development-Based Approval of Intravenous **Secukinumab** for the Treatment of Adult Patients with Active Psoriatic Arthritis, Active Ankylosing Spondylitis, and Active Non-Radiographic Axial Spondyloarthritis.

Pisal DS, Li Y, Golding A, Nair R, Nikolov NP, Madabushi R, Zhu H, Doddapaneni S, Sahajwalla C, Bi Y, Chen J.

*Clin Pharmacol Ther*. 2024 Oct 16. doi: 10.1002/cpt.3464. Online ahead of print.

PMID: 39411974



Model-Informed Drug Development-Based Approval of Intravenous **Secukinumab** for the Treatment of Adult Patients with Active Psoriatic Arthritis, Active Ankylosing Spondylitis, and Active Non-Radiographic Axial Spondyloarthritis.

Pisal DS, Li Y, Golding A, Nair R, Nikolov NP, Madabushi R, Zhu H, Doddapaneni S, Sahajwalla C, Bi Y, Chen J. Clin Pharmacol Ther. 2025 Feb;117(2):475-484. doi: 10.1002/cpt.3464. Epub 2024 Oct 16. PMID: 39411974   Otta M

**Interleukin-17** producing mucosal associated invariant T cells - emerging players in chronic inflammatory diseases?

Pisarska MM, Dunne MR, O'Shea D, Hogan AE. Eur J Immunol. 2020 Aug;50(8):1098-1108. doi: 10.1002/eji.202048645. Epub 2020 Jul 15.

PMID: 32617963 **Free article.** Review. Otettu 30.11.22

**Secukinumab efficacy in the treatment of nail psoriasis: a case series.**

Pistone G, Gurreri R, Tilotta G, Castelli E, Bongiorno MR.

J Dermatolog Treat. 2018;29(sup1):21-24 Otettu 9.3.20

Ref. katsottu 15.3.20 Maksullinen

**Scalp psoriasis: report of efficient treatment with secukinumab.**

Pistone G, Tilotta G, Gurreri R, Curiale S, Bongiorno MR.

J Dermatolog Treat. 2018 Oct 1:1-10 Otettu 9.3.20

Ref. katsottu 16.3.20 On maksullinen

Giuseppe Pistone, Pardo Nicola, Valentina Caputo,  
et al. A case of moderate hidradenitis suppurativa

and psoriasis- treated with secukinumab. Ann Dermatol. 2018;30(4): 462-464. Otettu 2.3.20

Ref. katsottu 6.3.20

[The role of IL-17 and IL-17 receptor inhibitors in the management of generalized pustular psoriasis.](#)

Plachouri KM, Chourdakis V, Georgiou S.

Drugs Today (Barc). 2019 Sep;55(9):587-593. ei ole M Ei ole GS

REPLY TO: **Interleukin-17**: a potential therapeutic target in COVID-19.

Piaserico S, Meneguzzo A, Messina F.

J Infect. 2020 Sep;81(3):e37-e38. doi:

10.1016/j.jinf.2020.06.063. Epub 2020 Jun 29.

PMID: 32610110 **Free PMC article.** Otettu 4.9.22

Real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications among patients with psoriatic arthritis treated with IL-17A inhibitors in the United States.

Pizzicato LN, et al. *J Manag Care Spec Pharm*. 2022. PMID: 36318701 [ei ole M](#)

The role of IL-17 and IL-17 receptor inhibitors in the management of generalized pustular psoriasis.

Plachouri KM, et al. *Drugs Today (Barc)*. 2019. PMID: 31584575 [Review. ei ole M](#)

103.

[What is the best treatment target in axial spondyloarthritis: tumour necrosis factor  \$\alpha\$ , interleukin 17, or both?](#)

Poddubnyy D, Sieper J.

Rheumatology (Oxford). 2017 Oct 12. doi:

10.1093/rheumatology/kex361. [Epub ahead of print]

PMID:

29040753    Otettu 28.5.18

[Similar articles](#)

[Axial spondyloarthritis - Update 2021](#)].

Poddubnyy D.

Dtsch Med Wochenschr. 2021 Feb;146(3):185-190. doi:

10.1055/a-1210-8841. Epub 2021 Jan 29.

PMID: 33513654 Review. German.    ei ole M

## Treatment of Axial Spondyloarthritis: What Does the Future Hold?

Poddubnyy D, Sieper J.

Curr Rheumatol Rep. 2020 Jul 20;22(9):47. doi: 10.1007/s11926-020-00924-5.

PMID: 32691259 [Free PMC article](#). Review. Otettu 3.9.22

## Managing Psoriatic Arthritis Patients Presenting with Axial Symptoms.

Poddubnyy D.

Drugs. 2023 Apr;83(6):497-505. doi:

10.1007/s40265-023-01857-w. Epub 2023 Mar 28.

PMID: 36976477 [Free PMC article](#). Otettu 14.6.23

Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with **secukinumab**: primary results from a randomized controlled phase-IIIb trial.

Poddubnyy D, Pournara E, Zielińska A, Baranauskaite A, Jiménez AM, Sadhu S, Schulz B, Rissler M, Perella C, Marzo-Ortega H.

Ther Adv Musculoskelet Dis. 2021 Oct

22;13:1759720X211051471. doi:

10.1177/1759720X211051471. eCollection 2021.

PMID: 34707696 [Free PMC article.](#) Otettu 3.3.22

[Treatment of moderate-to-severe psoriasis in adults: An expert consensus statement using a Delphi method to produce a decision-making algorithm.](#)

Poizeau F, Leducq S, Fardet L, Beylot-Barry M, Chaby G, Chastagner M, Corgibet F, Gouillon L, Jouan N, Jullien D, Acher A, Amatore F, Amici JM, Aubert H, Aubin F, Beneton N, Bouilly D, Bursztejn AC, Buzenet C, Chamaillard-Pujol M, Charles J, Cottencin-Charriere AC, Duval Modeste B, Fauconneau A, Fougerousse AC, Girard C, Goujon C, Khemis A, Le Ru Y, Lepelley-Dupont C, Mahé E, Marcellin X, Nicolas C, Pallure V, Parier J, Quiles N, Stoebner PE, Tauber M, Vermersch A, Viguier M, Villani AP, Chosidow O, Guillot B; Psoriasis Research Group (GRPso) and the Centre of Evidence of the French Society of Dermatology.

[Ann Dermatol Venereol. 2024 Sep;151\(3\):103287. doi: 10.1016/j.annder.2024.103287. Epub 2024 Jul 15.](#)

[PMID: 39013256](#) [Free article.](#) [Otettu 27.9.24](#)

[IL-17A, IL-17E and IL-17F as Potential Biomarkers for the Intensity of Low-Grade Inflammation and the Risk of Cardiovascular Diseases in Obese People.](#)

[Polak-Szczybyło E, Tabarkiewicz J.](#)



Nutrients. 2022 Feb 2;14(3):643. doi:  
10.3390/nu14030643.

PMID: 35277002 [Free PMC article.](#) Otettu 27.8.22

### [Innate Lymphocytes in Psoriasis.](#)

Polese B, Zhang H, Thurairajah B, King IL.

Front Immunol. 2020 Feb 21;11:242. doi:

10.3389/fimmu.2020.00242. eCollection 2020.

PMID: 32153574 [Free PMC article.](#) Otettu 6.9.22

### [\*\*Secukinumab in the Treatment of Generalized Pustular Psoriasis: A Case report.\*\*](#)

Polesie S, Lidholm AG.

Acta Derm Venereol. 2017 Jan 4;97(1):124-125. doi:

Otettu 27.5.18

## Free Article

### Similar articles

#### Predictors of **secukinumab** treatment response and continuation in axial spondyloarthritis: results from the EuroSpA research collaboration network.

Pons M, Georgiadis S, Hetland ML, Ahmadzay ZF, Rasmussen S, Christensen SN, Di Giuseppe D, Wallman JK, Pavelka K, Závada J, Codreanu C, Glinborg B, Loft AG, Santos H, Lourenço MH, Nissen MJ, Ciurea A, Kuusalo L, Rantalaiho V, Michelsen B, Mielnik P, Pirkmajer KP, Gudbjornsson B, Palsson O, van der Horst-Bruinsma I, van de Sande M, Castrejón I, Macfarlane GJ, Laas K, Østergaard M, Ørnbjerg LM.

J Rheumatol. 2025 Feb 1;jrheum.2024-0920. doi: 10.3899/jrheum.2024-0920. Online ahead of print.

PMID: 39892891 **Free article.** Otettu 1.3.25

Four-year **secukinumab** treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis.

Pons M, Georgiadis S, Østergaard M, Ahmadzay ZF, Glinborg B, Heberg J, Christensen SN, Rasmussen S, Loft AG, Castrejón I, Sánchez-Alonso F, Iannone F, Nordström D, Hokkanen AM, Ciurea A, Nissen MJ, Závada J, Pavelka K, Pirkmajer KP, Michelsen B, Mielnik P, Bernardes M, Khmelinskii N, Laas K, Vorobjov S, Codreanu C, Macfarlane GJ, Jones GT, Gudbjornsson B, Palsson O, Wallman JK, Horst-Bruinsma IV, Onen F, Hetland ML, Ørnbjerg LM.

Joint Bone Spine. 2024 Nov 26:105824. doi: 10.1016/j.jbspin.2024.105824. Online ahead of print. PMID: 39608666 **Free article.** Otettu 1.3.25

## The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials.

Potestio L, Martora F, Lauletta G, Vallone Y, Battista T, Megna M.

Clin Cosmet Investig Dermatol. 2024 Apr 10;17:829-842. doi: 10.2147/CCID.S462797. eCollection 2024.

PMID: 38616886 [Free PMC article](#). Review. Otettu 29.5.24

Regulatory T cells in psoriatic arthritis: an IL-17A-producing, Foxp3<sup>int</sup>CD161<sup>+</sup> RORγt<sup>+</sup> ICOS<sup>+</sup> phenotype, that associates with the presence of ADAMTSL5 autoantibodies.

Pouw JN, Olde Nordkamp MAM, van Kempen T, Concepcion AN, van Laar JM, van Wijk F, Spierings J, Leijten EFA, Boes M.

Sci Rep. 2022 Nov 30;12(1):20675. doi: 10.1038/s41598-022-24924-w.

PMID: 36450783 [Free PMC article](#). Otettu 14.6.23

**Secukinumab-Associated Crystalline Corneal Deposition.**

Power B, Pilson Q, Fulcher T.

Cornea. 2019 Feb;38(2):249-251. Otettu 29.2.20

Ref. katsottu 9.3.20

Durable remissions of guttate psoriasis following short courses of IL-**17** inhibitors.

Printy R, Rivera-Oyola R, Czernik A, Lebwohl M.

Int J Dermatol. 2021 Sep;60(9):1161-1162. doi: 10.1111/ijd.15478. Epub 2021 Mar 2.

PMID: 33650164 Otettu 1.12.22

**Interleukin-17** cytokines: Effectors and targets in psoriasis-A breakthrough in understanding and treatment.

Prinz I, Sandrock I, Mrowietz U.

J Exp Med. 2020 Jan 6;217(1):e20191397. doi:  
10.1084/jem.20191397.

PMID: 31727784    Otettu 21.9.20

Open-label, investigator-initiated, single-site  
exploratory trial evaluating **secukinumab**, an  
anti-interleukin-17A monoclonal antibody, for patients  
with moderate-to-severe hidradenitis suppurativa.

Prussick L, Rothstein B, Joshipura D, Saraiya A,  
Turkowski Y, Abdat R, Alomran A, Zancanaro P,  
Kachuk C, Dumont N, Gottlieb AB, Rosmarin D.

Br J Dermatol. 2019 Feb 22.    Otettu 29.2.20

204.

[Is secukinumab a safe alternative treatment for ankylosing spondylitis with Guillain Barré syndrome after anti-TNF- \$\alpha\$  treatment? Case report and literature review.](#)

Psarelis S, Hajineocli APD, Hadjicosta E, Elliott HSA, Johnson P.

Clin Rheumatol. 2017 May;36(5):1197-1199. doi:

Otettu 28.5.18

[Similar articles](#)

Lactate Buildup at the Site of Chronic Inflammation Promotes Disease by Inducing CD4<sup>+</sup> T Cell Metabolic Rewiring.

Pucino V, et al. Cell Metab. 2019. PMID: 31708446 Free PMC article. Otettu 8.9.22

Puel A, Döffinger R, Natividad A et al. (2010a)  
Autoantibodies against IL-17A, IL-17F, and IL-22 in  
patients with chronic mucocutaneous candidiasis and  
autoimmune polyendocrine syndrome type I. J Exp Med  
207:291–7 Otettu 8.3.20

Ref. katsottu 10.3.20

Puel A, Picard C, Cypowyj S et al. (2010b) Inborn errors  
of mucocutaneous immunity to *Candida albicans* in  
humans: a role for IL-17 cytokines? Curr Opin Immunol  
22:467–74 Otettu 8.3.20



Puel A, Cypowyj S, Bustamante J et al. (2011) Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. *Science* 332:65–8  
Otettu 8.3.20

Ref. ei otet

Puel A, Cypowyj S, Maródi L et al. (2012) Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. *Curr Opin Allergy Clin Immunol* 12:616–22 Otettu 8.3.20

The Role of the **Interleukin-17** Axis and Neutrophils in the Pathogenesis of Endemic and Systemic Mycoses.

Puerta-Arias JD, Mejía SP, González Á.

*Front Cell Infect Microbiol.* 2020 Dec 14;10:595301. doi: 10.3389/fcimb.2020.595301. eCollection 2020.

PMID: 33425780 **Free PMC article.** Otettu 2.9.22

Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022-2023.

Puig L, Sewerin P, Schuster C, Ng KJ, Papadimitropoulos M, Gadagamma S, Nuñez M, Lampropoulou A.

Adv Ther. 2025 Jul 17. doi:

10.1007/s12325-025-03258-9. Online ahead of print.

PMID: 40676380 Review. Otettu 28.7.25

The biological basis of disease recurrence in psoriasis: a historical perspective and current models.

Puig L, Costanzo A, Muñoz-Elías EJ, Jazra M, Wegner S, Paul CF, Conrad C.

Br J Dermatol. 2022 May;186(5):773-781. doi:  
10.1111/bjd.20963.

PMID: 34939663 **Free PMC article.** Otettu 27.8.22

Study of pathogenic T-helper cell subsets in Asian Indian patients with Takayasu arteritis.

Punithavathy PM, Telugu RB, Rao VM, Prabhu SB,  
Kabeerdoss J, Syed C, Joseph G, Danda D, Thomas M,  
Goel R.

Immunol Res. 2024 Feb 8. doi:  
10.1007/s12026-024-09459-8. Online ahead of print.  
PMID: 38326692 Otta M

Cost-effectiveness of **secukinumab** compared to other biologics in the treatment of ankylosing spondylitis in Finland.

Purmonen T, Puolakka K, Mishra D, Gunda P, Martikainen J.

Clinicoecon Outcomes Res. 2019 Feb 15;11:159-168.

**Free PMC Article   Otettu 29.2.20**

**Ref. katsottu 19.3.20**

.

Low-strength T-cell activation promotes Th17 responses.

Purvis HA, Stoop JN, Mann J, Woods S, Kozijn AE, Hambleton S, Robinson JH, Isaacs JD, Anderson AE, Hilkens CM.

Blood. 2010 Dec 2;116(23):4829-37. doi:  
10.1182/blood-2010-03-272153. Epub 2010 Aug 16.  
PMID:

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

[A negative feedback loop mediated by STAT3 limits  
human Th17 responses.](#)

Purvis HA, Anderson AE, Young DA, Isaacs JD, Hilkens  
CM.

J Immunol. 2014 Aug 1;193(3):1142-50. doi:  
10.4049/jimmunol.1302467. Epub 2014 Jun 27.

PMID:

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

Psoriasis: Association of interleukin-17 gene polymorphisms with severity and response to treatment.

Puşcaş AD, Cătană A, Puşcaş C, Roman II, Vornicescu C, Şomlea M, Orăsan RI.

Exp Ther Med. 2019 Aug;18(2):875-880. doi:

**Free PMC Article Otettu 29.2.20**

**Ref. katsottu 4.3.20**

.

Th17 cells, not IL-17+  $\gamma\delta$  T cells, drive arthritic bone destruction in mice and humans.

Pöllinger B, Junt T, Metzler B, Walker UA, Tyndall A, Allard C, Bay S, Keller R, Raulf F, Di Padova F, O'Reilly T, Horwood NJ, Patel DD, Littlewood-Evans A.  
J Immunol. 2011 Feb 15;186(4):2602-12.

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

Qian Y, Kang Z, Liu C, Li X (2010) IL-17 signaling in host defense and inflammatory diseases. Cell Mol Immunol 7:328–333    Otettu 9.3.16

Qian, X. et al. Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis. Cytokine **89**, 34–44 (2017).    Otettu 20.9.20

Safety and efficacy of **secukinumab** in psoriasis patients infected with hepatitis B virus: a retrospective study.

Qin H, et al. *Eur J Dermatol*. 2022. PMID: 36065536

English. Otettu 26.9.22

Qu N, Xu M, Mizoguchi I, Furusawa J, Kaneko K, Watanabe K, et al. Piv roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. *Clin Dev Immunol* 2013;2013:968549. ei oteta

[Perianal Dermatophytosis During \*\*Secukinumab\*\* Therapy for Plaque Psoriasis.](#)

Quach OL, Hsu S.

*JAMA Dermatol*. 2015 Dec 30:1-2. doi:

Otettu 9.3.16

[Similar articles](#)



## Interleukin-17-targeted treatment in patients with spondyloarthritis and associated cardiometabolic risk profile.

Queiro R, Aurrecoechea E, Alonso Castro S, Villa Blanco I, Brandy-Garcia A, Linge R.

Front Immunol. 2023 Jul 18;14:1203372. doi:

10.3389/fimmu.2023.1203372. eCollection 2023.

PMID: 37533855 [Free PMC article](#). Review. Otettu 12.10.23

## Cytokine Profiles Associated With Acute COVID-19 and Long COVID-19 Syndrome.

Queiroz MAF, Neves PFMD, Lima SS, Lopes JDC, Torres MKDS, Vallinoto IMVC, Bichara CDA, Dos Santos EF, de Brito MTFM, da Silva ALS, Leite MM, da Costa FP, Viana MNDSA, Rodrigues FBB, de Sarges KML, Cantanhede MHD, da Silva R, Bichara CNC, van den Berg AVS, Veríssimo AOL, Carvalho MDS, Henriques DF, Dos

Santos CP, Nunes JAL, Costa IB, Viana GMR, Carneiro FRO, Palacios VRDCM, Quaresma JAS, Brasil-Costa I, Dos Santos EJM, Falcão LFM, Vallinoto ACR.

Front Cell Infect Microbiol. 2022 Jun 30;12:922422. doi: 10.3389/fcimb.2022.922422. eCollection 2022.

PMID: 35846757 [Free PMC article](#). Otettu 27.8.22

Quintana, F. J., Basso, A. S., Iglesias, A. H., Korn, T., Farez, M. F., Bettelli, E., Caccamo, M. et al., Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008. 453: 65–71.

Otettu 9.3.16

Rachitskaya AV, Hansen AM, Horai R, Li Z, Villasmil R, Luger D, et al. NKT cells constitutively express IL-23 receptor and ROR $\gamma$ t and rapidly produce IL-17 upon

receptor ligation in an IL-6-independent fashion. J Immunol 2008;180:5167–71. Otettu 9.3.16

[Emerging drugs for the treatment of axial spondyloarthritis.](#)

Rademacher J, Poddubnyy D.

Expert Opin Emerg Drugs. 2018 Mar;23(1):83-96. doi: 10.1080/14728214.2018.1445719. Epub 2018 Mar 1.

PMID:

29475394 ei ole M

[Similar articles](#)

Radhakrishnan S, Cabrera R, Schenk EL, Nava-Parada P, Bell MP, Van Keulen VP, Marler RJ, Felts SJ, Pease LR (2008) Reprogrammed FoxP3+ T regulatory cells

become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo. J Immunol 181:3137–3147

Otettu 9.3.16

Cardiometabolic Risk in Psoriatic Arthritis: A Hidden Burden of Inflammation and Metabolic Dysregulation.

Radić M, Belančić A, Đogaš H, Vučković M, Sener YZ, Sener S, Fajkić A, Radić J.

Metabolites. 2025 Mar 18;15(3):206. doi:

10.3390/metabo15030206.

PMID: 40137170 [Free PMC article](#). Review. Otettu

4.6.25

Radstake TR, van Bon L, Broen J, Hussiani A, Hesselstrand R, Wuttge DM, Deng Y, Simms R, Lubberts E, Lafyatis R (2009) The pronounced Th17 profile in systemic sclerosis (SSc) together with

intracellular expression of TGFbeta and IFN- gamma distinguishes SSc phenotypes. PloS one 4:e5903  
Otettu 9.3.16

### Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases.

Rafael-Vidal C, Pérez N, Altabás I, Garcia S, Pego-Reigosa JM.

Int J Mol Sci. 2020 Sep 26;21(19):7100. doi: 10.3390/ijms21197100.

PMID: 32993066 [Free PMC article.](#) Otettu 3.9.22

Raffin C, Raimbaud I, Valmori D, Ayyoub M. Ex vivo IL-1 receptor type I expression in human CD4+ T cells identifies an early intermediate in the differentiation of Th17 from FOXP3+ naive regulatory T cells. J Immunol. 2011; 187:5196–5202. Otettu 17.3.20

Ref. ei katsot

Rahman, P., Inman, R.D., Gladman, D.D., Reeve, J.P., Peddle, L., and Maksymowych, W.P. (2008). Association of interleukin-23 receptor variants with ankylosing spondylitis. *Arthritis Rheum.* 58, 1020–1025.  
Otettu 16.3.20

Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis.

Rahmati S, O'Rielly DD, Li Q, Codner D, Dohey A, Jenkins K, Jurisica I, Gladman DD, Chandran V, Rahman P. *Sci Rep.* 2020 Dec 10;10(1):21703. doi: 10.1038/s41598-020-78866-2.  
PMID: 33303908 [Free PMC article.](#) Otettu 2.9.22

Rahman P, Strand V, McInnes I, Marzo-Ortega H, Dokoupilova E, Churchill M, Kandala S, Pricop L, Mpofu S. Secukinumab improves physical function, quality of life, fatigue and work productivity in patients with active psoriatic arthritis in FUTURE 2, a Phase 3 trial. Ann Rheum Dis. 2015;74:356. Abstrakti ei oteta

Possible autoimmune hemolytic anemia induced by **secukinumab**: a case report.

Rahman PA, Kalim H, Prawitasari S, Raharjo FM.

Pan Afr Med J. 2022 Jan 17;41:41. doi:

10.11604/pamj.2022.41.41.32191. eCollection 2022.

PMID: 35317476 **Free PMC article.** Otettu 26.8.22

## Pharmacological Rationale for Targeting IL-17 in Asthma.

Rahmawati SF, Te Velde M, Kerstjens HAM, Dömling ASS, Groves MR, Gosens R.

Front Allergy. 2021 Aug 30;2:694514. doi:

10.3389/falgy.2021.694514. eCollection 2021.

PMID: 35387016 [Free PMC article](#). Review. Otettu 27.8.22

## Characterization of Serum Cytokine Profiles of Patients with Active Lupus Nephritis.

Rahmé Z, Franco C, Cruciani C, Pettorossi F, Zaramella A, Realdon S, Iaccarino L, Frontini G, Moroni G, Doria A, Ghirardello A, Gatto M.

Int J Mol Sci. 2023 Oct 4;24(19):14883. doi:

10.3390/ijms241914883.

PMID: 37834330 [Free PMC article](#). Otettu 29.5.24



[Anti IL-17 therapy rapidly decreases osteoclast activity in psoriatic patients: a novel quality in addition to its efficacy and safety.](#)

Raimondo A, Lembo S, Caiazza G, Di Caprio R, Balato A.

G Ital Dermatol Venereol. 2018 Oct 29. [doi: 10.1016/j.gder.2018.09.001](#) Epub 2018 Oct 29.

Onset of spondyloarthritis in a patient treated with adalimumab for relapsing anterior uveitis - efficacy of **secukinumab** on the joint domain and on ocular inflammatory relapses: A case report.

Raimondo V.

Medicine (Baltimore). 2022 Nov 25;101(47):e31554. doi: 10.1097/MD.00000000000031554.

PMID: 36451402 [Free PMC article.](#) [otettu 12.6.23](#)

## **Secukinumab**, Pituitary Enlargement and Panhypopituitarism: Are They Related?

Ramalho D, Araújo A, Rocha G, Duarte-Ribeiro F.

Eur J Case Rep Intern Med. 2021 Dec 31;8(12):003099.  
doi: 10.12890/2021\_003099. eCollection 2021.

PMID: 35059351 **Free PMC article.** Otettu 3.3.22

## Bayesian trial of adalimumab versus **secukinumab** for children with juvenile idiopathic arthritis associated uveitis or chronic anterior uveitis.

Ramanan AV, Dick AD, Jaki T, Caruso G, Robertson DS, Jones AP, Hardwick B, Drake S, Balasubramaniam B, Ciurtin C, Foeldvari I, Kreps EO, Leahy A, May K, Quartier P, Robert MP, Simonini G, Guly C, Beresford MW.

Pediatr Rheumatol Online J. 2025 May 19;23(1):55. doi: 10.1186/s12969-025-01107-1.

PMID: 40390069 **Free PMC article.** Otettu 4.6.25

Diffusion dimensionality modeling of subcutaneous/intramuscular absorption of antibodies and long-acting injectables.

Ramanathan M, Krzyzanski W.

J Pharmacokinet Pharmacodyn. 2025 Apr 22;52(3):26.

doi: 10.1007/s10928-025-09973-8.

PMID: 40263185    Otta M

Ramesh R, Kozhaya L, McKevitt K, Djuretic IM, Carlson TJ, Quintero MA, et al. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med 2014;211:89–104.

Otettu 9.3.16

Ramgolam, V.S., Y. Sha, J. Jin, X. Zhang, and S. Markovic-Plese. 2009. IFN- beta inhibits human Th17 cell differentiation. *J. Immunol.* 183:5418– 5427 Otettu 15.3.20

Ref. katsottu 17.3.20

Ramirez-Carrozzi V, Sambandam A, Luis E et al. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. *Nat Immunol* 2011;12: 1159–66. Otettu 28.5.18

## ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.

Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, Landewé RBM, Van den Bosch FE, Boteva B, Bremander A, Carron P, Ciurea A, van Gaalen FA, Géher P, Gensler L, Hermann J, de Hooge M, Husakova M, Kiltz U, López-Medina C, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compán V, Nissen MJ, Pimentel-Santos FM, Poddubnyy D, Proft F, Rudwaleit M, Telkman M, Zhao SS, Ziade N, van der Heijde D.

Ann Rheum Dis. 2023 Jan;82(1):19-34. doi: 10.1136/ard-2022-223296. Epub 2022 Oct 21.

PMID: 36270658 **Free article.** **Otettu 12.10.23**

## Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis.

Ramiro S, Smolen JS, Landewé R, van der Heijde D, Dougados M, Emery P, de Wit M, Cutolo M, Oliver S, Gossec L.

Ann Rheum Dis. 2015 Dec 11. pii:  
annrheumdis-2015-208466. doi:  
10.1136/annrheumdis-2015-208466. [Epub ahead of  
print]  
PMID:  
ei oteta

[Similar articles](#)

340.

[Pharmacological treatment of psoriatic arthritis: a  
systematic literature review for the 2015 update of the  
EULAR recommendations for the management of  
psoriatic arthritis.](#)

Ramiro S, Smolen JS, Landewé R, van der Heijde D,  
Dougados M, Emery P, de Wit M, Cutolo M, Oliver S,  
Gossec L.

Ann Rheum Dis. 2016 Mar;75(3):490-8. doi: ei oteta

[Similar articles](#)

Four-year effectiveness, safety and drug retention rate of **secukinumab** in psoriatic arthritis: a real-life Italian multicenter cohort.

Ramonda R, Lorenzin M, Chimenti MS, Atzeni F, Semeraro A, D'Angelo S, Selmi C, Ortolan A, Marchesoni A, Manara M, Luchetti Gentiloni MM, Santo L, Salvarani C, Cauli A, Rossini M, Amato G, Cozzi G, Scagnellato L, Ferraioli M, Carriero A, Fracassi E, Giorgio F, Doria A, Foti R, Carletto A; on behalf Spondyloarthritis and Psoriatic Arthritis SIR Study Group "Antonio Spadaro".

Arthritis Res Ther. 2024 Sep 28;26(1):172. doi: 10.1186/s13075-024-03401-x.

PMID: 39342310 [Free PMC article](#). [Ottetu 24.10.24](#)

≤

Four-year real-world experience of **secukinumab** in a large Italian cohort of axial spondyloarthritis.

Ramonda R, Lorenzin M, Chimenti MS, D'Angelo S, Marchesoni A, Selmi C, Lubrano E, Santo L, Luchetti Gentiloni MM, Atzeni F, Cauli A, Manara M, Rossini M, Foti R, Cozzi G, Scagnellato L, Ferraioli M, Carriero A, Luciano N, Ruzzon F, Fatica M, Fracassi E, Doria A, Foti R, Carletto A.

Front Immunol. 2024 Jul 15;15:1435599. doi:

10.3389/fimmu.2024.1435599. eCollection 2024.

PMID: 39076975 [Free PMC article.](#) [Otettu 27.9.24](#)

Effectiveness and safety of **secukinumab** in axial spondyloarthritis: a 24-month prospective, multicenter real-life study.

Ramonda R, Lorenzin M, Sole Chimenti M, D'Angelo S, Marchesoni A, Salvarani C, Lubrano E, Costa L, Dal Bosco Y, Fracassi E, Ortolan A, Ferraioli M, Carriero A, Visalli E, Bixio R, Desiati F, Bergamini A, Pedrollo E, Doria A, Foti R, Carletto A.

Ther Adv Musculoskelet Dis. 2022 Apr

29;14:1759720X221090310. doi:

10.1177/1759720X221090310. eCollection 2022.



PMID: 35510168 [Free PMC article.](#) Otettu 26.8.22

Effectiveness and safety of **secukinumab** in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study.

Ramonda R, Lorenzin M, Carriero A, Chimenti MS, Scarpa R, Marchesoni A, Lubrano di Scorpaniello E, Salvarani C, Cauli A, Semeraro A, Santo L,, Doria A, Fracassi E, Virelli G, Masia M, Fanizzi R, Visalli E, Amato G, Carletto A, Foti R; on behalf Spondyloarthritis and Psoriatic Arthritis SIR Study Group "Antonio Spadaro".

RMD Open. 2021 Feb;7(1):e001519. doi: 10.1136/rmdopen-2020-001519.

PMID: 33593933 [Free PMC article.](#) Otettu 8.8.21

[IL-17 inhibition: is it the long-awaited savior for alopecia areata?](#)

Ramot Y, Marzani B, Pinto D, Sorbellini E, Rinaldi F.

Arch Dermatol Res. 2018 Mar 1. doi:

10.1007/s00403-018-1823-y. [Epub ahead of print]

Review.

PMID:

Otettu 28.5.18

[Similar articles](#)

Rana A, Minz RW, Aggarwal R, Anand S, Pasricha N, Singh S. Gene expression of cytokines (TNF-a, IFN-g), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus. Lupus. 2012;21(10):1105-1112.

Otettu 28.5.18

Rangachari M, Mauermann N, Marty RR, Dirnhofer S, Kurrer MO, Komnenovic V, et al. T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J Exp Med 2006;203:2009-19. Otettu 17.3.20

Ref. katsottu 18.3.20

[Vitamin D deficiency, interleukin 17, and vascular function in rheumatoid arthritis.](#)

Ranganathan P, Khalatbari S, Yalavarthi S, Marder W, Brook R, Kaplan MJ.

J Rheumatol. 2013 Sep;40(9):1529-34. doi: 10.3899/jrheum.130012. Epub 2013 Jul 1.

PMID:

23818717 Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Segmental stiff skin syndrome: a novel case with an interleukin-17C mutation successfully treated with secukinumab.

Rangu S, Rubin AI, Li D, Castelo-Soccio L.

Clin Exp Dermatol. 2020 Mar 25. doi:

Otettu 20.9.20

Rasmussen TK, Andersen T, Hvid M, Hetland ML, Hørslev-Petersen K, Stengaard-Pedersen K, et al. Increased interleukin 21 (IL-21) and IL-23 are associated with increased disease activity and with radiographic status in patients with early rheumatoid arthritis. J Rheumatol 2010;37: 2014-20. Otettu 4.3.16

Ratner M. IL-17-targeting biologics aim to become standard of care in psoriasis. Nat Biotechnol. 2015;33(1):3–4. Otettu 28.3.20

Real-Life Data of **Secukinumab** in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study.

Rattanakaemakorn P, Chevairsakul P, Wongpraparut C, Chiowchanwisawakit P, Tovanabutra N, Tantiwong P, Amornpinyo W, Chakkavittumrong P, Hanvivadhanakul P, Chaiamnuay S, Laodheerasiri S, Pattamadilok B, Choonhakarn C, Mahakkanukrauh A, Aiewruengsurat D, Sangmala S, Pretikul N, Sumethkul K, Satpanich P, Boonsiri M, Sangob N, Asawanonda P; PROMPT Study Group.

Dermatol Ther (Heidelb). 2024 Dec;14(12):3229-3241. doi: 10.1007/s13555-024-01299-6. Epub 2024 Nov 7. PMID: 39505788 **Free PMC article.** Otettu 1.3.25

**Interleukin-17A (IL-17A)**, a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms.

Raucci F, Mansour AA, Casillo GM, Saviano A, Caso F, Scarpa R, Mascolo N, Iqbal AJ, Maione F.

Autoimmun Rev. 2020 Jul;19(7):102572. doi:

10.1016/j.autrev.2020.102572. Epub 2020 May 3.

PMID: 32376393 [Free PMC article](#). Otettu 5.9.22

RavJørgensenAstrid-Helene,YaoYiqiu,FrancisThomsen Simon. Therapeutic response to secukinumab in a 36-year-old woman with hidradenitis suppurativa. Case Rep Dermatol Med. 2018;

2018, 8685136. Otettu 2.3.20

.

[IL-17 receptor and its functional significance in psoriatic arthritis.](#)

Raychaudhuri SP, Raychaudhuri SK, Genovese MC.  
Mol Cell Biochem. 2012 Jan;359(1-2):419-29. dSep 6.

[Similar articles](#)

Otettu 28.5.18

.

[Role of IL-17 in psoriasis and psoriatic arthritis.](#)

Raychaudhuri SP.  
Clin Rev Allergy Immunol. 2013 Apr;44(2):183-93. d.  
Otettu 31.5.2018

[Similar articles](#)

## Functional significance of MAIT cells in psoriatic arthritis.

Raychaudhuri SK, et al. *Cytokine*. 2020. PMID: 31541902  
Otettu 1.12.22

1. Raychaudhuri SK, Saxena A, Raychaudhuri SP.  
Role of IL-17 in the pathogenesis of psoriatic  
arthritis and axial spondyloarthritis. *Clin Rheumatol*.  
2015;34:1019–23. Otettu 15.3.20
2. Ref. katsottu 25.3.20



Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies.

Raychaudhuri SP, Wilken R, Sukhov AC,  
Raychaudhuri SK, Maverakis E.

J Autoimmun. 2017 Jan;76:21-37. doi:  
10.1016/j.jaut.2016.10.009. Epub 2016 Nov 9.

Review.

PMID:

27836567 Otettu 31.5.2018

[Similar articles](#)

Raychaudhuri SP, Raychaudhuri SK. Mechanistic rationales for targeting interleukin-17A in spondyloarthritis. Arthritis Res Ther. 2017;19:51. Otettu 7.3.20

Ref. katsottu 13.3.20

28. <https://doi.org/10.1186/s13075-017-1249-5>

Raychaudhuri SK, Abria C, Raychaudhuri SP.  
Regulatory role of the JAK STAT kinase signalling  
system on the IL-23/IL-17 cytokine axis in psoriatic  
arthritis. Annals of the rheumatic diseases 2017.

[CrossRef ] Otettu 18.3.20

Ref. katsottu 28.3.20

Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar  
AN, et al. Early rheumatoid arthritis is characterized by a  
distinct and transient synovial fluid cytokine profile of T  
cell and stromal cell  
origin. Arthritis Res Ther 2005;7:R784–95. Otettu  
31.5.2018

Raza A, Shata MT. Letter: pathogenicity of Th17 cells may differ in ulcerative colitis compared with Crohn's disease. Aliment Pharmacol Ther. 2012; 36:204. author reply 205. Otettu 20.9.20

**Secukinumab: Atopic dermatitis-like rash: 4 case reports**

Reactions weekly, 2025-01 (2041), p.360-360 Otta M

**[Psoriasis. Inhibition of IL-17 signaling pathway by Secukinumab].**

Recker K.

Med Monatsschr Pharm. 2014 Jul;37(7):267-8. German.

No abstract available.

PMID:

25065169    ei ole M

[Similar articles](#)

Effectiveness of **secukinumab** in hidradenitis  
suppurativa: an open study (20 cases).

Reguiaï Z, Fougèrousse AC, Maccari F, Bécherel PA.

J Eur Acad Dermatol Venereol. 2020 May 13. doi:

10.1111/jdv.16605. Online ahead of print.

PMID: 32401354    Otettu 20.9.20

**Secukinumab** shows high and sustained efficacy in nail  
psoriasis: 2.5-year results from the randomized  
placebo-controlled TRANSFIGURE study.

Reich K, Sullivan J, Arenberger P, Jazayeri S, Mrowietz U, Augustin M, Elewski B, You R, Regnault P, Frueh JA.  
Br J Dermatol. 2020 Jun 1. doi: 10.1111/bjd.19262.  
Online ahead of print.  
PMID: 32479641   Otettu 20.9.20

**Secukinumab** two weekly versus four weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study.

Reich K, Körber A, Mrowietz U, Sticherling M, Sieder C, Früh J, Bachhuber T.  
Br J Dermatol. 2020 Jul 11. doi: 10.1111/bjd.19398.  
Online ahead of print.  
PMID: 32652528   Otettu 20.9.20

Reich K, Burden AD, Eaton J Netal.BrJDer- matol 2012: 166: 179–188. Otettu 31.5.2018

[Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis.](#)

Reich K, Papp KA, Matheson RT, Tu JH, Bissonnette R, Bourcier M, Gratton D, Kunynetz RA, Poulin Y, Rosoph LA, Stingl G, Bauer WM, Salter JM, Falk TM, Blödorn-Schlicht NA, Hueber W, Sommer U, Schumacher MM, Peters T, Kriehuber E, Lee DM, Wieczorek GA, Kolbinger F, Bleul CC.

Exp Dermatol. 2015 Jul;24(7):529-35. doi:

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

K. Reich, J. Sullivan, P. Arenberger et al., “FRI0460 secukinumab shows significant efficacy in nail

psoriasis: week 32 results from the transfigure study,” *Annals of the Rheumatic Diseases*, vol. 75, Suppl 2, pp. 603-604, 2016.  
Ei oteta. On abstrakti.

**Secukinumab**, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.

Reich K, Blauvelt A, Armstrong A, Langley RG, Fox T, Huang J, Papavassilis C, Liang E, Lloyd P, Bruin G.

Br J Dermatol. 2017 Mar;176(3):752-758. doi:

Otettu 31.5.2018

[Similar articles](#)

Guselkumab versus **secukinumab** for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.

Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, Hsu MC, Branigan P, Blauvelt A.

Lancet. 2019 Aug 8. pii: S0140-6736(19)31773-8. doi:

Otettu 9.3.20

Ref. katsottu 17.3.20

**Secukinumab** dosing optimization in patients with moderate to severe plaque psoriasis: Results from the randomised, open-label OPTIMISE study.

Reich K, Puig L, Szepietowski JC, Paul C, Lacour JP, Tsianakas A, Sieder C, Rissler M, Pournara E, Orsenigo R.

Br J Dermatol. 2019 May 17. doi: 10.1111/bjd.18143.  
[Epub ahead of print] Otettu 29.2.20



**Secukinumab**, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years.

Reich K, Blauvelt A, Armstrong A, Langley RG, de Vera A, Kolbinger F, Spindeldreher S, Ren M, Bruin G.

J Eur Acad Dermatol Venereol. 2019 Apr 22. doi: Otettu 29.2.20

Long-term efficacy and safety of **secukinumab** in the treatment of the multiple manifestations of psoriatic disease.

Reich K, Warren RB, Coates LC, Di Comite G.

J Eur Acad Dermatol Venereol. 2019 Nov 30. Otettu 29.2.20

**Secukinumab** demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis.

Reich K, Baraliakos X, Coates LC, Elewski B, Bao W, Kasperek T, Gaillez C, Pournara E, Aassi M, Perella C, Gottlieb AB.

Br J Dermatol. 2022 Mar 8. doi: 10.1111/bjd.21233.

Online ahead of print.

PMID: 35257363   Otettu 1.12.22

Effect of **secukinumab** on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial.

Reich K, Sullivan J, Arenberger P, Mrowietz U, Jazayeri S, Augustin M, Parneix A, Regnault P, You R, Milutinovic M.

Br J Dermatol. 2019 Nov;181(5):954-966.   Otettu 29.2.20

## [Antibodies to watch in 2015.](#)

Reichert JM.

MAbs. 2015;7(1):1-8. doi:

10.4161/19420862.2015.988944. Review.

PMID:

25484055 Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

## **Identification of fused pyrimidines as interleukin 17 secretion inhibitors**

Reiersølmoen, Ann Christin ; Han, Jin ; Sundby, Eirik ; Hoff, Bård Helge

European journal of medicinal chemistry, 2018-07, Vol.155, p.562-578

*Inhibiting the interleukin 17 pathway is of interest in a number of autoimmune diseases...*

PEER REVIEWED Otta M

OPEN ACCESS

Paradoxical reaction to IL-17A inhibitor: a case report and literature review.

Ren J, Deng L, Guo S, Liu H.

Front Med (Lausanne). 2024 Apr 17;11:1364127. doi: 10.3389/fmed.2024.1364127. eCollection 2024.

PMID: 38695018 [Free PMC article](#). Otettu 29.5.24

**Secukinumab** Reduces Psoriasis-associated Pruritus and Regenerates the Cutaneous Nerve Architecture: Results from PSORITUS a Doubleblind, Placebo-controlled, Randomized Withdrawal Phase IIIb Study.

Renkhold L, Pereira MP, Loser K, Metze D, Baeumer D, Melzer N, Reinhardt M, Tsianakas A, Luger T, Mess C, Becker R, Hambüchen C, Agelopoulos K, Ständer S.

Acta Derm Venereol. 2024 Nov 20;104:adv40737. doi: 10.2340/actadv.v104.40737.

PMID: 39565228 [Free PMC article](#). Clinical Trial. Otettu 1.3.25

Renner, E.D., S. Rylaarsdam, S. Anover-Sombke, A.L. Rack, J. Reichenbach, J.C.Carey,Q.Zhu,A.F.Jansson,J.Barboza,L.F.Schimke,et al.2008.Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. *J.Allergy Clin. Immunol.* 122:181–187 Otettu 15.3.20

Ref. ei katsot.

**Secukinumab** is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting.

Reolid A, Armesto S, Sahuquillo-Torralba A, Torres T, Feltes R, Vilarrasa E, Belinchón I, Cueva P, Rodríguez L,

Romero-Maté A, Vidal D, Coto-Segura P, Herrera-Acosta E, Riera-Monroig J, Salgado L, Llamas-Velasco M, Daudén E.

J Am Acad Dermatol. 2022 Sep;87(3):705-709. doi: 10.1016/j.jaad.2022.05.047. Epub 2022 May 28.  
PMID: 35640798 Otettu 26.8.22

Drug Survival of Anti **Interleukin-17** and **Interleukin -23** Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study.

Repetto F, Roccuzzo G, Burzi L, Mastorino L, Dapavo P, Quaglino P, Ribero S.  
Acta Derm Venereol. 2023 Apr 19;103:adv5278. doi: 10.2340/actadv.v103.5278.  
PMID: 37073963 **Free PMC article.** Otettu 14.6.23

Res PCM, Piskin, Gamze, de Boer, Onno J, van derLoos, Chris M, Teeling, Peter, Bos, Jan D, Teunissen, Marcel BM (2010) Overrepresentation of IL-17A and IL-22 Producing CD8 T Cells in Lesional Skin Suggests Their Involvement in the Pathogenesis of Psoriasis. PLoS ONE 5: e14108. Otettu 31.5.2018

Blockade of interleukin seventeen (IL-17A) with **secukinumab** in hospitalized COVID-19 patients - the BISHOP study.

Resende GG, da Cruz Lage R, Lobê SQ, Medeiros AF, Costa E Silva AD, Nogueira Sá AT, Oliveira AJA, Sousa D, Guimarães HC, Gomes IC, Souza RP, Aguiar RS, Tunalá R, Forestiero F, Bueno Filho JSS, Teixeira MM.

Infect Dis (Lond). 2022 Aug;54(8):591-599. doi: 10.1080/23744235.2022.2066171. Epub 2022 Apr 29. PMID: 35485381 Clinical Trial. ei ole M

R. Reszke and J. C. Szepietowski, "Secukinumab in the treatment of psoriasis: an update," *Immunotherapy*, vol. 9, no. 3, pp. 229–238, 2017. Otettu 12.3.20

Ref. katsottu 23.3.20

Occurrence of Henoch-Schönlein purpura in a patient treated with **secukinumab**.

Reverte M, Etienne M, Fouchard M, Doucet L, Brenaut E, Misery L.

J Eur Acad Dermatol Venereol. 2019 Jul 7. doi:  
Otettu 29.2.20

Human IL-17A protein production is controlled through a PIP5K1 $\alpha$ -dependent translational checkpoint.



Revu SK, Yang W, Rajasundaram D, Brady A, Majumder S, Gaffen SL, Hawse W, Xia Z, McGeachy MJ.  
Sci Signal. 2023 Oct 24;16(808):eabo6555. doi:  
10.1126/scisignal.abo6555. Epub 2023 Oct 24.  
PMID: 37874883 [Free PMC article.](#) [Otettu 14.3.24](#)

Effectiveness and safety profile of **secukinumab** for the treatment of patients with generalized pustular psoriasis in daily practice.

Reymundo A, Vilarrasa E, Baniandrés O, Rodríguez-Fernández-Freire L, Feltes R, Llamas-Velasco M, Daudén E.

J Eur Acad Dermatol Venereol. 2022 Jun 11. doi:  
10.1111/jdv.18317. Online ahead of print.  
PMID: 35689497 [Otettu 1.12.22](#)

Effectiveness of **secukinumab** for the treatment of erythrodermic psoriasis:  
Multicentre study in daily practice.

Reymundo A, Armesto S, Rodríguez L, Baniandrés O, Sahuquillo-Torralba A, Torres T,  
de la Cueva P, Llamas-Velasco M, Daudén E.

J Eur Acad Dermatol Venereol. 2023 Jul 20. doi: 10.1111/jdv.19371. Online ahead of  
print.

PMID: 37471473   Otta M

Reynolds, J.M., Pappu, B.P., Peng, J., Martinez, G.J.,  
Zhang, Y., Chung, Y., Ma, L., Yang, X.O., Nurieva, R.I.,  
Tian, Q., and Dong, C. (2010). Toll-like receptor 2  
signaling in CD4(+) T lymphocytes promotes T helper 17  
responses and regulates the pathogenesis of  
autoimmune disease. Immunity 32, 692–702.   Otettu  
31.5.2018

Clinical and associated inflammatory biomarker features predictive of short-term outcomes in non-systemic juvenile idiopathic arthritis.

Rezaei E, et al. *Rheumatology (Oxford)*. 2020. PMID: 31919503 [Free PMC article](#). Otettu 7.9.22

Successful treatment of recalcitrant genital lichen planus with **secukinumab**.

Rezzag-Mahcene C, Cardot-Leccia N, Lacour JP, Montaudié H, Passeron T.

*J Eur Acad Dermatol Venereol*. 2021

May;35(5):e321-e323. doi: 10.1111/jdv.17068. Epub 2020 Dec 21.

PMID: 33617056 Otettu 1.12.22

Efficacy and Safety of **Secukinumab** in Patients with Plaque Psoriasis and Latent Tuberculosis.

Ribero S, Licciardello M, Quaglino P, Dapavo P.

Case Rep Dermatol. 2019 Sep 23;11(Suppl 1):23-28. doi: 10.1159/000501989. eCollection 2019 Sep-Dec.

PMID: 31662735 **Free PMC Article** **Otettu 29.2.20**

Effectiveness of **Secukinumab** in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting.

Ribero S, Ramondetta A, Fabbrocini G, Bettoli V, Potenza C, Chiricozzi A, Licciardello M, Marzano AV, Bianchi L, Rozzo G, Fania L, Marasca C, Odorici G, Mambrin A, Moltrasio C, Caposiena Caro RD, Skroza N, Quaglino P, Siliquini N, Dapavo P.

J Eur Acad Dermatol Venereol. 2021

Jul;35(7):e441-e442. doi: 10.1111/jdv.17178. Epub 2021 Mar 9.

PMID: 33594790 **Otettu 1.12.22**

Association between body composition and inflammation: A central role of IL-17 and IL-10 in diabetic and hypertensive elderly women.

Ribeiro IS, et al. *Exp Gerontol.* 2019. PMID: 31518664  
Otettu 1.12.22

Ribot, J.C., deBarros, A., Pang, D.J., Neves, J.F., Peperzak, V., Roberts, S.J., Girardi, M., Borst, J., Hayday, A.C., Pennington, D.J., and Silva-Santos, B. (2009). CD27 is a thymic determinant of the balance between interferon- gamma- and interleukin 17-producing gammadelta T cell subsets. *Nat. Immunol.* 10, 427–436. Otettu 31.5.2018

[First case of \*\*secukinumab\*\* successful therapy in a very elderly psoriatic patient.](#)

Ricceri F, Pescitelli L, Lazzeri L, Di Cesare A, Prignano F.

Dermatol Ther. 2018 Sep;31(5):e12668. Otettu 29.2.20

.

[\*\*Secukinumab\*\* induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.](#)

Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, Machacek M, Papavassilis C.

Br J Dermatol. 2013 Feb;168(2):402-11. d

Otettu 31.5.2018

[Similar articles](#)

[\*\*Secukinumab\*\* does not impair the immunogenic response to the influenza vaccine in patients.](#)

Richi P, Martín MD, de Ory F, Gutiérrez-Larraya R, Casas I, Jiménez-Díaz AM, Cava F, Muñoz-Fernandez S.

RMD Open. 2019 Sep 3;5(2):e001018. doi: 10.1136/rmdopen-2019-001018. eCollection 2019.

Free PMC Article Otettu 29.2.20

Ref. katsottu 8.3.20

## Cytokines in Systemic Lupus Erythematosus-Focus on TNF-alpha and IL-17.

Richter P, Macovei LA, Mihai IR, Cardoneanu A, Burlui MA, Rezus E.

Int J Mol Sci. 2023 Sep 22;24(19):14413. doi: 10.3390/ijms241914413.

PMID: 37833861 [Free PMC article](#). Review. Otettu 29.5.24

[Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month 12 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHO.](#)

Riedl E, Pinter A, Zaheri S, Costanzo A, Brnabic A, Konicek B, McKenzie R, Lampropoulou A, Rayes ME, Hastrup N, Schuster C.

Dermatol Ther (Heidelb). 2024 May;14(5):1327-1335. doi: 10.1007/s13555-024-01150-y. Epub 2024 Apr 22.

PMID: 38649673 [Free PMC article](#). Otettu 29.5.24

Axial spondyloarthritis: new advances in diagnosis and management.

Ritchlin C, Adamopoulos IE.

BMJ. 2021 Jan 4;372:m4447. doi: 10.1136/bmj.m4447.

PMID: 33397652 Review. Otettu 1.12.22

[New therapies for psoriasis and psoriatic arthritis.](#)

Ritchlin CT, Krueger JG.

Curr Opin Rheumatol. 2016 May;28(3):204-10.

Otettu 27.5.18

**[Free PMC Article](#)**



## [Similar articles](#)

### **IL-17 Cytokines and Chronic Lung Diseases.**

Ritzmann F, Lunding LP, Bals R, Wegmann M, Beisswenger C.

Cells. 2022 Jul 6;11(14):2132. doi: 10.3390/cells11142132.

PMID: 35883573 **Free PMC article.** Otettu 27.8.22

### **Preclinical studies and the function of IL-17 cytokines in COPD.**

Ritzmann F, Beisswenger C.

Ann Anat. 2021 Sep;237:151729. doi: 10.1016/j.aanat.2021.151729. Epub 2021 Mar 30.

PMID: 33798693 Review. Otettu 1.12.22

**Secukinumab-Induced Acute Autoimmune Hemolytic Anemia.**

Sébastien Rivas , Claire V, Thierry V, Marine A.

Ann Pharmacother. 2020 Feb 17    Otettu 9.3.20

Stress-induced despair behavior develops independently of the Ahr-ROR $\gamma$ t axis in CD4<sup>+</sup> cells.

Rivet-Noor CR, Merchak AR, Li S, Beiter RM, Lee S, Thomas JA, Fernández-Castañeda A, Shin JB, Gaultier A.

Sci Rep. 2022 May 21;12(1):8594. doi: 10.1038/s41598-022-12464-2.

PMID: 35597802 **Free PMC article.**    Otettu 27.8.22

Rizzo HL, Kagami S, Phillips KG, Kurtz SE, Jacques SL, Blauvelt A (2011) IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol 186:1495–1502. Otettu 7.3.20

Ref. katsottu 8.3.20

[https://doi.org/ 10.4049/jimmunol.1001001](https://doi.org/10.4049/jimmunol.1001001)

[gammadelta T cells: an important source of IL-17.](#)

Roark CL, Simonian PL, Fontenot AP, Born WK, O'Brien RL.

Curr Opin Immunol. 2008 Jun;20(3):353-7. doi: Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

## Synergistic Interaction Between High Bioactive IL-17A and Joint Destruction for the Occurrence of Cardiovascular Events in Rheumatoid Arthritis.

Robert M, Hot A, Mifsud F, Ndongo-Thiam N, Miossec P. Front Immunol. 2020 Aug 26;11:1998. doi: 10.3389/fimmu.2020.01998. eCollection 2020. PMID: 32983142 [Free PMC article](#). Otettu 3.9.22

## **Interleukin-17** and lupus: enough to be a target? For which patients?

Robert M, et al. Lupus. 2020. PMID: 31791181 Review. Otettu 7.9.22

## The Th17 Pathway in Vascular Inflammation: Culprit or Consort?

Robert M, Miossec P, Hot A.

Front Immunol. 2022 Apr 11;13:888763. doi:

10.3389/fimmu.2022.888763. eCollection 2022.

PMID: 35479069 [Free PMC article](#). Review. Otettu 27.8.22

## Deletion of IL-17ra in osteoclast precursors increases bone mass by decreasing osteoclast precursor abundance.

Roberts JL, Mella-Velazquez G, Dar HY, Liu G, Drissi H.

Bone. 2022 Apr;157:116310. doi:

10.1016/j.bone.2021.116310. Epub 2021 Dec 29.

PMID: 34973492 Otettu 1.12.22

Robertson J, Tindell A, Crosbie Stefan S. Real-world experience

of secukinumab for psoriatic arthritis and axial spondyloarthritis.

Rheumatology (Oxford). 2018;57(Key075):414.

ei oteta

Robinson, M.J., Osorio, F., Rosas, M., Freitas, R.P., Schweighoffer, E., Gross, O., Verbeek, J.S., Ruland, J., Tybulewicz, V., Brown, G.D., et al. (2009). Dectin- 2 is a Syk-coupled pattern recognition receptor crucial for Th17 responses to fungal infection. J. Exp. Med. 206, 2037–2051. Otettu 21.3.20

Robinson KM, Manni ML, Biswas PS, Alcorn JF (2013)  
Clinical consequences of targeting IL-17 and TH17 in  
autoimmune and allergic Disorders. Curr Allergy Asthma  
Rep 13: 10. Otettu 28.3.20

[Complete response of \*\*secukinumab\*\* in palmoplantar  
psoriasis.](#)

Rocamora V, Garcías-Ladaria J.

Dermatol Online J. 2017 Oct 15;23(10). pii: ei ole M

[Similar articles](#)

[Anti-IL17 \*\*Secukinumab\*\* in hidradenitis suppurativa: A long-term drug survival analysis.](#)

Roccuzzo G, Repetto F, Giordano S, Sarda C, Comes A, Dapavo P, Quaglino P, Ribero S.

Exp Dermatol. 2024 Jul;33(7):e15140. doi: 10.1111/exd.15140.

PMID: 39032087    Otta M

[Location of CD4+ T cell priming regulates the differentiation of Th1 and Th17 cells and their contribution to \*\*arthritis\*\*.](#)

Rodeghero R, Cao Y, Olalekan SA, Iwakua Y, Glant TT, Finnegan A.

J Immunol. 2013 Jun 1;190(11):5423-35. doi: 10.4049/jimmunol.1203045. Epub 2013 Apr 29.

PMID:

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)



Paradoxical psoriasiform alopecia secondary to **secukinumab**: a case report.

Rodríguez IS, Castillo Gutiérrez M, Pinedo-Moraleda F, Aranegui Arteaga B.

An Bras Dermatol. 2025 Jul 1;100(4):501155. doi: 10.1016/j.abd.2025.501155. Online ahead of print. PMID: 40602361 **Free PMC article.** Otettu 28.7.25

Candida infections in patients with psoriasis and psoriatic arthritis treated with **interleukin-17** inhibitors and their practical management.

Rodríguez-Cerdeira C, González-Cespón JL, Martínez-Herrera E, Carnero-Gregorio M, López-Barcenas A, Sergeev A, Saunte DM.

Ital J Dermatol Venerol. 2021 Oct;156(5):545-557. doi: 10.23736/S2784-8671.20.06580-3. Epub 2020 Oct 7.

PMID: 33026212 [Free article.](#) Otettu 3.9.22

Personalized **Secukinumab** Treatment in Patients with Plaque Psoriasis Using Model-Informed Precision Dosing.

Rodriguez-Fernandez K, Zarzoso-Foj J, Saez-Bello M, Mateu-Puchades A, Martorell-Calatayud A, Merino-Sanjuan M, Gras-Colomer E, Climente-Marti M, Mangas-Sanjuan V.

Pharmaceutics. 2024 Dec 10;16(12):1576. doi: 10.3390/pharmaceutics16121576.

PMID: 39771555 [Free PMC article.](#) Otettu 1.3.25

The onset of ulcerative colitis during treatment with **secukinumab**: can anti-IL-17A be a trigger for inflammatory bowel disease?

Rodríguez Moncada R, Vázquez Morón JM, Pallarés Manrique H.

Rev Esp Enferm Dig. 2019 Jul 23;111. doi: **Free Article** **ei oteta**

Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management.

Rodríguez-Cerdeira C, González-Cespón JL, Martínez-Herrera E, Carnero-Gregorio M, López-Barcenas A, Sergeev A, Saunte DM.

G Ital Dermatol Venereol. 2020 Oct 7. doi: 10.23736/S0392-0488.20.06580-3. Online ahead of print.

PMID: 33026212 **ei ole M**

IL-23/IL-17 axis and soluble receptors isoforms sIL-23R and sIL-17RA in patients with rheumatoid arthritis-presenting periodontitis.

Rodríguez-Montaña R, Bernard-Medina AG, Oregon-Romero E, Martínez-Rodríguez VMDC, Pita-López ML, Gómez-Meda BC, Guerrero-Velázquez C.

J Clin Lab Anal. 2021 Sep;35(9):e23963. doi: 10.1002/jcla.23963. Epub 2021 Aug 17.

PMID: 34403509 [Free PMC article](#). Otettu 29.8.22

How major fungal infections can initiate severe autoimmune diseases.

Roe K.

Microb Pathog. 2021 Dec;161(Pt A):105200. doi: 10.1016/j.micpath.2021.105200. Epub 2021 Sep 17.

PMID: 34537272 Review. Otettu 1.12.22

332.

[The Th17 pathway as a therapeutic target in rheumatoid arthritis and other autoimmune and inflammatory disorders.](#)

Roeleveld DM, van Nieuwenhuijze AE, van den Berg WB, Koenders MI.

BioDrugs. 2013 Oct;27(5):439-52. doi: Otettu  
31.5.2018

[Similar articles](#)

[Induced Treg-Derived Extracellular Vesicles Suppress CD4+ T-Cell-Mediated Inflammation and Ameliorate Bone Loss During Periodontitis Partly Through CD73/Adenosine-Dependent Immunomodulatory Mechanisms.](#)

Rojas C, García M, González-Osuna L, Campos-Mora M, de León EP, Sierra-Cristancho A, Terraza C, Cortez C, Sansores-España LD, Carvajal P, Bazoer J, Peng Q, Lawson C, Smyth LA, Pino-Lagos K, Vernal R.

J Extracell Vesicles. 2025 Jul;14(7):e70118. doi: 10.1002/jev2.70118.

PMID: 40620009 [Free PMC article.](#) Otettu 31.7.25

[Human Th17 cells.](#)

Romagnani S.

**Arthritis** Res Ther. 2008;10(2):206. doi: Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Romagnani S, Maggi E,, Cosmi L, Annunziato F.

Properties and origin of human Th17 cells. Mol Immunol.  
2009;47(1):3-7. Otettu 31.5.2018

[Profile of \*\*secukinumab\*\* in the treatment of psoriasis:  
current perspectives.](#)

Roman M, Madkan VK, Chiu MW.

Ther Clin Risk Manag. 2015 Dec 2;11:1767-77. doi.

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

[Association between Th-17 cytokine profile and clinical features in patients with spondyloarthritis.](#)

Romero-Sanchez C, Jaimes DA, Londoño J, De Avila J, Castellanos JE, Bello JM, Bautista W, Valle-Oñate R.

Clin Exp Rheumatol. 2011 Sep-Oct;29(5):828-34. Epub

Otettu 27.5.18

[Similar articles](#)

Successful treatment with **secukinumab** in an HIV-positive psoriatic patient after failure of apremilast.

Romita P, Foti C, Caliano G, Chiricozzi A.

Dermatol Ther. 2022 Aug;35(8):e15610. doi:

10.1111/dth.15610. Epub 2022 Jun 7.

PMID: 35634750 Otettu 26.8.22

[A new light on \*\*secukinumab\*\* in pediatric psoriasis.](#)

Romita P, Bonamonte D, DE Marco A, Mercurio SC, Calianno G, Chiricozzi A, Foti C.

Ital J Dermatol Venerol. 2024 May 2. doi: 10.23736/S2784-8671.24.07738-7. Online ahead of print.

PMID: 38695596 No abstract available. Otta M

[Infections in the era of immunobiologicals.](#)

Romiti R, Hirayama ALDS, Porro AM, Gonçalves HS, Miot LDB, Durães SMB, Marques SA.

An Bras Dermatol. 2024 Mar-Apr;99(2):167-180. doi: 10.1016/j.abd.2023.08.004. Epub 2024 Jan 17.

PMID: 38238209 **Free article.** Otettu 13.3.24



Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: A 104-week clinical study.

Rompoti N, Katsimbri P, Kokkalis G, Boumpas D, Ikonomidis I, Theodoropoulos K, Rigopoulos D, Papadavid E.

Dermatol Ther. 2019 Sep;32(5):e13006. doi: 10.1111/dth.13006. Epub 2019 Jul 15.  
PMID: 31228319 Otettu 23.9.20

Real world data from the use of **secukinumab** in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: A 104-week clinical study.

Rompoti N, Katsimbri P, Kokkalis G, Boumpas D, Ikonomidis I, Theodoropoulos K, Rigopoulos D, Papadavid E.

Dermatol Ther. 2019 Jun 22:e13006. doi: Otettu 29.2.20

[Real world data from a single Greek center on the use of \*\*secukinumab\*\* in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response.](#)

Rompoti N, Sidiropoulou P, Panagakis P, Stratigos A, Papoutsaki M, Stefanaki E, Vavouli C, Politou M, Mpefon A, Kostakis P, Rigopoulos D, Nicolaidou E.

J Eur Acad Dermatol Venereol. 2020 Jan 17 Otettu 29.2.20

Rong Z, Cheng L, Ren Y, Li Z, Li Y, Li X, Li H, Fu X Y, Chang Z. Interleukin-17F signaling requires ubiquitination of interleukin-17 receptor via TRAF6. Cell Signal 2007;19:1514–20. Otettu 31.5.2018

Rong Z, Wang A, Li Z, Ren Y, Cheng L, Li Y, Wang Y, Ren F, Zhang X, Hu J, Chang Z (2009) IL-17RD (Sef or IL-17RLM) interacts with IL-17 receptor and mediates IL-17 signaling. Cell Res 19:208–215 Otettu 17.3.20

Rong C, Hu W, Wu F et al. Interleukin-23 as a potential target for rheumatoid arthritis. Mol Cell Biochem 2012; 361:243-8. Otettu 17.3.20

[Repigmentation and new growth of hairs after anti-interleukin-17 therapy with \*\*secukinumab\*\* for psoriasis.](#)

Rongioletti F, Mugheddu C, Murgia S.

JAAD Case Rep. 2018 May 7;4(5):486-488. doi:

Otettu 3.9.18

[\*\*Free PMC Article\*\*](#)

[Similar articles](#)

[Real-World Utilization of Biologic and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs in Psoriatic Arthritis and Axial Spondyloarthritis: Insights from Sweden and Germany.](#)

Roque H, Dun AR, Cooper A, Kienzle S, Welby S, Wilke T, Song J, Abé C.

Adv Ther. 2025 May 22. doi:

10.1007/s12325-025-03216-5. Online ahead of print.

PMID: 40402376 Otettu 4.6.25

[Real-World Adherence and Drug Survival of Biologics among Patients with Ankylosing Spondylitis.](#)

Rosenberg V, Amital H, Chodick G, Faccin F, Watad A, McGonagle D, Gendelman O.

J Clin Med. 2024 Jul 31;13(15):4480. doi: 10.3390/jcm13154480.

PMID: 39124747 [Free PMC article.](#) Otettu 27.9.24

[Card9/neutrophil signalling axis promotes IL-17A-mediated ankylosing spondylitis.](#)

Rosenzweig HL, Vance EE, Asare-Konadu K, Koney KV, Lee EJ, Deodhar AA, Sen R, Caplan L, Napier RJ.

Ann Rheum Dis. 2024 Jan 11;83(2):214-222. doi:  
10.1136/ard-2022-223146.

PMID: 37813481 [Free PMC article.](#) Otettu 29.5.24

Targeting IL-17A for the treatment of pustular psoriasis:  
a comprehensive review.

Rosi E, Fastame MT, Di Cesare A, Prignano F.

Expert Opin Biol Ther. 2022 Aug 23. doi:

10.1080/14712598.2022.2116978. Online ahead of  
print.

PMID: 35997143 ei ole M

Innate Cells: The Alternative Source of IL-17 in Axial and  
Peripheral Spondyloarthritis?

Rosine N, Miceli-Richard C.

Front Immunol. 2021 Jan 8;11:553742. doi:

10.3389/fimmu.2020.553742. eCollection 2020.

PMID: 33488572 [Free PMC article](#). Otettu 4.2.21

[Focal bone involvement in inflammatory arthritis: the role of IL17.](#)

Rossini M, Viapiana O, Adami S, Idolazzi L, Fracassi E, Gatti D.

Rheumatol Int. 2015 Oct 31.

Otettu 31.5.2018

[Similar articles](#)

6. Rossini M, Viapiana O, Adami S, Idolazzi L, Fracassi E, Gatti D. Focal bone involvement in inflammatory arthritis: the role of IL17. Rheumatol Int. 2016;36:469–82. Otettu 15.3.20

Rossol M, Kraus S, Pierer M, Baerwald C, Wagner U (2012) The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes Th17 expansion. Arthritis Rheum 64: 671–677. Otettu 31.5.2018

.  
[IL-17 patterns in synovium, serum and synovial fluid from treatment-naïve, early rheumatoid arthritis patients.](#)

Roşu A, Mărgăritescu C, Stepan A, Muşetescu A, Ene M.

Rom J Morphol Embryol. 2012;53(1):73-80.

PMID:

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)



**Secukinumab for the maintenance of glucocorticoid-free remission in a patient with giant cell arteritis and psoriatic arthritis.**

R Ž, Tomšić M, Hocevar A.

Rheumatology (Oxford). 2018 May 1;57(5):934-936.

Otettu 31.5.2018

[Similar articles](#)

**Secukinumab for treating plaque psoriasis.**

Rothstein B, Gottlieb A.

Expert Opin Biol Ther. 2016 Jan;16(1):119-28. doi: Epub

Ei ole M ei ole GS

[Similar articles](#)

Rovedatti L, Kudo T, Biancheri P, et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut. 2009;58:1629–1636. Otettu 15.3.20

IL-17: good fear no tears.

Rua R, Pujol N.

Nat Immunol. 2020 Nov;21(11):1315-1316. doi: 10.1038/s41590-020-0792-4.

PMID: 32958929 Otettu 3.9.22

Ruan Q, Kameswaran V, Zhang Y, Zheng S, Sun J, Wang J, DeVirgiliis J, Liou HC, Beg AA, Chen YH. The Th17 immune response is controlled by the

Rel-RORgamma-RORgamma T transcriptional axis. J  
Exp Med. 2011; 208:2321–2333. [PubMed: 22006976]  
Otettu 31.5.2018

gammadelta T cells respond directly and selectively to  
the skin commensal yeast *Malassezia* for  
**IL-17**-dependent fungal control.

Ruchti F, Tuor M, Mathew L, McCarthy NE,  
LeibundGut-Landmann S.

PLoS Pathog. 2024 Jan 12;20(1):e1011668. doi:  
10.1371/journal.ppat.1011668. eCollection 2024 Jan.  
PMID: 38215167 **Free PMC article.** Otettu 13.3.24

Ruddy MJ, Wong GC, Liu XK, et al.: Functional  
cooperation between interleukin-17 and tumor necrosis  
factor-alpha is mediated by CCAAT/enhancer-binding

protein family members. J Biol Chem 2004,  
279:2559–2567. Otettu 19.3.20  
Ref. ei otet.

Ruddy MJ, Shen F, Smith JB, Sharma A, Gaffen SL.  
2004. In- terleukin-17 regulates expression of the CXC  
chemokine LIX/ CXCL5 in osteoblasts: implications for  
inflammation and neutrophil recruitment. J Leukoc Biol  
76(1):135–144.  
Otettu 31.5.2018

[Of Mice and Men: Defining the Role of \*\*Interleukin 17\*\* in  
Rheumatoid Arthritis.](#)

Ruderman EM.

J Rheumatol. 2015 Jul;42(7):1069-71. doi:

[Similar articles](#)

Select item. Otettu 4.3.16

Critical role of **interleukin (IL)-17** in inflammatory and immune disorders: An updated review of the evidence focusing in controversies.

Ruiz de Morales JMG, Puig L, Daudén E, Cañete JD, Pablos JL, Martín AO, Juanatey CG, Adán A, Montalbán X, Borrueal N, Ortí G, Holgado-Martín E, García-Vidal C, Vizcaya-Morales C, Martín-Vázquez V, González-Gay MÁ. *Autoimmun Rev.* 2020 Jan;19(1):102429. doi: 10.1016/j.autrev.2019.102429. Epub 2019 Nov 15. PMID: 31734402    Otettu 21.9.20

Drug survival, discontinuation rates, and safety profile of **secukinumab** in real-world patients: a 152-week, multicenter, retrospective study.

Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Galán-Gutierrez M, Armario-Hlta JC, Martinez-Pilar L.

*Int J Dermatol.* 2020 Mar 15    Otettu 29.3.20

IL-17A moonlighting in lung type 2 immunity.

Ruscher R, Giacomini PR.

Mucosal Immunol. 2020 Nov;13(6):849-851. doi:

10.1038/s41385-020-0329-z. Epub 2020 Jul 29.

PMID: 32728131 [Free PMC article.](#) Otettu 3.9.22

The assessment of the drug retention rate of **secukinumab** in patients with psoriatic arthritis in a real-life multicentre cohort.

Ruscitti P, Pantano I, Perrotta FM, Celletti E, Volpe P, Ciliento MS, Marino V, Raimondi M, Gaggiano E, Mauro D, Cataldi G, Italiano N, Di Muzio C, Navarini L, Zicolella R, Gabini M, Cipollone F, Lubrano E, Giacomelli R, Ciccia F, Cipriani P.

Clin Exp Rheumatol. 2023 Jul 24. doi:

10.55563/clinexprheumatol/tpp63h. Online ahead of print.

PMID: 37497733 Otettu 12.10.23

[A narrative review of the literature: The role of biologics and JAK inhibitors in vitiligo.](#)

Russell R, Daniel BS.

Australas J Dermatol. 2024 Aug 1. doi:  
10.1111/ajd.14353. Online ahead of print.  
PMID: 39087440 Otettu 27.9.24

Russell CB, Kerkof K, Bigler J, et al. Blockade of the IL-17R with AMG827 leads to rapid reversal of gene expression and histopathologic abnormalities in human psoriatic skin. J Invest Dermatol. 2010;130:S46 Ei oteta

Disease Activity and Bone Microarchitectural Phenotype  
in Patients With Axial Spondyloarthritis.

Russell L, Mannstadt I, Ashany D, Mintz DN, Yuan W, Heiting C, Glaser KK, Tornberg H, McMahon D, Goodman SM, Stein EM.

HSS J. 2024 Jul 31:15563316241268001. doi:  
10.1177/15563316241268001. Online ahead of print.  
PMID: 39564426 [Free PMC article.](#) Otettu 1.3.25

IL-17A and TNF Modulate Normal Human Spinal  
Entheseal Bone and Soft Tissue Mesenchymal Stem Cell  
Osteogenesis, Adipogenesis, and Stromal Function.

Russell T, Watad A, Bridgewood C, Rowe H, Khan A, Rao A, Loughenbury P, Millner P, Dunsmuir R, Cuthbert R, Altaie A, Jones E, McGonagle D.

Cells. 2021 Feb 6;10(2):341. doi:  
10.3390/cells10020341.  
PMID: 33562025 [Free PMC article.](#) Otettu 31.8.22



Cytokine "fine tuning" of enthesis tissue homeostasis as a pointer to spondyloarthritis pathogenesis with a focus on relevant TNF and IL-17 targeted therapies.

Russell T, Bridgwood C, Rowe H, Altaie A, Jones E, McGonagle D.

Semin Immunopathol. 2021 Apr;43(2):193-206. doi: 10.1007/s00281-021-00836-1. Epub 2021 Feb 5.

PMID: 33544244 [Free PMC article](#). Otettu 31.8.22

Long-Term Drug Survival and Effectiveness of **Secukinumab** in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study.

Russo F, Galluzzo M, Stingeni L, Persechino S, Zichichi L, Conti A, Giofrè C, Dini V, Vispi M, Atzori L, Cattaneo A, Parodi A, Bardazzi F, Stinco G, Dapavo P, Girolomoni G, Musumeci ML, Papini M, Venturini M, Dastoli S, Di Nuzzo

S, Fargnoli MC, Pagnanelli G, Bernardini N, Gambini DM, Malagoli P, Mazzatenta C, Peris K, Zalaudek I, Fabbrocini G, Loconsole F, Vassallo C, Pietroleonardo L, Prignano F, Franchi C, Offidani AM, Bonifati C, Di Lernia V, Gigante G, Bartezaghi MS, Franchi M, Ursoleo P, Aloisi E.

Clin Cosmet Investig Dermatol. 2023 Dec  
12;16:3561-3574. doi: 10.2147/CCID.S416149.  
eCollection 2023.

PMID: 38107670 [Free PMC article.](#) Otettu 4.3.24

Ruth JH, Shahrara S, Park CC, Morel JC, Kumar P, Qin S, et al. Role of macrophage inflammatory protein-3a and its ligand CCR6 in rheumatoid arthritis. Lab Invest 2003;83:579-88. Otettu 20.9.20

57. Rutz, S.; Eidenschenk, C.; Ouyang, W. IL-22, not simply a Th17 cytokine. *Immunol. Rev.* **2013**, 252, 116–132. [[CrossRef](#)] [[PubMed](#)] Otettu 8.3.20

Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. Ruysen-Witrant A, et al. *RMD Open*. 2020. PMID: 32094304 [Free PMC article](#). Otettu 6.9.22

[Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis.](#)

Ryoo JY, Yang HJ, Ji E, Yoo BK.

*Ann Pharmacother*. 2016 Jan 18. pii:

3. 2016;50:341–351.

Otettu 31.5.2018

[Similar articles](#)

Ryu S, Lee JH, Kim SI. 2006. IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes. Clin Rheumatol 25(1):16–20.

Otettu 31.5.2018

533.

[IL-17 boosts proinflammatory outcome of antiviral response in human cells.](#)

Ryzhakov G, Lai CC, Blazek K, To KW, Hussell T, Udalova I.

J Immunol. 2011 Nov 15;187(10):5357-62. doi: 10.4049/jimmunol.1100917. Epub 2011 Sep 30.

PMID:

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)